

DOCTORAL THESIS

Toxicity of Amyloid Beta
Peptides and the Effect of
 α -lipoic Acid in Cellular and
Fruit Fly Models of
Alzheimer's Disease

Kristel Metsla

TALLINN UNIVERSITY OF TECHNOLOGY
DOCTORAL THESIS
76/2025

Toxicity of Amyloid Beta Peptides and the Effect of α -lipoic Acid in Cellular and Fruit Fly Models of Alzheimer's Disease

KRISTEL METSLA



TALLINN UNIVERSITY OF TECHNOLOGY

School of Science

Department of Chemistry and Biotechnology

This dissertation was accepted for the defence of the degree of Doctor of Philosophy in Gene Technology on 19/09/2025.

Supervisor:

Professor Peep Palumaa
School of Science
Tallinn University of Technology
Tallinn, Estonia

Co-supervisor:

Adjunct Professor Vello Tõugu
School of Science
Tallinn University of Technology
Tallinn, Estonia

Opponents:

Assistant Professor Axel Abelein
Department of Medicine
Karolinska Institute
Stockholm, Sweden

Professor Emeritus Aleksandr Žarkovski
Faculty of Medicine
Institute of Biomedicine and Translational Medicine
University of Tartu
Tartu, Estonia

Defence of the thesis: 29/10/2025, Tallinn

Declaration:

Hereby I declare that this doctoral thesis, my original investigation and achievement, submitted for the doctoral degree at Tallinn University of Technology has not been submitted for doctoral or equivalent academic degree.

Kristel Metsla

Signature



Copyright: Kristel Metsla, 2025

ISSN 2585-6898 (publication)

ISBN 978-9916-80-387-5 (publication)

ISSN 2585-6901 (PDF)

ISBN 978-9916-80-388-2 (PDF)

DOI <https://doi.org/10.23658/taltech.76/2025>

Printed by EVG Print

Metsla, K. (2025). *Toxicity of Amyloid Beta Peptides and the Effect of α -lipoic Acid in Cellular and Fruit Fly Models of Alzheimer's Disease* [TalTech Press]. <https://doi.org/10.23658/taltech.76/2025>

TALLINNA TEHNIKAÜLIKOO
DOKTORITÖÖ
76/2025

Amüloid beeta peptiidide toksilisus ning α -lipoehappe mõju Alzheimeri tõve rakulistes ja äädikakärbse mudelites

KRISTEL METSLA



Contents

List of Publications	6
Author's Contribution to the Publications	7
Introduction	8
Abbreviations	9
1 Review of the Literature.....	10
1.1 Alzheimer's Disease	10
1.2 Amyloid Beta Peptides.....	10
1.3 Hypotheses of AD	13
1.3.1 Amyloid Cascade Hypothesis	14
1.3.2 Neurotransmitter Hypotheses	14
1.3.2.1 The Cholinergic Hypothesis.....	15
1.3.2.2 The Noradrenergic Hypothesis.....	15
1.3.2.3 The Dopaminergic Hypothesis	15
1.3.3 Metal Ion Hypothesis	16
1.4 The Role of Metals in the Brain and AD.....	16
1.4.1 The Role of Copper in AD	18
1.5 Risk Factors and Prevention of AD.....	19
1.6 Treatment of AD	19
1.6.1 Metalloregulatory Clinical Trials	21
1.6.2 Alpha-Lipoic Acid.....	22
1.7 Models to Study AD	23
1.7.1 Cellular Models of AD.....	23
1.7.2 Drosophila Melanogaster as a Model Organism.....	25
Aims of the Study	27
Materials and Methods.....	28
Results	29
Discussion.....	31
Conclusions	35
References	36
Acknowledgements.....	61
Abstract.....	62
Lühikokkuvõte.....	63
Appendix 1	65
Appendix 2	83
Appendix 3	95
Curriculum vitae.....	111
Elulookirjeldus.....	112

List of Publications

The list of publications, on the basis of which the thesis has been prepared:

- I Krishtal, J., Bragina, O., **Metsla, K.**, Palumaa, P., & Tõugu, V. (2017). In situ fibrillizing amyloid-beta 1-42 induces neurite degeneration and apoptosis of differentiated SH-SY5Y cells. *PLoS One*, 12(10), e0186636. <https://doi.org/10.1371/journal.pone.0186636>
- II Krishtal, J., **Metsla, K.**, Bragina, O., Tõugu, V., & Palumaa, P. (2019). Toxicity of Amyloid- β Peptides Varies Depending on Differentiation Route of SH-SY5Y Cells. *Journal of Alzheimer's disease: JAD*, 71(3), 879–887. <https://doi.org/10.3233/JAD-190705>
- III **Metsla, K.***, Kirss, S.*, Laks, K., Sildnik, G., Palgi, M., Palumaa, T., Tõugu, V., & Palumaa, P. (2022). α -Lipoic Acid Has the Potential to Normalize Copper Metabolism, Which Is Dysregulated in Alzheimer's Disease. *Journal of Alzheimer's disease: JAD*, 85(2), 715–728. <https://doi.org/10.3233/JAD-215026>

*These authors contributed equally to this publication.

Author's Contribution to the Publications

Contribution to the papers in this thesis are:

- I Cell growth and differentiation, A β 40 and A β 42 toxicity experiments, measurement of caspase activity, preparation of microscopy slides, preparation of the manuscript.
- II Cell growth and differentiation, A β 42 toxicity experiments, immunocytochemistry and microscopy, preparation of the manuscript.
- III Cell growth and differentiation, toxicity experiments, sample preparation for ICP-MS experiments, *Drosophila melanogaster* maintenance and husbandry, feeding of *Drosophila* with lipoic acid, *Drosophila* negative geotaxis experiments, preparation of the manuscript.

Introduction

Alzheimer's disease (AD), the most common type of dementia, is the 7th leading cause of mortality in the USA and one of the costliest diseases for society. AD is a global public health concern and unfortunately, there is no treatment to cure it, making its research particularly important. *In vitro* experiments, especially those employing neuronal cell lines, play an essential role in advancing our understanding of neurodegenerative diseases, including AD. Human neuroblastoma SH-SY5Y cells are one of the most used cellular models of neurodegenerative diseases. Although widely used, they are commonly used in the undifferentiated state, which is not representative of mature neurons. The major advantages of using SH-SY5Y cells are their human origin and ability to differentiate into various types of neuron-like cells resembling the neurons in the human brain. Moving beyond cell culture studies, *Drosophila melanogaster* is a widely used, cost-effective, simple model organism for studying human diseases, including AD, at the organismal level. Accumulation of amyloid beta (A β) peptides and metal ion imbalance, especially copper, are characteristic features of AD. However, the role of A β and the exact mechanism of toxicity are largely unknown. Restoration of copper homeostasis has also not been successful so far. The current thesis included the development of cell culture models with different neuronal phenotypes suitable for studying the effects of A β peptides and potential drug candidates. Cell viability measurements with WST-1 and membrane permeability tests with propidium iodide demonstrated that cholinergic and noradrenergic cells were susceptible to A β toxicity, whereas dopaminergic cells were nearly resistant. In addition to the investigation of A β on neuron-like cells, one of the obtained differentiated cultures was successfully used to show that a natural compound, α -lipoic acid was able to redistribute copper from the extracellular to the intracellular environment. Moreover, it rescued AD model flies from developing an AD phenotype. The differentiated cell culture models obtained can be used to study more precise mechanisms of A β toxicity and to screen potential drug candidates at the cellular level. The results also point to α -lipoic acid as a compound that may help improve some of the underlying copper-related pathological mechanisms of this devastating disease.

Abbreviations

A β	Amyloid beta
APP	Amyloid precursor protein
ACh	Acetylcholine
ACH	Amyloid cascade hypothesis
ACH2.0	Amyloid cascade hypothesis 2.0
AChE	Acetylcholinesterase
AD	Alzheimer's disease
AICD	Amyloid precursor protein intracellular domain
α -LA	Alpha lipoic acid
BACE1	β -site APP cleaving enzyme 1
BBB	Blood brain barrier
BDNF	Brain-derived neurotrophic factor
ChAT	Choline acetyltransferase
CSF	Cerebrospinal fluid
CTR1	Copper transporter 1
DA	Dopamine
dbcAMP	Dibutyryl cyclic adenosine monophosphate
DHLA	Dihydrolipoic acid
DMT1	Divalent metal transporter 1
EOAD	Early-onset AD
FAD	Familial AD
GWAS	Genome-wide association study
LC	Locus coeruleus
LOAD	Late-onset AD
MD	Menkes disease
NFT	Neurofibrillary tangle
NA	Noradrenaline
PD	Parkinson's disease
PSEN1	Presenilin 1
PSEN2	Presenilin 2
RA	Retinoic acid
ROS	Reactive oxygen species
SMVT	Sodium-dependent multivitamin transporter
SNP	Single nucleotide polymorphism
SOD1	Superoxide dismutase 1
TH	Tyrosine hydroxylase
TPA	12-O-tetradecanoylphorbol-13-acetate
VACHT	Vesicular acetylcholine transporter
VTA	Ventral tegmental area
WD	Wilson disease
WHO	World Health Organization

1 Review of the Literature

1.1 Alzheimer's Disease

AD is a progressive, multifactorial neurodegenerative disease that slowly destroys memory, thinking, behaviour, and eventually the ability to carry out simple tasks (Selkoe, 2001). According to the World Health Organization (WHO), over 55 million people worldwide live with dementia, and AD contributes to 60–70% of these cases (World Health Organization, 2023). Moreover, 22% of all persons aged 50 and above have some form of AD, ranging from preclinical to late stages (Gustavsson et al., 2023).

AD is pathologically defined by extensive neuronal loss and the combined presence of extracellular metal-enriched amyloid plaques composed of A β peptides and intracellular neurofibrillary tangles (NFT) composed of hyperphosphorylated tau proteins (Alzheimer et al., 1995). Other abnormalities linked to AD include altered levels of neurotransmitters, metal ions, and overproduction of reactive oxygen species (ROS) (Yang et al., 2023; Babic Leko et al., 2023; Manoharan et al., 2016).

AD can be divided into different types based on genetic predisposition and the age of onset. Based on the age of onset AD can be divided into early-onset (EOAD) and late-onset (LOAD) forms. EOAD is estimated to account for only 5–10% of all disease cases (Ayodele et al., 2016). Some cases of EOAD are caused by gene mutations that can be passed from parent to child, also known as familial AD (FAD). FAD is caused by mutations in amyloid precursor protein (APP), presenilin 1 (PSEN1), or presenilin 2 (PSEN2). Although very rare, these mutations have extremely significant implications. In total, ~330 pathogenic or likely pathogenic mutations have been reported in these three genes (Xiao et al., 2021). Several APP mutations have been identified within the A β sequence, e.g., Flemish (A692G), Dutch (E693Q), Arctic (E693G), and Iowa (D694N) (Grabowski et al., 2001; Cras et al., 1998). Most people have the late-onset sporadic form, in which symptoms become apparent after the age of 65. There is no specific gene that directly causes LOAD, however, the apolipoprotein E ϵ 4 allele (ApoE4) is the strongest known genetic risk factor that increases the risk of developing AD up to 15-fold (Corder et al., 1993; Troutwine et al., 2022). In addition, many AD-related single-nucleotide polymorphisms (SNPs) have been discovered by genome-wide association studies (GWASs) (Escott-Price, Hardy 2022; Andrews et al., 2023). Although SNPs have a smaller impact, they may be helpful in early disease prediction.

As AD exerts a huge economic burden on society and a psychological burden on patients and caregivers, there is an urgent need to find cost-effective strategies for both the prevention and treatment of this multifactorial disease.

1.2 Amyloid Beta Peptides

Amyloid plaques, one of the two lesions required for the neuropathological diagnosis of AD, are mainly composed of A β peptides but also contain high concentrations of metal ions (Rajendran et al., 2009). A β peptides are generated from APP by enzymes that cleave it into smaller fragments. APP is a single-pass transmembrane protein that is especially abundant in neurons. APP can be cleaved by amyloidogenic or non-amyloidogenic pathways (**Figure 1, top**), both are present also in healthy individuals (O'Brien & Wong, 2011). In the non-amyloidogenic pathway, APP is cleaved by α -secretase within the A β sequence, producing the neuroprotective sAPP α and preventing A β formation. Subsequent γ -secretase cleavage generates the p3 peptide. In contrast, the amyloidogenic

pathway is the major source of A β peptides. In the amyloidogenic pathway, the first cleavage of APP is usually performed by an enzyme called β -site APP cleaving enzyme 1 (BACE1, also known as β -secretase), which cuts the protein into two fragments: a large extracellular portion, sAPP β , and a smaller piece C99 that remains in the cell membrane. The remaining fragment is subsequently cleaved by an enzyme called γ -secretase, a multi-subunit complex consisting of four different proteins (PSEN1 or PSEN2, nicastrin, APH-1, PEN-2), that releases A β peptide from the membrane (Zhang et al., 2014). Depending on the cleavage sites, the length of the peptides can vary from 37 to 43 amino acids. Of these peptides, the two most abundant A β species found in amyloid plaques are composed of 40 and 42 amino acid residues – A β 40 and A β 42, respectively. Although less abundant, A β 42 is more amyloidogenic and toxic due to two additional hydrophobic amino acids in the C-terminus (Mrdenovic et al. 2022) (**Figure 1, bottom**).




Figure 1. Top: Schematic representation of APP processing pathways. APP undergoes proteolytic cleavage by α -, β -, and γ -secretases (abbreviated as α , β , and γ), resulting in either the non-amyloidogenic or amyloidogenic processing. Cleavage products include soluble APP fragments (sAPP α , sAPP β), C-terminal fragments (C83, C99), A β or p3, and the APP intracellular domain (AICD). The figure was created with BioRender. **Bottom:** Amino acid sequence of A β showing the main α -, β -, and γ -secretase cleavage sites and amino acid residues participating in binding of Cu(II) ions (light pink). Two extra C-terminal amino acid residues making A β 42 more prone to aggregation, are marked in red. The figure was created with BioRender.

In addition to the well-known α -, β -, and γ -secretases, some other secretases have been identified that also contribute to the processing of APP. These include η -secretase, which generates longer APP fragments with potential neurotoxic effects, δ -secretase, which enhances amyloidogenic processing by facilitating β -secretase cleavage, and meprin- β , a metalloprotease capable of cleaving APP at an alternative β -like site (Willem et al., 2015; Zhang et al., 2015; Bien et al., 2012). While their exact roles are still being elucidated, these additional secretases may also impact APP metabolism and AD progression.

The exact role of A β is unclear, but in physiological conditions, it may be important for normal development, neuronal growth and survival, synaptic function, and, in low concentrations, may even exhibit neuroprotective properties against oxidative stress, toxins, and pathogens (Bishop & Robinson, 2004; Bernabeu-Zornoza et al., 2019). In pathological conditions, overproduction, misfolding, and impaired clearance of A β occur, the ratio of A β 42/A β 40 changes, and the levels of toxic A β 42 increase (Mrdenovic et al. 2022). An increased A β 42/A β 40 ratio is associated with enhanced neurotoxicity in cultured mouse hippocampal neurons and affects behaviour and learning in mice *in vivo* (Kuperstein et al., 2010). In humans, A β 42/A β 40 ratio is widely used as a biomarker in cerebrospinal fluid (CSF) and plasma for the diagnosis of AD. A decreased ratio is usually observed in AD patients reflecting the deposition of A β 42 in plaques and the relative abundance of A β 40 in circulation (Pérez-Grijalba et al., 2019; Doecke et al., 2020).

A β can exist in multiple assembly states – monomers, oligomers, protofibrils, fibrils. Soluble monomers can aggregate into oligomers, protofibrils and fibrils. Fibrils are large and insoluble and can assemble into plaques (Hardy & Selkoe, 2002). Monomeric A β binds metal ions, e.g. Cu(II), Zn(II), Fe(II), and Pb(IV), in the N-terminal region (Wärmländer et al., 2019). Amino acid residues involved in Cu(II) coordination are Asp1, His6, His13, and His14 (Faller & Hureau, 2009) (**Figure 1, bottom**). The most toxic form of A β is still a subject of debate. While monomers and fibrils are generally considered non-toxic, oligomers and protofibrils are widely regarded as the most neurotoxic species (Chen et al., 2023; Tolar et al., 2021). In addition, toxic effects have been attributed to A β -copper complexes (Smith et al., 2006). A β accumulation does not always correlate with neuronal loss and cognitive decline (Aizenstein et al., 2008), and later studies have shown that even the extent of brain damage has a weak correlation with cognitive symptoms, likely due to large individual differences in baseline cognitive reserve (Morbelli & Nobili, 2014). Moreover, A β deposition has even been suggested to play a protective role (Rischel et al., 2023).

A β is one of the potential biomarkers to indicate early stages of the disease and can be detected using imaging technologies, blood plasma, or CSF test (Schindler et al., 2019; Hansson et al., 2018). Studies have shown that A β 42 is lower in AD CSF compared to healthy controls, and the decline is evident even 25 years before the appearance of the symptoms (Motter et al., 1995; Bateman et al., 2012). On the other hand, high CSF A β 42 levels predict normal cognition in amyloid-positive individuals with *APP*, *PSEN1*, or *PSEN2* genetic mutations (Sturchio et al., 2022).

Numerous studies have focused on understanding the toxicity of A β and its role in AD progression, but the precise mechanism by which A β neurotoxicity is mediated is unclear. However, it is known that A β interacts with plasma membrane and cellular organelle membranes and may change their properties (Sasahara et al., 2013). In addition, A β may form pores in the membrane that allow a dysregulated influx of Ca²⁺ ions into the cells that may ultimately lead to cell death (Di Scala et al., 2016; Dhaouadi et al., 2023).

Accumulation of A β in the mitochondria has also been observed to precede extracellular A β deposition. Intramitochondrial A β can interact with mitochondrial proteins and cause their dysfunction (Caspersen et al., 2005). By targeting mitochondria, A β 42 has been shown to induce apoptotic cell death by activating the caspase signalling pathway (Han et al, 2017; Keil et al., 2004).

The events preceding A β accumulation play an important role in AD pathogenesis, however, their exact contributions and the mechanisms underlying A β toxicity are unclear and need thorough investigations.

1.3 Hypotheses of AD

Since the description of AD in 1906, several hypotheses have been proposed to describe the cause of the disease, and these hypotheses have also been the basis for drug development. Some of the most popular hypotheses are shown in **Figure 2** and important hypotheses in the context of this thesis are described in more detail in the following chapters.




Figure 2. Some of the hypotheses of AD. The figure was created with Canva.

1.3.1 Amyloid Cascade Hypothesis

Amyloid cascade hypothesis (ACH), described by Hardy and Higgins in 1992, posits that the deposition of A β is the central event in AD pathology, and that hyperphosphorylation of tau, the formation of NFT, cell damage and dementia follow as a direct result of this deposition (Hardy & Higgins, 1992). The hypothesis has been modified throughout the years. In 2002, Hardy and Selkoe proposed that soluble A β oligomers, but not monomers or insoluble fibrils, are the toxic entities responsible for synaptic dysfunction in AD (Hardy & Selkoe, 2002).

Recently, another reformulation of ACH was proposed called amyloid cascade hypothesis 2.0 (ACH2.0) (Volloch & Rits-Volloch, 2023). Compared to the original ACH, ACH2.0 suggests that toxicity is driven by intracellular rather than extracellular A β . Although APP-derived A β is normally secreted from the cell membrane after proteolytic cleavage, there are two ways it can end up in the cell. First, the cellular uptake of secreted A β constitutes its conversion to intracellular A β . A prerequisite to the uptake of A β appears to be the formation of A β aggregates from “stickier” A β 42, which are taken up twice as efficiently as other A β species. The cellular uptake of A β is mediated by multiple receptors and depends on ApoE isoforms, with ApoE4 being significantly more efficient than the other variants. Another source of APP-derived intracellular A β is its retention within neurons. Although the vast majority of APP-derived A β results from the γ -cleavage of APP on the plasma membrane and is secreted, a small fraction undergoes γ -cleavage on the internal membranes, and the derived A β is retained as intracellular A β (Volloch & Rits-Volloch, 2023). Intraneuronally-accumulated, APP-derived intracellular A β triggers a relatively benign cascade that activates the APP-independent intracellular A β -generating pathway, which, in turn, initiates the second devastating cascade that includes tau pathology and leads to neuronal loss (Volloch & Rits-Volloch, 2022). The important role of intracellular A β is also indicated by the fact that in AD patients, intraneuronal A β precedes both extracellular A β deposition and intracellular NFT formation (Gouras et al., 2000).

ACH has been considered the central and most influential hypothesis in AD research for the past three decades. Therefore, A β has been the most extensively investigated and commonly targeted molecule for the development of AD therapy.

1.3.2 Neurotransmitter Hypotheses

Beyond the well-established amyloid and tau hypotheses, alterations in neurotransmitter systems have been implicated in AD. Brain changes may start more than 20 years before the AD symptoms appear, and brain atrophy may start 13 years before the expected onset of symptoms (Gordon et al., 2018). The brain contains various types of neurons that are often defined by the identity of the neurotransmitters they release. Studies have shown that multiple neurotransmitter systems, e.g. cholinergic, dopaminergic, glutamatergic, serotonergic, noradrenergic, and GABAergic, are involved in the development and progression of AD (Chakraborty et al., 2019; Carello-Collar et al, 2023; Gannon et al., 2015; Conway, 2020; Pan et al., 2019; Ferreira-Vieria et al., 2016), further reflecting the heterogeneity of the disease. Alterations to the neurotransmitter systems and corresponding hypotheses relevant to the context of this thesis will be described in more detail.

1.3.2.1 The Cholinergic Hypothesis

The cholinergic system plays an important role in memory and learning (Hasselmo, 2006). Cholinergic neurons are mainly located in the striatum and basal forebrain, including the nucleus basalis of Meynert (Ahmed et al., 2019).

The cholinergic hypothesis is the earliest theory explaining the pathogenesis of AD (Francis et al., 1999). The theory arose when decreased cholinergic activity in AD patients' brains was discovered. Degeneration and reduction of cholinergic neurons and severe deficiency of acetylcholine (ACh), a neurotransmitter that plays a vital role in memory, attention, learning, and neuroplasticity, are characteristic of AD pathogenesis (Chen et al., 2022). Additionally, AD patients exhibit reduced activity of choline acetyltransferase (ChAT), an enzyme responsible for ACh synthesis in the hippocampus, temporal, and frontal cortex (Rinne et al., 1988). A large body of evidence collected over the decades suggests that cerebral loss of cholinergic innervation in AD patients' cerebral cortex is correlated with cognitive impairment (Hampel et al., 2019).

Three of the currently used symptom-relieving drugs, donepezil, galantamine, and rivastigmine, were developed based on this hypothesis. These are acetylcholinesterase inhibitors that slow down the hydrolysis of ACh, thus increasing the availability of ACh in synapses. Unfortunately, their effect appears to be temporary, and efficacy in improving cognition is low (Moreta et al., 2021).

1.3.2.2 The Noradrenergic Hypothesis

It was described already in the early 1980s that locus coeruleus (LC), the major noradrenergic nucleus of the brain, degenerates early in AD before the appearance of pathological features (Mann et al., 1980). LC is a small nucleus in the pons of the brainstem where most of the central nervous system (CNS) noradrenaline (NA) is produced, and it is crucial for regulating attention, arousal, and cognitive functions. It has also been demonstrated that the overall neuronal loss is the greatest in LC and exceeds the cholinergic neuronal loss in the nucleus basalis of Meynert (Zarow et al., 2003). This is noteworthy as neuronal loss in the nucleus basalis is generally considered a hallmark sign of AD.

It has been hypothesized that early loss of noradrenergic neurons and reduction of NA in the brain lead to cognitive dysfunction and neurodegeneration. The involvement of NA in AD was first suggested when a marked loss of noradrenergic neurons in the LC of patients with AD was identified (Bondareff et al., 1982). Atrophy of LC has been detected in mild cognitive impairment as well as in the case of AD. In addition, volumetric reduction of LC was seen in cognitively normal people who later progressed to a diagnosis of AD dementia (Dutt et al., 2020). Moreover, postmortem analysis has shown that LC is among the first brain regions where A β is deposited and NFT start to accumulate (Thal et al., 2002; Braak et al., 2011).

1.3.2.3 The Dopaminergic Hypothesis

Another catecholamine neurotransmitter, dopamine (DA), is also linked to the pathology of dementia. Dopaminergic neurons are mainly located in the substantia nigra and ventral tegmental areas (VTA), but can be found in raphe nuclei, hypothalamus and olfactory bulb (Fu et al., 2016; Pignatelli & Belluzzi, 2017; Fontaine et al., 2015; Lin et al., 2020).

More than 50% of AD patients have concomitant parkinsonism with DA system disorders, e.g. rigidity, resting tremor, and reduced DA transporter availability (Sasaki, 2018). Evidence from both an early-stage AD genetic mouse model (Tg2576) and AD

patients suggests that DA neurons in the VTA undergo degeneration (Nobili et al., 2017; De Marco & Venneri, 2018), which reduces hippocampal dopaminergic innervation (Spoletti et al., 2024). It has been hypothesized that diminished dopaminergic VTA activity may be pivotal for the earliest pathological features of AD (De Marco & Venneri, 2018). Behavioural and psychological symptoms of dementia are present since the earliest AD stages, and dopaminergic dysfunction likely plays a role in their manifestation (Serra et al., 2010). Dopaminergic system has a seizure-modulating effect (Bozzi & Borrelli, 2013), and it has been demonstrated that seizures can occur early in AD, even before memory problems become apparent (Vossel et al., 2013).

Additionally, reduced levels of DA and its receptors have been reported in the brains of AD patients and meta-analyses indicate that DA depletion is associated with faster cognitive decline (Storga et al., 1996; Karrer et al. 2017; Pan et al., 2019). Interestingly, a protective effect of DA and its derivatives on A β aggregation and toxicity has been demonstrated (Nam et al., 2018).

1.3.3 Metal Ion Hypothesis

The dyshomeostasis of metal ions has been implicated in a wide range of diseases, such as AD, Parkinson disease (PD), Wilson disease (WD), Menkes disease (MD), cardiovascular disease, and metabolic syndrome (Bush, 2003; Pyatha et al., 2022; Bandmann et al., 2015; Kaler, 2011; Ding et al., 2022). In the CNS, copper, iron, and zinc ions are essential enzyme cofactors, and are required for mitochondrial and neuronal function. In healthy brains, levels of free metal ions are strictly regulated, and their concentrations are very low. The metal ion hypothesis proposes that disruptions in the homeostasis and distribution of metal ions, especially copper, iron and zinc, contribute to AD by promoting A β deposition, tau hyperphosphorylation, neuronal death and neuroinflammation (Bush & Tanzi, 2008; Chen et al., 2023).

Recently, a new copper imbalance hypothesis has been proposed by Squitti et al. (Squitti et al., 2021). Although the dysregulation of Cu has been known to participate in AD for a long time, the authors theorize that the imbalance of copper due to a gradual shift from strongly protein-bound intracellular pools to extracellular pools of loosely bound toxic metal ions is among the contributing early drivers of AD. Supporting evidence includes findings of reduced total copper in AD brain tissue, elevated levels of non-ceruloplasmin-bound copper in serum and CSF, and correlations between increased labile copper and cognitive decline (James et al., 2012; Squitti et al., 2021).

1.4 The Role of Metals in the Brain and AD

Although various metals play essential roles in the human body, the dysregulated homeostasis of essential metals and exposure to non-essential metals may contribute to AD pathologies. Increased metal concentrations in the brain may lead to oxidative stress, neuroinflammation, A β aggregation, and tau hyperphosphorylation (Wallin et al., 2017; Ashok et al., 2015; Pathak & Sriram, 2023). Non-essential heavy metals such as lead, cadmium, mercury, and an essential heavy metal, manganese, affect cognitive function and may contribute to cognitive decline (Lee et al., 2022; Li et al., 2018; Xu et al., 2018; Menezes-Filho et al., 2011).

Studies have shown that the homeostasis of essential metals, especially iron, zinc, and copper, is altered in AD, and high concentrations of these metal ions have been found in amyloid plaques of AD patients' brains (Miller et al., 2006). Many regions of A β and

domains of APP bind metal ions, especially zinc and copper ions, with high affinity (Faller & Hureau, 2009; Bush et al., 1993; Hesse et al., 1994). In addition, calcium and magnesium ions have also been implicated in AD pathogenesis (Casella & Cecchi, 2021; Du et al., 2022).

Redox active metal ions, iron and copper, can catalyse the production of ROS, and especially of hydroxyl radical ($\text{HO}\cdot$), via Fenton or Haber-Weiss reactions. The Fenton reaction describes the formation of the most toxic and reactive $\text{HO}\cdot$ by a reaction between Fe^{2+} and H_2O_2 . In the Haber-Weiss reaction, iron catalyses the generation of $\text{HO}\cdot$ and OH^- from the reaction of H_2O_2 and O_2^- . Although these reactions were initially discovered with the participation of iron, they also proceed with other metals, including copper, but may sometimes be named slightly differently, such as Fenton-like (Meyerstein, 2021). In general, the brain is more vulnerable to oxidative stress than other organs due to its high lipid content, low levels of antioxidants, and extremely high energy requirements (Lee et al., 2020). Even though the brain represents about 2% of total body weight, it accounts for about 20% of the body's oxygen consumption (Koeppen, 1999).

Iron is the most abundant trace element in the human body. In the brain, iron is involved in oxygen transport, mitochondrial respiration, DNA synthesis, myelin synthesis, and both the synthesis and metabolism of neurotransmitters (Ward et al., 2014). The concentration of iron in the brain is approximately 0.72 mM. Brain iron levels increase with aging and abnormal iron accumulation has been observed in different regions of the AD brain (Acosta-Cabronero et al., 2016). In amyloid plaques, the concentration of iron is approximately 0.94 mM (Lovell et al., 1998). Iron dyshomeostasis may cause oxidative stress in the brain, leading to cellular damage. Studies have found intracellular iron accumulation before the formation of amyloid plaques (Smith et al., 1997). In 2012, a novel iron-dependent cell death termed ferroptosis was discovered by Dixon et al. (Dixon et al., 2012), and it has been hypothesized to have a role in AD progression (Bao et al., 2021).

Zinc is the second most abundant trace element in the body. In the brain, zinc is a structural or functional component of many essential proteins and an important regulator of synaptic activity and neuronal plasticity (Li et al., 2022). The brain contains approximately 1.5% of the total body's zinc. The concentration of Zn in serum is approximately 15 μM , while in the brain it is 10 times higher, reaching 150 μM (Takeda, 2000). In amyloid plaques the concentration of zinc can be as high as 1 mM (Lovell et al., 1998). Zinc protects cells from oxidative stress by increasing the synthesis of a powerful antioxidant glutathione (Cortese et al., 2008). On the other hand, increased intracellular zinc levels may induce neuronal death by inhibiting mitochondrial energy production (Sheline et al., 2000; Brown et al., 2000). More than 2-fold increase in zinc levels has been detected in AD brains compared with normal control subjects (Religa et al., 2006).

Copper is the third most abundant trace element in the body, and the brain contains approximately 9% of the total body's copper (Zatta et al., 2008). In the brain, it is crucial for both general and more brain-specific metabolic processes, acting as a cofactor for enzymes involved in energy metabolism (cytochrome c oxidase), neurotransmitter biosynthesis (dopamine β -hydroxylase), iron metabolism (ceruloplasmin), antioxidant defence (SOD1), etc (Arredondo & Núñez, 2005). The concentration of copper ions in amyloid plaques is approximately 0.4 mM (Lovell et al., 1998).

1.4.1 The Role of Copper in AD

Copper is an essential trace element that is vital for the proper functioning of all organisms. Copper is mainly present in two redox states, Cu(I) and Cu(II). It is closely associated with the oxidative stress hypothesis of AD, which proposes that the imbalance between ROS production and antioxidant defence is a key driver of neurodegeneration (Butterfield & Halliwell, 2019; Roy et al., 2023). As a redox-active metal, copper can catalyse Fenton-like reactions that convert H_2O_2 into highly reactive $HO\cdot$, thereby exacerbating oxidative damage and promoting A β aggregation, tau hyper-phosphorylation, and mitochondrial dysfunction (Barnham et al., 2004; Bagheri et al., 2018). Copper metabolism must be tightly regulated to provide a sufficient supply for the metalation of cuproenzymes and, on the other hand, to prevent copper-induced oxidative stress. Generally, optimal copper levels are necessary for normal brain functioning, and imbalance may lead to disease. Two of the best-studied disorders related to impaired copper metabolism are MD and WD, of which MD is caused by ATP7A mutations leading to copper deficiency and WD is caused by ATP7B mutations leading to copper overload (Bull et al., 1993). AD is somewhere in between, as AD patients show decreased levels of copper in the brain tissues and increased levels of copper in blood serum and CSF (Squitti et al., 2021; Grotto & Glaser, 2024; Hozumi et al., 2011).

In humans, copper is unevenly distributed in the brain, and its levels generally decline with age (Bonilla et al., 1984). Highest copper levels are found in the LC, substantia nigra, and hippocampus (Warren et al., 1960). In AD patients, reduced copper levels have been observed in the hippocampus and amygdala, which are associated with learning and memory and usually show severe histopathological alterations (Deibel et al., 1996). Some studies even suggest that higher brain copper levels may protect from cognitive decline (Agarwal et al., 2022).

Copper enters the brain through the blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier (BCB). BBB cells express copper transporters CTR1, ATP7A, and ATP7B. CTR1 is responsible for copper uptake. The efflux of copper from brain cells is mainly mediated by ATP7A and ATP7B, which are regulated by copper levels. The role of ATP7B is less clear; it may also be involved in copper buffering (Roy & Lutsenko, 2024). Copper uptake can be alternatively mediated by non-specific divalent metal transporter 1 (DMT1). Because free copper ions can generate ROS, excess cellular copper in the brain is safely stored through binding to copper chaperones and metallothioneins (Tapia et al., 2004). In the extracellular space, copper can be taken up by neighbouring cells or cleared into the CSF (Ohrvik & Thiele, 2014; Monnot et al., 2012). Under physiological conditions, the concentration of free copper ions is very low – less than one per cell (Rae et al., 1999).

Historically, the prevailing view was that copper bound to A β in amyloid plaques contributed to AD pathogenesis mainly through redox cycling between Cu(I) and Cu(II), generating ROS and promoting oxidative stress (Opazo et al., 2002; Cheignon et al., 2018). However, more recent studies have refined this understanding. It has been shown that in plaques, copper preferentially binds to N-terminally truncated A β species such as A β ₄₋₄₀ or A β ₄₋₄₂, which contain a high-affinity ATCUN binding site. These truncated peptides exhibit sub-picomolar affinity for Cu(II) and form redox-inactive complexes that significantly suppress ROS generation compared to full-length A β (Stefaniak & Bal, 2019). This suggests that the plaque-bound pool of copper is largely redox-silent, and that the redox-active, potentially toxic copper species in AD are more likely to reside in soluble or loosely bound pools rather than in the fibrillar plaque core.

Copper is implicated in multiple disease processes and pathological mechanisms. In AD brains, increased levels of loosely bound labile copper have been reported (James et al., 2012). As evidence points to A β oligomers as key neurotoxic species, Cu(II) may stabilize these oligomeric states and modulate their generation (Sharma et al., 2013). Copper is also involved in tau pathology as it can bind tau and potentially initiate tau hyperphosphorylation and fibril formation, leading to synaptic failure and neuronal death (Bacchella et al., 2020). Additionally, decreased levels or activity of several copper-binding proteins, including superoxide dismutase 1 (SOD1), cytochrome c oxidase, and metallothionein-3 have been reported in AD (Murakami et al., 2011; Morais et al., 2021; Yu et al., 2001). Presenilins, which mediate the proteolytic cleavage of APP, can promote cellular uptake of copper (Southon et al., 2013; Greenough et al., 2011). Furthermore, excessive dietary copper intake from drinking water and supplements has been proposed as a contributing factor to AD development (Brewer, 2019).

1.5 Risk Factors and Prevention of AD

While some risk factors like age and genetics cannot be changed, other factors can be managed to help reduce the risk of getting AD. As with many other diseases, a healthy lifestyle helps decrease the risk of developing AD. A 2024 report published in *The Lancet*, found that nearly half of global dementia cases could be delayed or prevented by eliminating, treating, or reducing 14 risk factors (Livingston et al., 2024). These risk factors are a lower level of education, hearing loss, hypertension, physical inactivity, diabetes, social isolation, excessive alcohol consumption, air pollution, smoking, obesity, traumatic brain injury, depression, high LDL cholesterol, and untreated vision loss.

In addition, various nutritional interventions may improve cognitive functions and slow the progression of AD. Healthy eating, especially Mediterranean diet, appears to reduce the risk of cognitive decline (Carcía-Casares et al., 2021). Gut microbiota is also associated with cognitive functioning through the gut-brain axis (González Cordero et al., 2022). Studies show that AD patients appear to have lower plasma levels of carotenoids, vitamins A, C, and E (Qu et al., 2021; Mullan et al., 2018; Hamid et al., 2022). Vitamin B supplementation is associated with slowing cognitive decline (Wang et al., 2022) and vitamin D supplementation may also reduce dementia and AD risk (Zhang et al., 2024). Moreover, levels of some micronutrients are significantly lower even in the brains of AD patients, further indicating the importance of a healthy diet and proper supplementation (Dorey et al., 2023).

Genetic testing and personalized medicine are also emerging and may prove to be useful early preventive measures. Recent findings indicate that approximately 95% of APOE4 homozygotes exhibit preclinical signs of AD that were evident nearly 20 years before clinical AD diagnosis (Forte et al., 2024).

1.6 Treatment of AD

To date, there is no effective treatment to prevent or halt the progression of AD. Thus, drugs that can prevent AD or cease its progression are urgently needed. As of January 1, 2024, there were 164 clinical trials assessing 127 drugs (Cummings et al., 2024).

Currently used drugs are divided into two groups, symptom-relieving drugs and drugs that change the progression of the disease (**Table 1**). Three of the five symptom-relieving drugs are cholinesterase inhibitors: donepezil, rivastigmine, and galantamine. The fourth,

memantine, is an NMDA receptor antagonist that regulates glutamate activity, and the fifth, Namzaric, is a combination of cholinesterase inhibitor donepezil and glutamate regulator memantine (2024 Alzheimer’s disease facts and figures, 2024).

Table 1. Currently approved and used AD drugs and their mechanisms of action.

Drug	Target	Description	References
Symptom-relieving drugs			
Donepezil	Acetylcholinesterase	Increases ACh levels by inhibiting its breakdown in the synaptic cleft	Rogers & Friedhoff, 1996
Rivastigmine	Acetylcholinesterase, butyrylcholinesterase	Increases ACh levels by inhibiting both acetylcholinesterase and butyrylcholinesterase	Nordberg et al., 2013
Galantamine	Acetylcholinesterase, nicotinic receptors	Increases ACh levels and enhances nicotinic receptor activity	Coyle & Kershaw, 2001
Memantine	NMDA receptor	Antagonizes NMDA receptors to regulate glutamate activity, reducing excitotoxicity	Tampi et al., 2007
Namzaric	Acetylcholinesterase, NMDA receptor	Combination drug of Donepezil & Memantine targeting cholinergic dysfunction and glutamate activity	Deardorff & Grossberg, 2016
Anti-amyloid therapies			
Aducanumab*	Aggregated forms of A β	Monoclonal antibody (mAB) binding to aggregated soluble and insoluble forms of A β	Dhillon, 2021
Lecanemab	Soluble A β protofibrils	mAB targeting soluble A β protofibrils to reduce neurotoxic aggregation	Van Dyck et al., 2023
Donanemab	A β plaques	mAB targeting a specific A β epitope (N3pG) to promote plaque clearance	Shukla & Misra, 2023

*Although aducanumab is no longer in clinical use since 2024, it played a pivotal role as the first disease-modifying therapy to receive FDA approval for AD.

The use of drugs that change disease progression started in June 2021, when an accelerated approval was given to a new drug, aducanumab, which helps to reduce amyloid deposits in the brain and may therefore help to slow the progression of AD. This was the first treatment to affect the underlying cause of the disease, although it has not been shown to affect clinical outcomes, e.g., cognitive decline (Dhillon, 2021).

Lecanemab is the second amyloid-targeting drug approved by the FDA in 2023 that is used to treat early AD or mild dementia due to AD with elevated brain A β (van Dyck et al., 2023; U.S. Food and Drug Administration, 2023). In 2024, the third anti-amyloid drug donanemab received approval from the FDA. Poor clinical improvement of anti-amyloid therapies and unknown long-term side effects suggest that amyloid may not be the optimal target (Piller, 2022; Dantas et al., 2024).

In addition to pharmacological treatments, non-drug interventions such as physical activity, memory exercise, music and art-based therapies, and dancing have been shown to support cognitive function and improve daily living in individuals with AD (2024 Alzheimer's disease facts and figures, 2024; De la Rosa et al., 2020).

1.6.1 Metalloregulatory Clinical Trials

The restoration of metal homeostasis may be one way to treat AD and various metalloregulatory approaches have already been tested. One approach is taking metal supplements. Although several studies have proposed a positive effect of Cu and Zn supplementation on cognitive performance, the improvement of cognitive function has not been confirmed (Bagheri et al., 2018). A pilot phase 2 clinical trial did not show any effect of oral copper supplementation on cognition in mild AD patients (Kessler et al., 2008). In a six-month randomized, double-blind trial of a novel zinc formulation, participants aged 70 years or older showed slower cognitive decline and reduced serum free copper compared with placebo group (Brewer & Kaur, 2013; National Library of Medicine, 2011). A phase II trial registered in the EU Clinical Trials Register evaluated zinc sulphate in individuals with prodromal AD but was ended prematurely without published results (European Medicines Agency, 2019).

Another approach is the chelation of excess Zn, Cu, or Fe ions. Although high-affinity chelators may be very effective, they may also remove metals from essential metalloproteins and pathways. Because metals are critical to many vital cellular processes, the chelator must be carefully selected, and metal ionophores are preferred. Several copper ionophores have been tested, but unfortunately, they are not effective enough without severe side effects. Clioquinol, a moderate chelator of Cu, Zn, and Fe, has been tested in phase 2 clinical trials (Ritchie et al., 2003). Although it decreased A β aggregation and improved the cognitive behaviour of mice, it was banned due to neurotoxicity. PBT2, a derivative of clioquinol, showed improvement in the learning and memory capacity of APP transgenic mice and was proposed as a candidate disease-modifying drug. Unfortunately, it did not show significant results in phase 2 trials either (Adlard et al., 2008; Villemagne et al., 2017).

Recently, a phase 2 clinical trial studied the effect of iron chelator deferiprone on cognitive decline in AD (U.S. National Library of Medicine, 2017). Results presented at Alzheimer's Association International Conference in August 2024 revealed that deferiprone treatment caused significant acceleration of cognitive decline. It could be discussed whether the dose was inappropriate, or iron is important for cognition in AD (Alzheimer's Association, 2024).

Considering the inefficacy of synthetic chelators and the occurrence of adverse effects, it is necessary to identify better alternatives for the restoration of metal homeostasis in AD.

1.6.2 Alpha-Lipoic Acid

Alpha-lipoic acid (α -LA), is a naturally occurring antioxidant that is endogenously synthesized, found in several foods, and available as a dietary supplement. It has been considered a promising substance for the prevention and treatment of neurodegenerative disorders, including AD. The antioxidant properties of α -LA include ROS scavenging, regeneration of endogenous antioxidants, repair of oxidative damage, and metal chelating capacity (Biewenga et al., 1997). α -LA shows antioxidant, anti-inflammatory, antiapoptotic, glioprotective, and metal chelating properties in both *in vivo* and *in vitro* studies (Kaur et al., 2021). Furthermore, α -LA has been shown to reverse age-associated loss of neurotransmitters, e.g. DA, NA, serotonin, and their receptors (Arivazhagan & Panneerselvam, 2002).

α -LA functions as a cofactor in several mitochondrial multienzyme complexes, including the glycine decarboxylase complex, pyruvate dehydrogenase complex, α -ketoglutarate dehydrogenase complex, branched-chain α -ketoacid dehydrogenase complex (Solomonson & DeBerardinis, 2018). This role depends on lipoylation, a process in which α -LA is covalently attached to specific lysine residues of these enzymes (Rowland et al., 2018). Structurally, α -LA contains two sulfhydryl groups, which can be oxidized to form a disulfide bond (**Figure 3**). Its reduced form, dihydrolipoic acid (DHLA), predominates in the intracellular reducing environment and exhibits stronger antioxidant and metal-chelating activity compared to α -LA. While both α -LA and DHLA can scavenge ROS, only DHLA can repair oxidative damage and regenerate endogenous antioxidants such as vitamins C, E, and glutathione (Biewenga et al., 1997).




Figure 3. The oxidized and reduced forms of lipoic acid. The figure was created with BioRender.

α -LA exists as two optical isomers: the R- and S- enantiomers. Only the R-enantiomer is endogenously synthesized and can be covalently bound to proteins via lipoylation. Most commercial supplements contain a racemic mixture of R- and S-lipoic acid (Shay et al., 2009). α -LA is absorbed from the diet and can easily cross the BBB (Biewenga

et al., 1997). Although the exact mechanisms of its cellular uptake remain unclear, α -LA is believed to be transported via several pathways, including the proton-linked monocarboxylic acid transporter and the sodium-dependent multivitamin transporter (SMVT) (Takaishi et al., 2007; Zehnpfennig et al., 2015).

Beyond its antioxidant properties, α -LA role in mitochondrial metabolism also links it to copper homeostasis. Recent study by Tsvetkov et al. demonstrated that copper binds with very high affinity to the lipoyl groups of TCA cycle enzymes, causing their aggregation, disruption of iron-sulfur cluster proteins, and mitochondrial dysfunction, leading to a distinct form of cell death termed cuproptosis. This mechanism highlights the central role of lipoylation in copper biology and mitochondrial integrity, both of which are altered in AD (Tsvetkov et al., 2022).

α -LA has been studied for its potential therapeutic applications across a range of health conditions. It was first proposed as an effective antioxidant due to its ability to prevent the deficiency symptoms of vitamins C and E (Rosenberg & Culik, 1959). It is currently used in the treatment of diabetic polyneuropathy (Ziegler et al., 2004) and has also been used in managing hepatic diseases (Berkson, 1999). A 2018 meta-analysis found that α -LA supplementation significantly reduced fasting glucose, insulin, hemoglobin A1c, triglycerides, total- and low-density lipoprotein-cholesterol levels in individuals with metabolic disorders (Akbari et al., 2018). Another clinical trial demonstrated beneficial effects of α -LA supplementation on blood pressure (Vajdi et al., 2023). In a 16-month trial in patients with mild to moderate AD, 600 mg/day α -LA was associated with slower cognitive decline, with the greatest improvements seen in patients with insulin resistance (Fava et al., 2013). In a small, randomized, placebo-controlled pilot trial, a combination of omega-3 fatty acids and α -LA was shown to slow cognitive and functional decline in patients with AD (Shinto et al., 2014). In animal models, dietary supplementation with α -LA improved memory and learning and reduced hippocampal-dependent memory deficits of aged Tg2576 mice, without affecting A β levels (Quinn et al., 2007).

Despite these findings, the exact mechanism by which α -LA may influence copper metabolism and neurodegenerative processes remain unclear.

1.7 Models to Study AD

1.7.1 Cellular Models of AD

A variety of *in vitro* cellular models are widely used to investigate the pathology and progression of AD, as well as for drug screening. Among them are primary neuronal cultures, induced pluripotent stem cells (iPSCs), 3D-cell models, and cancer cell lines, including rat PC12 cells, mouse Neuro-2A cells, and human neuroblastoma SH-SY5Y cells (Choi et al., 2016).

The SH-SY5Y cell line is a thrice-cloned subline of SK-N-SH cell line originally derived from a metastatic bone marrow biopsy of a female neuroblastoma patient. It serves as a good model for the study of neurodegenerative disorders since the cells can be differentiated into various neuronal phenotypes in response to specific chemical compounds. Neuroblastoma cell lines are generally comprised of three different cell types: neuroblastic N-type, non-neuronal epithelial- or glial-like S-type, and intermediate I-type cells (Ross et al., 1995; Campos Cogo et al., 2020). The SH-SY5Y line is primarily derived from N-type cells, but there are also several other cells present, making it a heterogeneous culture (Bell et al., 2013).

Undifferentiated SH-SY5Y cells exhibit low expression of ChAT and tyrosine hydroxylase (TH), markers of cholinergic and dopaminergic neurons, respectively (Kovalevich & Langford, 2013). However, various studies have managed to differentiate SH-SY5Y cells toward cholinergic, noradrenergic, dopaminergic, and more recently, glutamatergic phenotypes (Martin et al., 2022). Cell treatment with retinoic acid (RA) followed by BDNF increases the expression of ChAT and VACHT, and activity of acetylcholinesterase (AChE), indicative of cholinergic differentiation (**Figure 4**) (Goldie et al., 2014). Sequential treatment with RA followed by phorbol esters (TPA, MPA) induces a dopaminergic phenotype, as evidenced by increased TH and dopamine transporter (DAT) expression, and elevated dopamine D2 and D3 receptor levels (Avola et al., 2018; Presgraves et al., 2004). Dibutyl cAMP treatment promotes noradrenergic differentiation, indicated by increased TH expression and NA content (Kume et al., 2008).




Figure 4. Comparison of undifferentiated and differentiated SH-SY5Y cells. The figure was created with Canva.

Although SH-SY5Y cells differentiated into different neuronal phenotypes using previously mentioned agents have been used in various experiments (Pifferi et al., 2024; Presgraves et al., 2004; Arun et al., 2006), their susceptibility to A β has not been thoroughly studied or compared.

1.7.2 *Drosophila Melanogaster* as a Model Organism

The fruit fly *Drosophila melanogaster* has been used as a model organism for genetic studies longer than any other. There are many advantages of using *Drosophila* as a model organism. It has a short lifespan, requires only 9 days to progress from a fertilized egg to an adult, and the maintenance and breeding are cheap and easy. More than 76% of the genes that cause human diseases have a homolog in fruit flies, and mutants can now be obtained for essentially any gene (Reiter et al., 2001). Neurodegenerative diseases, including AD, can be easily modeled using *Drosophila*, and several different transgenic lines have been generated that can be bought from stock centers, e.g., Bloomington Drosophila Stock Center. The most widely used AD models are flies expressing human A β , which are generated using UAS-GAL4 system (Nitta & Suggie, 2022). This two-component system is based on crossing a driver line that provides cell- or tissue-specific GAL4 expression with a responder line carrying human A β under the control of Upstream Activation Sequence (UAS) that binds GAL4. When these two lines are crossed, GAL4 binds to UAS and A β is expressed in the desired cells or tissues in the progeny (Brand & Perrimon, 1993).

Different phenotypes and markers can be measured in AD fly models. Longevity measurement is a great indicator of a fly's overall viability and neurological health. Behavioral assays, e.g. negative geotaxis assay (**Figure 5**), and aversive phototaxis suppression assay, represent a good method to measure locomotor activity, learning, and memory functions in *Drosophila* (Ali et al., 2011).




Figure 5. Negative geotaxis experiment setup. Fruit flies have a natural upward climbing behaviour after being tapped to the bottom of a test tube. Healthy flies climb up quickly, but diseased flies remain at the bottom of the test tube. The figure was created with Canva.

Drosophila eye is also an excellent model system. While the normal compound eye of a fruit fly consists of regularly arranged ommatidia, mutations and toxic compounds can disrupt it and lead to different eye phenotypes, e.g. rough or smooth (Finelli et al., 2004).

AD model flies have been used in various types of experiments. It has been shown that the expression of A β 42 in the brain reduces the lifespan of flies and induces a rough eye phenotype that worsens with age (Finelli et al., 2004). *Drosophila* AD models have been used to study the influence of metal ions on A β -induced neurodegeneration (Ott et al., 2015; Hua et al., 2011; Singh et al., 2013; Rival et al., 2009). Singh et al showed that feeding flies expressing human A β 42 with copper-supplemented food caused severe eye degeneration with dark patches and a novel copper chelator, which they called compound L, rescued this severe phenotype (Singh et al, 2013). Rival et al. showed that flies expressing A β 42 were more sensitive to oxidative stress and had also higher levels of oxidative damage compared to control flies and flies expressing A β 40 (Rival et al., 2009). They also showed that iron-binding protein ferritin suppressed the toxicity of A β 42 and restored the survival and locomotion function to normal. In their experiments, clioquinol increased the lifespan of A β 42-expressing flies and reduced iron levels in the brain. Hua et al showed that dietary supplementation with zinc and iron exacerbated eye damage caused by eye-specific A β 42 expression, but the administration of metal chelators DP-109 or bathocuproine sulphonate (BCS) were able to ameliorate it (Hua et al., 2011).

Aims of the Study

1. To develop a differentiated neuron-like SH-SY5Y cell culture suitable for the studies of A β toxicity and screening of potential therapeutic compounds.
2. To compare the susceptibility of three different neuron-like cell types, cholinergic, noradrenergic, and dopaminergic, to A β toxicity.
3. To investigate the effect of α -lipoic acid on copper translocation in neuron-like SH-SY5Y cell culture.
4. To study the effect of α -lipoic acid in *Drosophila melanogaster* AD model.

Materials and Methods

The following methods, described in more detail in the respective articles, were used in the study:

- Cultivation and differentiation of SH-SY5Y cell line (Publications I, II, III)
- WST-1 assay for cell viability assessment (Publications I, II)
- Propidium iodide (PI) staining for the detection of dead/permeabilized cells (Publication I, II, III)
- Measurement of caspase activity (Publication I)
- Preparation of A β peptides for experiments (Publications I, II)
- Immunocytochemistry (Publications I, II)
- Microscopy (Publications I, II, III)
- Assessment of neurite abnormalities through image analysis (Publication I)
- ICP-MS analysis (Publication III)
- Breeding and crossing of *Drosophila melanogaster* (Publication III)
- Feeding and maintenance of *Drosophila melanogaster* (Publication III)
- Negative geotaxis experiments with *Drosophila melanogaster* (Publication III)
- Scanning Electron Microscopy (SEM) for evaluation of eye phenotype in *Drosophila melanogaster*

Results

Publication I

- The toxicity of A β 40 and A β 42 was compared in undifferentiated and RA/BDNF-differentiated SH-SY5Y cells after 48 and 72 hours of incubation. The results are as follows:
 - 20 μ M A β 40 had no toxic effect on undifferentiated cells at either 48 or 72 hours, as assessed by the WST-1 cell viability assay and PI staining. In fact, after 48 hours, cell viability increased by 11%.
 - 20 μ M A β 42 reduced viability of undifferentiated cells by 16% after 48 hours, but did not affect cell permeability. However, after 72 hours, 20 μ M A β 42 did not alter cell viability but increased cell permeability by 30%.
 - 20 μ M A β 40 had no statistically significant effect on RA/BDNF-differentiated cells at either 48 or 72 hours.
 - 20 μ M A β 42 did not significantly affect RA/BDNF-differentiated cells after 48 hours. However, the highest toxicity was observed after 72 hours, where A β 42 caused a 42.7% reduction in cell viability and a 50% increase in cell permeability.
- Overall, RA/BDNF differentiation of SH-SY5Y cells increased susceptibility to A β peptide toxicity compared to undifferentiated cells.
- A β 42 induced apoptosis of differentiated SH-SY5Y cells, whereas A β 40 did not, as determined with caspase-3/7 activity measurement.
- Both A β 40 and A β 42 induced neurite beading and fragmentation in differentiated cell culture, but A β 42 had a much more pronounced effect.
- A β 42 aggregates covered both cell bodies and neurites, whereas the less amyloidogenic A β 40 partially covered only the cell bodies, as determined by immunocytochemistry.
- Fibrillar aggregates were present in the cell culture exposed to A β 42 after 48 hours but not in the cell culture exposed to A β 40.
- The addition of preformed A β 42 fibrils to differentiated cells did not result in toxicity.

Publication II

- Differentiation of SH-SY5Y cells using three different protocols (RA/BDNF, RA/TPA, dbcAMP) induced β -III tubulin positive neurite outgrowth and network formation.
- The RA/BDNF-differentiated culture was the most homogenous, whereas dbcAMP and RA/TPA-differentiated cultures contained small populations of undifferentiated cells.
- The toxicity of 10 μ M and 20 μ M A β 42 after 48 hours of incubation was compared in undifferentiated and differentiated SH-SY5Y cells. The results are as follows:
 - 10 μ M A β 42 did not affect cell viability or membrane permeability in undifferentiated SH-SY5Y cells, as determined by the WST-1 cell viability assay and PI staining, respectively. However, 20 μ M A β 42 decreased cell viability by 43% and increased dead cell count by 1.8-fold.
 - Noradrenergic dbcAMP-differentiated cells were most sensitive to A β 42 toxicity in a concentration-dependent manner. At 10 μ M A β 42, viability decreased by 49%, and cell permeability increased by 1.37-fold. At 20 μ M A β 42, viability

- decreased by 63%, and dead cell count increased by 1.94-fold compared to control.
- Cholinergic RA/BDNF-differentiated cells were also sensitive to A β 42 toxicity after 48 hours, although the effect was independent of concentration. At 10 μ M A β 42, viability decreased by 41%, and cell permeability increased by 1.84-fold. At 20 μ M A β 42, viability decreased by 23%, and dead cell count increased by 1.61-fold.
 - Dopaminergic RA/TPA-differentiated cells were resistant to A β 42 toxicity after 48 hours, with no statistically significant effect observed at either 10 μ M or 20 μ M concentrations.
 - Although sensitivities of the differentiated cultures to A β 42 varied, the peptide uniformly covered cell bodies and neurites in all cell cultures.

Publication III

- α -lipoic acid facilitated the distribution of copper from the extracellular to the intracellular space in SH-SY5Y cell cultures in a concentration-dependent manner.
- Two copper chelators used in the treatment of WD were also studied, but did not exhibit similar results with α -lipoic acid:
 - D-penicillamine did not affect intracellular copper concentration
 - Trientine decreased intracellular copper concentration
- The ability of α -lipoic acid to redistribute copper was more pronounced in RA/BDNF-differentiated, neuron-like SH-SY5Y cells compared to undifferentiated cells.
- α -lipoic acid and trientine did not exhibit toxicity alone or in the presence of copper ions as determined with PI staining. However, D-penicillamine was toxic in the presence of copper ions.
- Supplementation with α -lipoic acid protected a *Drosophila melanogaster* AD model expressing A β with the Iowa mutation from developing the AD phenotype, but it did not reverse an already established phenotype.
- α -lipoic acid slightly alleviated copper-induced smooth eye defects in *Drosophila melanogaster* AD model.

Discussion

In the current study, SH-SY5Y cells were used to explore various aspects related to AD at the cellular level. The cells were induced to become more neuron-like by treatment with agents that have previously been shown to promote different neuronal phenotypes.

SH-SY5Y cells are commonly used in neurodegenerative disease research, however, they are typically utilized in their undifferentiated state, which does not accurately replicate the characteristics of real neurons. First, in Publication I, the effects of A β 40 and A β 42 were studied in both undifferentiated and differentiated SH-SY5Y cells. Differentiation was achieved using RA and BDNF, which are known to induce a cholinergic neuronal phenotype (de Medeiros et al., 2019). The differentiation resulted in a neuron-like culture with long beta-III tubulin-positive neurites and inhibited proliferation. RA/BDNF-differentiated SH-SY5Y cells were more sensitive to A β toxicity compared to undifferentiated cells, as evidenced by cell viability measurement with WST-1 and PI staining. The fact that undifferentiated cells continue to proliferate may also affect viability measurements. A β 42 was found to exhibit higher toxicity than A β 40, inducing apoptotic cell death as measured by caspase 3/7 activity. Similar results have been observed in primary cultured mouse cerebral cortical neurons by Han et al. who demonstrated that A β 42 induces apoptosis via the caspase pathway (Han et al., 2017). However, in primary cultured rat cortical neurons, Boland et al. showed that A β 40 also induces apoptotic cell death, but through a Ca²⁺-dependent protease, calpain, suggesting that A β 40 may activate a different apoptotic pathway (Boland et al., 2003). Although both peptides, A β 40 and A β 42, induced neuronal abnormalities, such as beading and fragmentation, the effect was more pronounced with A β 42.

The question of which form of A β is the most toxic has been the subject of long debate. In the 1990s, when the amyloid cascade hypothesis was proposed, neurotoxicity was primarily attributed to large, insoluble A β fibrils (Hardy & Higgins, 1992). Later, A β oligomers were thought to be the main culprits of neuronal damage (Lambert et al., 1998), and until now, toxicity is primarily attributed to A β oligomers and protofibrils. Some studies suggest even a protective role for amyloid accumulation and deposits (Rischel et al., 2023; Huang et al., 2021). In our experiments, mature fibrils did not show acute toxicity toward cultured cells, whereas toxicity emerged during fibril formation (Publication I). Nevertheless, these results do not exclude the possibility that mature fibrils could have other, potentially harmful effects *in vivo*.

Since A β peptides tend to self-assemble, the method used to prepare these peptides for toxicity experiments has a significant impact on the results. In Publication II, a slightly modified peptide preparation protocol was implemented, which resulted in increased toxicity. In contrast to the initial protocol used in Publication I, where HFIP-pretreated peptides were dissolved at neutral pH, the protocol in Publication II involved incubating the HFIP-treated aliquots in 10 mM NaOH on ice. Such alkali conditions were applied to reduce pre-aggregates in the solution and achieve a more uniform monomeric peptide composition. Previous studies have shown that NaOH pretreatment increases the proportion of low molecular weight A β species, such as monomers and dimers (Fezoui et al., 2000), which may explain the increased toxicity.

Considering the complexity of AD and knowing that various types of neurons are destroyed in the disease, in Publication II we aimed to model different neuronal phenotypes to investigate the effect of A β on these distinct cell types. Our experiments focused on A β 42, as it exhibited higher toxicity in our initial cell culture model used in

Publication I. Several agents can be used to differentiate SH-SY5Y cells into more mature neuronal cells. In addition to the RA/BDNF differentiation method used in Publication I, we employed two additional differentiation protocols to study the effects of A β 42. DbcAMP was used to induce a noradrenergic neuronal phenotype, while RA followed by TPA was used to induce a dopaminergic neuronal phenotype in SH-SY5Y cells. We found that cholinergic and noradrenergic cultures were more vulnerable to A β toxicity, which aligns with the observation that noradrenergic and cholinergic neurons are among the first to degenerate in AD (Mann et al., 1980; Zarow et al., 2003; Ferreira-Vieira et al., 2016). Interestingly, 10 μ M A β 42 exhibited greater toxicity than 20 μ M A β 42 in RA/BDNF-differentiated cholinergic cells, whereas in other differentiation routes, toxicity followed a concentration-dependent pattern. This effect may be attributed to differences in A β 42 aggregation dynamics, cellular receptor expression, and membrane interactions specific to RA/BDNF differentiation. Differentiation agents may affect the cell's gene expression and function in distinct ways, which can influence their susceptibility to A β toxicity. DbcAMP has been shown to enhance A β -induced nitric oxide release, a known mediator of neurodegeneration (Pyo et al., 1999). In addition, it has been shown that dbcAMP increases the expression of APP, which could potentially lead to an increase in A β production (Sagy-Bross et al., 2015). However, other studies have suggested that dbcAMP can protect neurons from degeneration by promoting the production of BDNF (Abd-El-Basset & Rao, 2018). BDNF may enhance NMDA receptor function, and A β oligomers are known to interact with NMDA receptors, potentially mediating the toxic effects (Caldeira et al., 2007; Afonso et al., 2019; Ortiz-Sanz et al., 2022; Taniguchi et al., 2022). Looyenga et al. showed that RA/TPA differentiation of SH-SY5Y cells enhances resistance to the neurotoxic compound 6-OHDA toxicity compared to undifferentiated cells, which may help explain the results observed with A β (Looyenga et al., 2013). Some studies have shown that dopaminergic cells are generally more resistant to oxidative stress, which may account for their increased resistance to A β toxicity (Kweon et al., 2004; Nakamura et al., 2001). Better tolerance to oxidative stressors may mean that a longer incubation time is required to achieve a toxic effect with A β . A deeper understanding of how A β affects different neuronal cell types may provide insights into the mechanisms of neurodegeneration and lead to improved treatments for AD. Since different patients experience different symptoms based on the specific neurotransmitter system that is most affected, a one-size-fits-all approach may not be effective, and a more personalized or multi-targeted treatment strategy could improve the treatment outcomes.

A β has been the primary target for recent drug developments. One of the anti-amyloid drugs, lecanemab, targets preferentially soluble A β protofibrils. Other anti-amyloid drugs have been developed to target mainly amyloid plaques. However, the effectiveness of anti-amyloid therapies remains uncertain, as the link between amyloid removal and cognitive improvement has not been fully established. These therapies also have side effects, such as brain swelling and microhemorrhages, and their long-term efficacy is still under investigation (Salloway et al., 2022; Honig et al., 2024). Therefore, it is crucial to identify and study the upstream events preceding amyloid accumulation.

Given the increasing evidence implicating the role of copper in the pathogenesis of AD, we next investigated the effect of copper in cell culture. Our group has previously shown that a natural compound, reduced dihydro-lipoic acid, has a substantial Cu(I)-binding affinity (Smirnova et al., 2018). Since copper is misdistributed in AD, with deficiencies in the brain tissue and excess in plasma and serum (Squitti et al., 2021),

we aimed to explore whether α -LA could restore the normal copper balance and facilitate the transport of copper from the extracellular to the intracellular environment (Publication III). For that purpose, we used undifferentiated and cholinergic RA/BDNF-differentiated SH-SY5Y cell cultures. First, to exclude a potential toxicity of α -LA in the presence of copper ions, PI-staining was performed on differentiated cells. The study also included two copper chelators, DPA and TETA, commonly used in the treatment of WD. Individually, all tested agents and copper ions were non-toxic. Furthermore, α -LA and TETA remained non-toxic in the presence of copper ions. However, DPA exhibited toxicity at higher concentrations in the presence of copper. Interestingly, DPA treatment has been associated with neurological worsening in WD patients (Brewer et al., 1987; Kumar et al., 2022; Antos et al., 2023). Next, we studied the effect of α -LA and other chelators on the distribution of copper ions in cell culture and found that α -LA promoted the relocation of copper from the extracellular to the intracellular space in a concentration-dependent manner. The effect was more pronounced in neuron-like RA/BDNF-differentiated cells compared to undifferentiated cells. Unlike α -LA, other chelators did not exhibit similar effect. DPA had no impact on intracellular copper content, while TETA reduced intracellular copper levels.

Although technological advancements are progressing rapidly, the demand for accurate cell culture models remains high. Differentiated SH-SY5Y cells have become an essential model for studying AD due to their ability to mimic various neuronal phenotypes, including cholinergic, noradrenergic, and dopaminergic cells. Such models allow to explore the disease's complex molecular and cellular mechanisms and continue to play an important role in basic mechanistic research and early-stage drug screening, complementing more advanced models.

We also aimed to investigate the effect of α -LA *in vivo* using a *Drosophila* AD model. We conducted negative geotaxis locomotor activity experiments and found that α -LA supplementation helped to rescue *Drosophila melanogaster* AD models with the overexpression of human A β carrying the Iowa mutation from developing AD-like phenotype. However, α -LA had no effect on the phenotype once it had already developed, indicating only a preventive effect. Additionally, α -LA slightly alleviated the copper-induced smooth eye phenotype in a *Drosophila* AD model where APP and BACE1 were overexpressed in the eye photoreceptor cells. It is known that high doses of Cu negatively impact *Drosophila* development, viability, and locomotor behavior (Ding & Wang, 2006). Furthermore, Cu exposure has been shown to reduce memory retention in *Drosophila* (Zamberlan et al., 2020). Previous studies with α -LA in *Drosophila* have demonstrated its positive effects, including improved lifespan and resistance to oxidative stress in wild-type *Drosophila* (Chattopadhyay et al., 2024). Moreover, α -LA has been shown to improve motor activity and lifespan in a mutant hSOD1 *Drosophila* model of amyotrophic lateral sclerosis (Wang et al., 2018).

It is crucial to identify easily measurable biomarkers that can help detect AD in its early stages, as once the brain has already undergone significant degeneration, it becomes irreversible. Genetic testing and personalized medicine may also enable easier identification of individuals at risk. Studies have shown that a subset of AD patients with elevated copper levels carry a specific ATP7B haplotype, which may predispose them to copper imbalance (Squitti et al., 2021). Recently, the FDA approved a blood test for AD that offers a less invasive and more accessible diagnostic option. By measuring the key biomarkers, phosphorylated tau (pTau217) and A β 42, the test enables accurate detection

of AD pathology in individuals aged 55 and older with cognitive symptoms, supporting earlier diagnosis and timely intervention.

As the Danish philosopher Desiderius Erasmus wisely stated in the 1500s, “Prevention is better than cure” (Erasmus, circa 1500). This timeless insight emphasizes the importance of proactive measures in alleviating the onset and progression of AD. Considering the growing prevalence of AD and its multifactorial aetiology, it is crucial to prioritize strategies aimed at preventing or delaying its onset. A comprehensive approach to prevention, encompassing not only healthy lifestyle modifications but also appropriate nutritional and supplement interventions, plays a pivotal role in alleviating both the economic and societal burdens associated with this devastating disease. Given that α -LA is safe and already used as a dietary supplement, it could be suitable for AD prevention and could potentially benefit individuals with a genetic predisposition to copper imbalance or those in the early stages of AD. α -LA is a well-researched compound with a favorable safety profile and low toxicity, even at relatively high doses (Fogacci et al., 2020; Derosa et al., 2020). It has been widely used in the treatment of various conditions, such as diabetic peripheral neuropathy, where its antioxidant and neuroprotective properties are well documented (Han et al., 2012; Pingali et al., 2024). Given its established clinical use, α -LA is a promising repurposing drug candidate for the treatment of AD. Although several clinical studies have investigated the effect of α -LA on AD, the current evidence remains limited and inconclusive (Hager et al., 2007; Shinto et al., 2014; Galasko et al., 2012). Most trials have been small-scale, open-label or lacked accurate controls, making it difficult to make clearly defined conclusions about the efficacy of α -LA. To better evaluate the therapeutic effect of α -LA in AD, larger, well-designed, placebo-controlled clinical trials are needed.

Conclusions

- Human neuroblastoma SH-SY5Y cells can be differentiated into various types of neuron-like cells that resemble mature neurons both in appearance and chemical properties.
- Differentiation route of SH-SY5Y cells affects susceptibility to A β 42 toxicity: RA/BDNF-differentiated cholinergic cells and dbcAMP-differentiated noradrenergic cells are highly susceptible to A β toxicity, whereas RA/TPA-differentiated dopaminergic cells are resistant to A β .
- Experiments in cell culture and *Drosophila melanogaster* revealed that a natural compound α -lipoic acid has the potential to normalize dysregulated copper metabolism characteristic of AD:
 - 1) α -lipoic acid can translocate copper from extracellular environment to the cells in a concentration-dependent manner both in undifferentiated and RA/BDNF-differentiated cholinergic SH-SY5Y cells, however, the effect was greater in differentiated cells.
 - 2) α -lipoic acid protected AD model flies from developing AD-like phenotype.
 - 3) α -lipoic acid slightly weakened copper-induced eye defects in AD model flies.
- Differentiated SH-SY5Y cells and *Drosophila melanogaster* provide good models to study different aspects of AD and to screen new potential therapeutic agents at the cellular and organismal level.

References

- 2024 Alzheimer's disease facts and figures. (2024). *Alzheimer's & dementia: the journal of the Alzheimer's Association*, 20(5), 3708–3821. <https://doi.org/10.1002/alz.13809>
- Abd-El-Basset, E. M., & Rao, M. S. (2018). Dibutyl Cyclic Adenosine Monophosphate Rescues the Neurons from Degeneration in Stab Wound and Excitotoxic Injury Models. *Frontiers in neuroscience*, 12, 546. <https://doi.org/10.3389/fnins.2018.00546>
- Acosta-Cabronero, J., Betts, M. J., Cardenas-Blanco, A., Yang, S., & Nestor, P. J. (2016). In Vivo MRI Mapping of Brain Iron Deposition across the Adult Lifespan. *The Journal of neuroscience: the official journal of the Society for Neuroscience*, 36(2), 364–374. <https://doi.org/10.1523/JNEUROSCI.1907-15.2016>
- Adlard, P. A., Cherny, R. A., Finkelstein, D. I., Gautier, E., Robb, E., Cortes, M., Volitakis, I., Liu, X., Smith, J. P., Perez, K., Laughton, K., Li, Q. X., Charman, S. A., Nicolazzo, J. A., Wilkins, S., Deleva, K., Lynch, T., Kok, G., Ritchie, C. W., Tanzi, R. E., ... Bush, A. I. (2008). Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. *Neuron*, 59(1), 43–55. <https://doi.org/10.1016/j.neuron.2008.06.018>
- Afonso, P., De Luca, P., Carvalho, R. S., Cortes, L., Pinheiro, P., Oliveiros, B., Almeida, R. D., Mele, M., & Duarte, C. B. (2019). BDNF increases synaptic NMDA receptor abundance by enhancing the local translation of Pyk2 in cultured hippocampal neurons. *Science signaling*, 12(586), eaav3577. <https://doi.org/10.1126/scisignal.aav3577>
- Agarwal, P., Ayton, S., Agrawal, S., Dhana, K., Bennett, D. A., Barnes, L. L., Leurgans, S. E., Bush, A. I., & Schneider, J. A. (2022). Brain copper may protect from cognitive decline and Alzheimer's disease pathology: a community-based study. *Molecular psychiatry*, 27(10), 4307–4313. <https://doi.org/10.1038/s41380-022-01802-5>
- Ahmed, N. Y., Knowles, R., & Dehorter, N. (2019). New Insights into Cholinergic Neuron Diversity. *Frontiers in molecular neuroscience*, 12, 204. <https://doi.org/10.3389/fnmol.2019.00204>
- Aizenstein, H. J., Nebes, R. D., Saxton, J. A., Price, J. C., Mathis, C. A., Tsopelas, N. D., Ziolk, S. K., James, J. A., Snitz, B. E., Houck, P. R., Bi, W., Cohen, A. D., Lopresti, B. J., DeKosky, S. T., Halligan, E. M., & Klunk, W. E. (2008). Frequent amyloid deposition without significant cognitive impairment among the elderly. *Archives of neurology*, 65(11), 1509–1517. <https://doi.org/10.1001/archneur.65.11.1509>
- Akbari, M., Ostadmohammadi, V., Lankarani, K. B., Tabrizi, R., Kolahdooz, F., Khatibi, S. R., & Asemi, Z. (2018). The effects of alpha-lipoic acid supplementation on glucose control and lipid profiles among patients with metabolic diseases: A systematic review and meta-analysis of randomized controlled trials. *Metabolism: clinical and experimental*, 87, 56–69. <https://doi.org/10.1016/j.metabol.2018.07.002>
- Ali, Y. O., Escala, W., Ruan, K., & Zhai, R. G. (2011). Assaying locomotor, learning, and memory deficits in *Drosophila* models of neurodegeneration. *Journal of visualized experiments: JoVE*, (49), 2504. <https://doi.org/10.3791/2504>

Alzheimer, A., Stelzmann, R. A., Schnitzlein, H. N., & Murtagh, F. R. (1995). An English translation of Alzheimer's 1907 paper, "Über eine eigenartige Erkrankung der Hirnrinde". *Clinical anatomy* (New York, N.Y.), 8(6), 429–431. <https://doi.org/10.1002/ca.980080612>

Alzheimer's Association. (2024). A trial of the iron-chelator deferiprone in Alzheimer's disease. *Alzheimer's Association International Conference*. Retrieved September 2024, from <https://alz.confex.com/alz/2024/meetingapp.cgi/Paper/86330>

Andrews, S. J., Renton, A. E., Fulton-Howard, B., Podlesny-Drabiniok, A., Marcora, E., & Goate, A. M. (2023). The complex genetic architecture of Alzheimer's disease: novel insights and future directions. *EBioMedicine*, 90, 104511. <https://doi.org/10.1016/j.ebiom.2023.104511>

Antos, A., Członkowska, A., Smolinski, L., Bembenek, J., Przybyłkowski, A., Skowrońska, M., Kurkowska-Jastrzębska, I., & Litwin, T. (2023). Early neurological deterioration in Wilson's disease: a systematic literature review and meta-analysis. *Neurological sciences: official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology*, 44(10), 3443–3455. <https://doi.org/10.1007/s10072-023-06895-6>

Arivazhagan, P., & Panneerselvam, C. (2002). Neurochemical changes related to ageing in the rat brain and the effect of DL-alpha-lipoic acid. *Experimental gerontology*, 37(12), 1489–1494. [https://doi.org/10.1016/s0531-5565\(02\)00122-5](https://doi.org/10.1016/s0531-5565(02)00122-5)

Arredondo, M., & Núñez, M. T. (2005). Iron and copper metabolism. *Molecular aspects of medicine*, 26(4-5), 313–327. <https://doi.org/10.1016/j.mam.2005.07.010>

Arun, P., Madhavarao, C. N., Moffett, J. R., & Namboodiri, M. A. (2006). Regulation of N-acetylaspartate and N-acetylaspartylglutamate biosynthesis by protein kinase activators. *Journal of neurochemistry*, 98(6), 2034–2042. <https://doi.org/10.1111/j.1471-4159.2006.04068.x>

Ashok, A., Rai, N. K., Tripathi, S., & Bandyopadhyay, S. (2015). Exposure to As-, Cd-, and Pb-mixture induces A β , amyloidogenic APP processing and cognitive impairments via oxidative stress-dependent neuroinflammation in young rats *Toxicological sciences: an official journal of the Society of Toxicology*, 143(1), 64–80. <https://doi.org/10.1093/toxsci/kfu208>

Avola, R., Graziano, A. C. E., Pannuzzo, G., Albouchi, F., & Cardile, V. (2018). New insights on Parkinson's disease from differentiation of SH-SY5Y into dopaminergic neurons: An involvement of aquaporin4 and 9. *Molecular and cellular neurosciences*, 88, 212–221. <https://doi.org/10.1016/j.mcn.2018.02.006>

Ayodele, T., Rogaeva, E., Kurup, J. T., Beecham, G., & Reitz, C. (2021). Early-Onset Alzheimer's Disease: What Is Missing in Research? *Current neurology and neuroscience reports*, 21(2), 4. <https://doi.org/10.1007/s11910-020-01090-y>

Babić Leko, M., Langer Horvat, L., Španić Popovački, E., Zubčić, K., Hof, P. R., & Šimić, G. (2023). Metals in Alzheimer's Disease. *Biomedicines*, 11(4), 1161. <https://doi.org/10.3390/biomedicines11041161>

- Bacchella, C., Gentili, S., Bellotti, D., Quartieri, E., Draghi, S., Baratto, M. C., Remelli, M., Valensin, D., Monzani, E., Nicolis, S., Casella, L., Tegoni, M., & Dell'Acqua, S. (2020). Binding and Reactivity of Copper to R₁ and R₃ Fragments of tau Protein. *Inorganic chemistry*, 59(1), 274–286. <https://doi.org/10.1021/acs.inorgchem.9b02266>
- Bagheri, S., Squitti, R., Haertlé, T., Siotto, M., & Saboury, A. A. (2018). Role of Copper in the Onset of Alzheimer's Disease Compared to Other Metals. *Frontiers in aging neuroscience*, 9, 446. <https://doi.org/10.3389/fnagi.2017.00446>
- Bandmann, O., Weiss, K. H., & Kaler, S. G. (2015). Wilson's disease and other neurological copper disorders. *The Lancet. Neurology*, 14(1), 103–113. [https://doi.org/10.1016/S1474-4422\(14\)70190-5](https://doi.org/10.1016/S1474-4422(14)70190-5)
- Bao, W. D., Pang, P., Zhou, X. T., Hu, F., Xiong, W., Chen, K., Wang, J., Wang, F., Xie, D., Hu, Y. Z., Han, Z. T., Zhang, H. H., Wang, W. X., Nelson, P. T., Chen, J. G., Lu, Y., Man, H. Y., Liu, D., & Zhu, L. Q. (2021). Loss of ferroportin induces memory impairment by promoting ferroptosis in Alzheimer's disease. *Cell death and differentiation*, 28(5), 1548–1562. <https://doi.org/10.1038/s41418-020-00685-9>
- Barnham, K. J., Masters, C. L., & Bush, A. I. (2004). Neurodegenerative diseases and oxidative stress. *Nature reviews. Drug discovery*, 3(3), 205–214. <https://doi.org/10.1038/nrd1330>
- Bateman, R. J., Xiong, C., Benzinger, T. L., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., Holtzman, D. M., Santacruz, A., Buckles, V., Oliver, A., Moulder, K., Aisen, P. S., Ghetti, B., Klunk, W. E., McDade, E., Martins, R. N., ... Dominantly Inherited Alzheimer Network (2012). Clinical and biomarker changes in dominantly inherited Alzheimer's disease. *The New England journal of medicine*, 367(9), 795–804. <https://doi.org/10.1056/NEJMoa1202753>
- Bell, N., Hann, V., Redfern, C. P., & Cheek, T. R. (2013). Store-operated Ca(2+) entry in proliferating and retinoic acid-differentiated N- and S-type neuroblastoma cells. *Biochimica et biophysica acta*, 1833(3), 643–651. <https://doi.org/10.1016/j.bbamcr.2012.11.025>
- Berkson B. M. (1999). A conservative triple antioxidant approach to the treatment of hepatitis C. Combination of alpha lipoic acid (thioctic acid), silymarin, and selenium: three case histories. *Medizinische Klinik (Munich, Germany)*, 94 Suppl 3, 84–89. <https://doi.org/10.1007/BF03042201>
- Bernabeu-Zornoza, A., Coronel, R., Palmer, C., Monteagudo, M., Zambrano, A., & Liste, I. (2019). Physiological and pathological effects of amyloid- β species in neural stem cell biology. *Neural regeneration research*, 14(12), 2035–2042. <https://doi.org/10.4103/1673-5374.262571>
- Bien, J., Jefferson, T., Causević, M., Jumpertz, T., Munter, L., Multhaup, G., Weggen, S., Becker-Pauly, C., & Pietrzik, C. U. (2012). The metalloprotease meprin β generates amino terminal-truncated amyloid β peptide species. *The Journal of biological chemistry*, 287(40), 33304–33313. <https://doi.org/10.1074/jbc.M112.395608>

Biewenga, G. P., Haenen, G. R., & Bast, A. (1997). The pharmacology of the antioxidant lipoic acid. *General pharmacology*, 29(3), 315–331. [https://doi.org/10.1016/s0306-3623\(96\)00474-0](https://doi.org/10.1016/s0306-3623(96)00474-0)

Bishop, G. M., & Robinson, S. R. (2004). Physiological roles of amyloid-beta and implications for its removal in Alzheimer's disease. *Drugs & aging*, 21(10), 621–630. <https://doi.org/10.2165/00002512-200421100-00001>

Boland, B., & Campbell, V. (2003). beta-Amyloid (1-40)-induced apoptosis of cultured cortical neurones involves calpain-mediated cleavage of poly-ADP-ribose polymerase. *Neurobiology of aging*, 24(1), 179–186. [https://doi.org/10.1016/s0197-4580\(02\)00060-x](https://doi.org/10.1016/s0197-4580(02)00060-x)

Bondareff, W., Mountjoy, C. Q., & Roth, M. (1982). Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus ceruleus) in senile dementia. *Neurology*, 32(2), 164–168. <https://doi.org/10.1212/wnl.32.2.164>

Bonilla, E., Salazar, E., Villasmil, J. J., Villalobos, R., Gonzalez, M., & Davila, J. O. (1984). Copper distribution in the normal human brain. *Neurochemical research*, 9(11), 1543–1548. <https://doi.org/10.1007/BF00964589>

Bozzi, Y., & Borrelli, E. (2013). The role of dopamine signaling in epileptogenesis. *Frontiers in cellular neuroscience*, 7, 157. <https://doi.org/10.3389/fncel.2013.00157>

Braak, H., Thal, D. R., Ghebremedhin, E., & Del Tredici, K. (2011). Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. *Journal of neuropathology and experimental neurology*, 70(11), 960–969. <https://doi.org/10.1097/NEN.0b013e318232a379>

Brand, A. H., & Perrimon, N. (1993). Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. *Development (Cambridge, England)*, 118(2), 401–415. <https://doi.org/10.1242/dev.118.2.401>

Brewer G. J. (2019). Avoiding Alzheimer's disease: The important causative role of divalent copper ingestion. *Experimental biology and medicine (Maywood, N.J.)*, 244(2), 114–119. <https://doi.org/10.1177/1535370219827907>

Brewer, G. J., & Kaur, S. (2013). Zinc deficiency and zinc therapy efficacy with reduction of serum free copper in Alzheimer's disease. *International journal of Alzheimer's disease*, 2013, 586365. <https://doi.org/10.1155/2013/586365>

Brewer, G. J., Terry, C. A., Aisen, A. M., & Hill, G. M. (1987). Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy. *Archives of neurology*, 44(5), 490–493. <https://doi.org/10.1001/archneur.1987.00520170020016>

Brown, A. M., Kristal, B. S., Effron, M. S., Shestopalov, A. I., Ullucci, P. A., Sheu, K. F., Blass, J. P., & Cooper, A. J. (2000). Zn²⁺ inhibits alpha-ketoglutarate-stimulated mitochondrial respiration and the isolated alpha-ketoglutarate dehydrogenase complex. *The Journal of biological chemistry*, 275(18), 13441–13447. <https://doi.org/10.1074/jbc.275.18.13441>

- Bull, P. C., Thomas, G. R., Rommens, J. M., Forbes, J. R., & Cox, D. W. (1993). The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. *Nature genetics*, 5(4), 327–337. <https://doi.org/10.1038/ng1293-327>
- Bush A. I. (2003). The metallobiology of Alzheimer's disease. *Trends in neurosciences*, 26(4), 207–214. [https://doi.org/10.1016/S0166-2236\(03\)00067-5](https://doi.org/10.1016/S0166-2236(03)00067-5)
- Bush, A. I., & Tanzi, R. E. (2008). Therapeutics for Alzheimer's disease based on the metal hypothesis. *Neurotherapeutics: the journal of the American Society for Experimental NeuroTherapeutics*, 5(3), 421–432. <https://doi.org/10.1016/j.nurt.2008.05.001>
- Bush, A. I., Multhaup, G., Moir, R. D., Williamson, T. G., Small, D. H., Rumble, B., Pollwein, P., Beyreuther, K., & Masters, C. L. (1993). A novel zinc(II) binding site modulates the function of the beta A4 amyloid protein precursor of Alzheimer's disease. *The Journal of biological chemistry*, 268(22), 16109–16112. [https://doi.org/10.1016/S0021-9258\(19\)85394-2](https://doi.org/10.1016/S0021-9258(19)85394-2)
- Butterfield, D. A., & Halliwell, B. (2019). Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease. *Nature reviews. Neuroscience*, 20(3), 148–160. <https://doi.org/10.1038/s41583-019-0132-6>
- Caldeira, M. V., Melo, C. V., Pereira, D. B., Carvalho, R. F., Carvalho, A. L., & Duarte, C. B. (2007). BDNF regulates the expression and traffic of NMDA receptors in cultured hippocampal neurons. *Molecular and cellular neurosciences*, 35(2), 208–219. <https://doi.org/10.1016/j.mcn.2007.02.019>
- Campos Cogo, S., Gradowski Farias da Costa do Nascimento, T., de Almeida Brehm Pinhatti, F., de França Junior, N., Santos Rodrigues, B., Cavalli, L. R., & Elifio-Esposito, S. (2020). An overview of neuroblastoma cell lineage phenotypes and *in vitromodels*. *Experimental biology and medicine (Maywood, N.J.)*, 245(18), 1637–1647. <https://doi.org/10.1177/1535370220949237>
- Carello-Collar, G., Bellaver, B., Ferreira, P. C. L., Ferrari-Souza, J. P., Ramos, V. G., Therriault, J., Tissot, C., De Bastiani, M. A., Soares, C., Pascoal, T. A., Rosa-Neto, P., Souza, D. O., & Zimmer, E. R. (2023). The GABAergic system in Alzheimer's disease: a systematic review with meta-analysis. *Molecular psychiatry*, 28(12), 5025–5036. <https://doi.org/10.1038/s41380-023-02140-w>
- Casella, R., & Cecchi, C. (2021). Calcium Dyshomeostasis in Alzheimer's Disease Pathogenesis. *International journal of molecular sciences*, 22(9), 4914. <https://doi.org/10.3390/ijms22094914>
- Caspersen, C., Wang, N., Yao, J., Sosunov, A., Chen, X., Lustbader, J. W., Xu, H. W., Stern, D., McKhann, G., & Yan, S. D. (2005). Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. *FASEB journal: official publication of the Federation of American Societies for Experimental Biology*, 19(14), 2040–2041. <https://doi.org/10.1096/fj.05-3735fje>
- Chakraborty, S., Lennon, J. C., Malkaram, S. A., Zeng, Y., Fisher, D. W., & Dong, H. (2019). Serotonergic system, cognition, and BPSD in Alzheimer's disease. *Neuroscience letters*, 704, 36–44. <https://doi.org/10.1016/j.neulet.2019.03.050>

- Chattopadhyay, D., Philip, S. M., Prabhakar, G., & Machamada Bheemaiah, M. (2024). Influence of α -lipoic acid on longevity and stress resistance in *Drosophila melanogaster* fed with a high-fat diet. *Biogerontology*, 25(6), 1097–1114. <https://doi.org/10.1007/s10522-024-10124-8>
- Cheignon, C., Tomas, M., Bonnefont-Rousselot, D., Faller, P., Hureau, C., & Collin, F. (2018). Oxidative stress and the amyloid beta peptide in Alzheimer's disease. *Redox biology*, 14, 450–464. <https://doi.org/10.1016/j.redox.2017.10.014>
- Chen, L. L., Fan, Y. G., Zhao, L. X., Zhang, Q., & Wang, Z. Y. (2023). The metal ion hypothesis of Alzheimer's disease and the anti-neuroinflammatory effect of metal chelators. *Bioorganic chemistry*, 131, 106301. <https://doi.org/10.1016/j.bioorg.2022.106301>
- Chen, Z. L., Singh, P. K., Calvano, M., Norris, E. H., & Strickland, S. (2023). A possible mechanism for the enhanced toxicity of beta-amyloid protofibrils in Alzheimer's disease. *Proceedings of the National Academy of Sciences of the United States of America*, 120(36), e2309389120. <https://doi.org/10.1073/pnas.2309389120>
- Chen, Z. R., Huang, J. B., Yang, S. L., & Hong, F. F. (2022). Role of Cholinergic Signaling in Alzheimer's Disease. *Molecules (Basel, Switzerland)*, 27(6), 1816. <https://doi.org/10.3390/molecules27061816>
- Choi, S. H., Kim, Y. H., Quinti, L., Tanzi, R. E., & Kim, D. Y. (2016). 3D culture models of Alzheimer's disease: a road map to a "cure-in-a-dish". *Molecular neurodegeneration*, 11(1), 75. <https://doi.org/10.1186/s13024-016-0139-7>
- Conway M. E. (2020). Alzheimer's disease: targeting the glutamatergic system. *Biogerontology*, 21(3), 257–274. <https://doi.org/10.1007/s10522-020-09860-4>
- Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science (New York, N.Y.)*, 261(5123), 921–923. <https://doi.org/10.1126/science.8346443>
- Cortese, M. M., Suschek, C. V., Wetzel, W., Kröncke, K. D., & Kolb-Bachofen, V. (2008). Zinc protects endothelial cells from hydrogen peroxide via Nrf2-dependent stimulation of glutathione biosynthesis. *Free radical biology & medicine*, 44(12), 2002–2012. <https://doi.org/10.1016/j.freeradbiomed.2008.02.013>
- Coyle, J., & Kershaw, P. (2001). Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease. *Biological psychiatry*, 49(3), 289–299. [https://doi.org/10.1016/s0006-3223\(00\)01101-x](https://doi.org/10.1016/s0006-3223(00)01101-x)
- Cras, P., van Harskamp, F., Hendriks, L., Ceuterick, C., van Duijn, C. M., Stefanko, S. Z., Hofman, A., Kros, J. M., Van Broeckhoven, C., & Martin, J. J. (1998). Presenile Alzheimer dementia characterized by amyloid angiopathy and large amyloid core type senile plaques in the APP 692Ala-->Gly mutation. *Acta neuropathologica*, 96(3), 253–260. <https://doi.org/10.1007/s004010050892>

Cummings, J., Zhou, Y., Lee, G., Zhong, K., Fonseca, J., & Cheng, F. (2024). Alzheimer's disease drug development pipeline: 2024. *Alzheimer's & dementia (New York, N. Y.)*, 10(2), e12465. <https://doi.org/10.1002/trc2.12465>

Dantas, J. M., Mutarelli, A., Navalha, D. D. P., Dagostin, C. S., Romeiro, P. H. C. L., Felix, N., Nogueira, A., Batista, S., Teixeira, L., & Caramelli, P. (2024). Efficacy of anti-amyloid- β monoclonal antibody therapy in early Alzheimer's disease: a systematic review and meta-analysis. *Neurological sciences: official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology*, 45(6), 2461–2469. <https://doi.org/10.1007/s10072-023-07194-w>

Deardorff, W. J., & Grossberg, G. T. (2016). A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer's disease. *Drug design, development and therapy*, 10, 3267–3279. <https://doi.org/10.2147/DDDT.S86463>

De la Rosa, A., Olaso-Gonzalez, G., Arc-Chagnaud, C., Millan, F., Salvador-Pascual, A., García-Lucerga, C., Blasco-Lafarga, C., García-Dominguez, E., Carretero, A., Correias, A. G., Viña, J., & Gomez-Cabrera, M. C. (2020). Physical exercise in the prevention and treatment of Alzheimer's disease. *Journal of sport and health science*, 9(5), 394–404. <https://doi.org/10.1016/j.jshs.2020.01.004>

De Marco, M., & Venneri, A. (2018). Volume and Connectivity of the Ventral Tegmental Area are Linked to Neurocognitive Signatures of Alzheimer's Disease in Humans. *Journal of Alzheimer's disease: JAD*, 63(1), 167–180. <https://doi.org/10.3233/JAD-171018>

De Medeiros, L. M., De Bastiani, M. A., Rico, E. P., Schonhofen, P., Pfaffenseller, B., Wollenhaupt-Aguiar, B., Grun, L., Barbé-Tuana, F., Zimmer, E. R., Castro, M. A. A., Parsons, R. B., & Klamt, F. (2019). Cholinergic Differentiation of Human Neuroblastoma SH-SY5Y Cell Line and Its Potential Use as an In vitro Model for Alzheimer's Disease Studies. *Molecular neurobiology*, 56(11), 7355–7367. <https://doi.org/10.1007/s12035-019-1605-3>

Deibel, M. A., Ehmann, W. D., & Markesbery, W. R. (1996). Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: possible relation to oxidative stress. *Journal of the neurological sciences*, 143(1-2), 137–142. [https://doi.org/10.1016/s0022-510x\(96\)00203-1](https://doi.org/10.1016/s0022-510x(96)00203-1)

Derosa, G., D'Angelo, A., Preti, P., & Maffioli, P. (2020). Safety and Efficacy of Alpha Lipoic Acid During 4 Years of Observation: A Retrospective, Clinical Trial in Healthy Subjects in Primary Prevention. *Drug design, development and therapy*, 14, 5367–5374. <https://doi.org/10.2147/DDDT.S280802>

Dhaouadi, N., Vitto, V. A. M., Pinton, P., Galluzzi, L., & Marchi, S. (2023). Ca²⁺ signaling and cell death. *Cell calcium*, 113, 102759. <https://doi.org/10.1016/j.ceca.2023.102759>

Dhillon S. (2021). Aducanumab: First Approval. *Drugs*, 81(12), 1437–1443. <https://doi.org/10.1007/s40265-021-01569-z>

Di Scala, C., Yahi, N., Boutemour, S., Flores, A., Rodriguez, L., Chahinian, H., & Fantini, J. (2016). Common molecular mechanism of amyloid pore formation by Alzheimer's β -amyloid peptide and α -synuclein. *Scientific reports*, 6, 28781. <https://doi.org/10.1038/srep28781>

Ding, L., & Wang, Y. (2006). Effect of copper on the development, protein and esterase isozymes of *Drosophila melanogaster*. *Integrative zoology*, 1(2), 73–77. <https://doi.org/10.1111/j.1749-4877.2006.00017.x>

Ding, J., Liu, Q., Liu, Z., Guo, H., Liang, J., & Zhang, Y. (2022). Associations of the Dietary Iron, Copper, and Selenium Level With Metabolic Syndrome: A Meta-Analysis of Observational Studies. *Frontiers in nutrition*, 8, 810494. <https://doi.org/10.3389/fnut.2021.810494>

Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason, C. E., Patel, D. N., Bauer, A. J., Cantley, A. M., Yang, W. S., Morrison, B., 3rd, & Stockwell, B. R. (2012). Ferroptosis: an iron-dependent form of nonapoptotic cell death. *Cell*, 149(5), 1060–1072. <https://doi.org/10.1016/j.cell.2012.03.042>

Doecke, J. D., Pérez-Grijalba, V., Fandos, N., Fowler, C., Villemagne, V. L., Masters, C. L., Pesini, P., Sarasa, M., & AIBL Research Group (2020). Total A β 42/A β 40 ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis. *Neurology*, 94(15), e1580–e1591. <https://doi.org/10.1212/WNL.0000000000009240>

Dorey, C. K., Gierhart, D., Fitch, K. A., Crandell, I., & Craft, N. E. (2023). Low Xanthophylls, Retinol, Lycopene, and Tocopherols in Grey and White Matter of Brains with Alzheimer's Disease. *Journal of Alzheimer's disease: JAD*, 94(1), 1–17. <https://doi.org/10.3233/JAD-220460>

Du, K., Zheng, X., Ma, Z. T., Lv, J. Y., Jiang, W. J., & Liu, M. Y. (2022). Association of Circulating Magnesium Levels in Patients with Alzheimer's Disease From 1991 to 2021: A Systematic Review and Meta-Analysis. *Frontiers in aging neuroscience*, 13, 799824. <https://doi.org/10.3389/fnagi.2021.799824>

Dutt, S., Li, Y., Mather, M., Nation, D. A., & Alzheimer's Disease Neuroimaging Initiative (2020). Brainstem Volumetric Integrity in Preclinical and Prodromal Alzheimer's Disease. *Journal of Alzheimer's disease: JAD*, 77(4), 1579–1594. <https://doi.org/10.3233/JAD-200187>

Escott-Price, V., & Hardy, J. (2022). Genome-wide association studies for Alzheimer's disease: bigger is not always better. *Brain communications*, 4(3), fcac125. <https://doi.org/10.1093/braincomms/fcac125>

Esmieu, C., Ferrand, G., Borghesani, V., & Hureau, C. (2021). Impact of N-Truncated A β Peptides on Cu- and Cu(A β)-Generated ROS: Cu Matters!. *Chemistry (Weinheim an der Bergstrasse, Germany)*, 27(5), 1777–1786. <https://doi.org/10.1002/chem.202003949>

European Medicines Agency. (2019). *Trial results for clinical trial ID 2019-000604-15/IT*. European Union Clinical Trials Register. Retrieved October 9, 2024, from <https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000604-15/IT>

Faller, P., & Hureau, C. (2009). Bioinorganic chemistry of copper and zinc ions coordinated to amyloid-beta peptide. *Dalton transactions (Cambridge, England: 2003)*, (7), 1080–1094. <https://doi.org/10.1039/b813398k>

Fava, A., Pirritano, D., Plastino, M., Cristiano, D., Puccio, G., Colica, C., Ermio, C., De Bartolo, M., Mauro, G., & Bosco, D. (2013). The Effect of Lipoic Acid Therapy on Cognitive Functioning in Patients with Alzheimer's Disease. *Journal of neurodegenerative diseases*, 2013, 454253. <https://doi.org/10.1155/2013/454253>

Ferreira-Vieira, T. H., Guimaraes, I. M., Silva, F. R., & Ribeiro, F. M. (2016). Alzheimer's disease: Targeting the Cholinergic System. *Current neuropharmacology*, 14(1), 101–115. <https://doi.org/10.2174/1570159x13666150716165726>

Fezoui, Y., Hartley, D. M., Harper, J. D., Khurana, R., Walsh, D. M., Condron, M. M., Selkoe, D. J., Lansbury, P. T., Jr, Fink, A. L., & Teplow, D. B. (2000). An improved method of preparing the amyloid beta-protein for fibrillogenesis and neurotoxicity experiments. *Amyloid: the international journal of experimental and clinical investigation: the official journal of the International Society of Amyloidosis*, 7(3), 166–178. <https://doi.org/10.3109/13506120009146831>

Finelli, A., Kelkar, A., Song, H. J., Yang, H., & Konsolaki, M. (2004). A model for studying Alzheimer's A β 42-induced toxicity in *Drosophila melanogaster*. *Molecular and cellular neurosciences*, 26(3), 365–375. <https://doi.org/10.1016/j.mcn.2004.03.001>

Fogacci, F., Rizzo, M., Krogager, C., Kennedy, C., Georges, C. M. G., Knežević, T., Liberopoulos, E., Vallée, A., Pérez-Martínez, P., Wenstedt, E. F. E., Šatrauskienė, A., Vrablík, M., & Cicero, A. F. G. (2020). Safety Evaluation of α -Lipoic Acid Supplementation: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Clinical Studies. *Antioxidants (Basel, Switzerland)*, 9(10), 1011. <https://doi.org/10.3390/antiox9101011>

Fontaine, R., Affaticati, P., Bureau, C., Colin, I., Demarque, M., Dufour, S., Vernier, P., Yamamoto, K., & Pasqualini, C. (2015). Dopaminergic Neurons Controlling Anterior Pituitary Functions: Anatomy and Ontogenesis in Zebrafish. *Endocrinology*, 156(8), 2934–2948. <https://doi.org/10.1210/en.2015-1091>

Fortea, J., Pegueroles, J., Alcolea, D., Belbin, O., Dols-Icardo, O., Vaqué-Alcázar, L., Videla, L., Gispert, J. D., Suárez-Calvet, M., Johnson, S. C., Sperling, R., Bejanin, A., Lleó, A., & Montal, V. (2024). APOE4 homozygosity represents a distinct genetic form of Alzheimer's disease. *Nature medicine*, 30(5), 1284–1291. <https://doi.org/10.1038/s41591-024-02931-w>

Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999). The cholinergic hypothesis of Alzheimer's disease: a review of progress. *Journal of neurology, neurosurgery, and psychiatry*, 66(2), 137–147. <https://doi.org/10.1136/jnnp.66.2.137>

Fu, Y., Paxinos, G., Watson, C., & Halliday, G. M. (2016). The substantia nigra and ventral tegmental dopaminergic neurons from development to degeneration. *Journal of chemical neuroanatomy*, 76(Pt B), 98–107. <https://doi.org/10.1016/j.jchemneu.2016.02.001>

- Galasko, D. R., Peskind, E., Clark, C. M., Quinn, J. F., Ringman, J. M., Jicha, G. A., Cotman, C., Cottrell, B., Montine, T. J., Thomas, R. G., Aisen, P., & Alzheimer's Disease Cooperative Study (2012). Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. *Archives of neurology*, 69(7), 836–841. <https://doi.org/10.1001/archneurol.2012.85>
- Gannon, M., Che, P., Chen, Y., Jiao, K., Roberson, E. D., & Wang, Q. (2015). Noradrenergic dysfunction in Alzheimer's disease. *Frontiers in neuroscience*, 9, 220. <https://doi.org/10.3389/fnins.2015.00220>
- García-Casares, N., Gallego Fuentes, P., Barbancho, M. Á., López-Gigosos, R., García-Rodríguez, A., & Gutiérrez-Bedmar, M. (2021). Alzheimer's Disease, Mild Cognitive Impairment and Mediterranean Diet. A Systematic Review and Dose-Response Meta-Analysis. *Journal of clinical medicine*, 10(20), 4642. <https://doi.org/10.3390/jcm10204642>
- Goldie, B. J., Barnett, M. M., & Cairns, M. J. (2014). BDNF and the maturation of posttranscriptional regulatory networks in human SH-SY5Y neuroblast differentiation. *Frontiers in cellular neuroscience*, 8, 325. <https://doi.org/10.3389/fncel.2014.00325>
- González Cordero, E. M., Cuevas-Budhart, M. A., Pérez Morán, D., Trejo Villeda, M. A., & Gomez-Del-Pulgar G^a-Madrid, M. (2022). Relationship Between the Gut Microbiota and Alzheimer's Disease: A Systematic Review. *Journal of Alzheimer's disease: JAD*, 87(2), 519–528. <https://doi.org/10.3233/JAD-215224>
- Gordon, B. A., Blazey, T. M., Su, Y., Hari-Raj, A., Dincer, A., Flores, S., Christensen, J., McDade, E., Wang, G., Xiong, C., Cairns, N. J., Hassenstab, J., Marcus, D. S., Fagan, A. M., Jack, C. R., Jr, Hornbeck, R. C., Paumier, K. L., Ances, B. M., Berman, S. B., Brickman, A. M., ... Benzinger, T. L. S. (2018). Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. *The Lancet. Neurology*, 17(3), 241–250. [https://doi.org/10.1016/S1474-4422\(18\)30028-0](https://doi.org/10.1016/S1474-4422(18)30028-0)
- Gouras, G. K., Tsai, J., Naslund, J., Vincent, B., Edgar, M., Checler, F., Greenfield, J. P., Haroutunian, V., Buxbaum, J. D., Xu, H., Greengard, P., & Relkin, N. R. (2000). Intraneuronal Aβ₄₂ accumulation in human brain. *The American journal of pathology*, 156(1), 15–20. [https://doi.org/10.1016/s0002-9440\(10\)64700-1](https://doi.org/10.1016/s0002-9440(10)64700-1)
- Grabowski, T. J., Cho, H. S., Vonsattel, J. P., Rebeck, G. W., & Greenberg, S. M. (2001). Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy. *Annals of neurology*, 49(6), 697–705. <https://doi.org/10.1002/ana.1009>
- Greenough, M. A., Volitakis, I., Li, Q. X., Laughton, K., Evin, G., Ho, M., Dalziel, A. H., Camakaris, J., & Bush, A. I. (2011). Presenilins promote the cellular uptake of copper and zinc and maintain copper chaperone of SOD1-dependent copper/zinc superoxide dismutase activity. *The Journal of biological chemistry*, 286(11), 9776–9786. <https://doi.org/10.1074/jbc.M110.163964>

Gustavsson, A., Norton, N., Fast, T., Frölich, L., Georges, J., Holzapfel, D., Kirabali, T., Krolak-Salmon, P., Rossini, P. M., Ferretti, M. T., Lanman, L., Chadha, A. S., & van der Flier, W. M. (2023). Global estimates on the number of persons across the Alzheimer's disease continuum. *Alzheimer's & dementia: the journal of the Alzheimer's Association*, 19(2), 658–670. <https://doi.org/10.1002/alz.12694>

Hager, K., Kenklies, M., McAfoose, J., Engel, J., & Münch, G. (2007). Alpha-lipoic acid as a new treatment option for Alzheimer's disease--a 48 months follow-up analysis. *Journal of neural transmission. Supplementum*, (72), 189–193. https://doi.org/10.1007/978-3-211-73574-9_24

Hamid, M., Mansoor, S., Amber, S., & Zahid, S. (2022). A quantitative meta-analysis of vitamin C in the pathophysiology of Alzheimer's disease. *Frontiers in aging neuroscience*, 14, 970263. <https://doi.org/10.3389/fnagi.2022.970263>

Hampel, H., Mesulam, M. M., Cuello, A. C., Khachaturian, A. S., Vergallo, A., Farlow, M. R., Snyder, P. J., Giacobini, E., & Khachaturian, Z. S. (2019). Revisiting the Cholinergic Hypothesis in Alzheimer's Disease: Emerging Evidence from Translational and Clinical Research. *The journal of prevention of Alzheimer's disease*, 6(1), 2–15. <https://doi.org/10.14283/jpad.2018.43>

Han, T., Bai, J., Liu, W., & Hu, Y. (2012). A systematic review and meta-analysis of α -lipoic acid in the treatment of diabetic peripheral neuropathy. *European journal of endocrinology*, 167(4), 465–471. <https://doi.org/10.1530/EJE-12-0555>

Han, X. J., Hu, Y. Y., Yang, Z. J., Jiang, L. P., Shi, S. L., Li, Y. R., Guo, M. Y., Wu, H. L., & Wan, Y. Y. (2017). Amyloid β -42 induces neuronal apoptosis by targeting mitochondria. *Molecular medicine reports*, 16(4), 4521–4528. <https://doi.org/10.3892/mmr.2017.7203>

Hansson, O., Seibyl, J., Stomrud, E., Zetterberg, H., Trojanowski, J. Q., Bittner, T., Lifke, V., Corradini, V., Eichenlaub, U., Batrla, R., Buck, K., Zink, K., Rabe, C., Blennow, K., Shaw, L. M., Swedish BioFINDER study group, & Alzheimer's Disease Neuroimaging Initiative (2018). CSF biomarkers of Alzheimer's disease concord with amyloid- β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. *Alzheimer's & dementia: the journal of the Alzheimer's Association*, 14(11), 1470–1481. <https://doi.org/10.1016/j.jalz.2018.01.010>

Hardy, J. A., & Higgins, G. A. (1992). Alzheimer's disease: the amyloid cascade hypothesis. *Science (New York, N.Y.)*, 256(5054), 184–185. <https://doi.org/10.1126/science.1566067>

Hardy, J., & Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. *Science (New York, N.Y.)*, 297(5580), 353–356. <https://doi.org/10.1126/science.1072994>

Hasselmo M. E. (2006). The role of acetylcholine in learning and memory. *Current opinion in neurobiology*, 16(6), 710–715. <https://doi.org/10.1016/j.conb.2006.09.002>

Hesse, L., Beher, D., Masters, C. L., & Multhaup, G. (1994). The beta A4 amyloid precursor protein binding to copper. *FEBS letters*, 349(1), 109–116. [https://doi.org/10.1016/0014-5793\(94\)00658-x](https://doi.org/10.1016/0014-5793(94)00658-x)

- Honig, L. S., Sabbagh, M. N., van Dyck, C. H., Sperling, R. A., Hersch, S., Matta, A., Giorgi, L., Gee, M., Kanekiyo, M., Li, D., Purcell, D., Dhadda, S., Irizarry, M., & Kramer, L. (2024). Updated safety results from phase 3 lecanemab study in early Alzheimer's disease. *Alzheimer's research & therapy*, 16(1), 105. <https://doi.org/10.1186/s13195-024-01441-8>
- Hozumi, I., Hasegawa, T., Honda, A., Ozawa, K., Hayashi, Y., Hashimoto, K., Yamada, M., Koumura, A., Sakurai, T., Kimura, A., Tanaka, Y., Satoh, M., & Inuzuka, T. (2011). Patterns of levels of biological metals in CSF differ among neurodegenerative diseases. *Journal of the neurological sciences*, 303(1-2), 95–99. <https://doi.org/10.1016/j.jns.2011.01.003>
- Hua, H., Münter, L., Harmeier, A., Georgiev, O., Multhaup, G., & Schaffner, W. (2011). Toxicity of Alzheimer's disease-associated A β peptide is ameliorated in a *Drosophila* model by tight control of zinc and copper availability. *Biological chemistry*, 392(10), 919–926. <https://doi.org/10.1515/BC.2011.084>
- Huang, Y., Happonen, K. E., Burrola, P. G., O'Connor, C., Hah, N., Huang, L., Nimmerjahn, A., & Lemke, G. (2021). Microglia use TAM receptors to detect and engulf amyloid β plaques. *Nature immunology*, 22(5), 586–594. <https://doi.org/10.1038/s41590-021-00913-5>
- James, S. A., Volitakis, I., Adlard, P. A., Duce, J. A., Masters, C. L., Cherny, R. A., & Bush, A. I. (2012). Elevated labile Cu is associated with oxidative pathology in Alzheimer disease. *Free radical biology & medicine*, 52(2), 298–302. <https://doi.org/10.1016/j.freeradbiomed.2011.10.446>
- Kaler S. G. (2011). ATP7A-related copper transport diseases-emerging concepts and future trends. *Nature reviews. Neurology*, 7(1), 15–29. <https://doi.org/10.1038/nrneurol.2010.180>
- Karrer, T. M., Josef, A. K., Mata, R., Morris, E. D., & Samanez-Larkin, G. R. (2017). Reduced dopamine receptors and transporters but not synthesis capacity in normal aging adults: a meta-analysis. *Neurobiology of aging*, 57, 36–46. <https://doi.org/10.1016/j.neurobiolaging.2017.05.006>
- Kaur, D., Behl, T., Sehgal, A., Singh, S., Sharma, N., Chigurupati, S., Alhowail, A., Abdeen, A., Ibrahim, S. F., Vargas-De-La-Cruz, C., Sachdeva, M., Bhatia, S., Al-Harrasi, A., & Bungau, S. (2021). Decrypting the potential role of α -lipoic acid in Alzheimer's disease. *Life sciences*, 284, 119899. <https://doi.org/10.1016/j.lfs.2021.119899>
- Keil, U., Bonert, A., Marques, C. A., Scherping, I., Weyermann, J., Strosznajder, J. B., Müller-Spahn, F., Haass, C., Czech, C., Pradier, L., Müller, W. E., & Eckert, A. (2004). Amyloid beta-induced changes in nitric oxide production and mitochondrial activity lead to apoptosis. *The Journal of biological chemistry*, 279(48), 50310–50320. <https://doi.org/10.1074/jbc.M405600200>
- Kessler, H., Bayer, T. A., Bach, D., Schneider-Axmann, T., Supprian, T., Herrmann, W., Haber, M., Multhaup, G., Falkai, P., & Pajonk, F. G. (2008). Intake of copper has no effect on cognition in patients with mild Alzheimer's disease: a pilot phase 2 clinical trial. *Journal of neural transmission (Vienna, Austria: 1996)*, 115(8), 1181–1187. <https://doi.org/10.1007/s00702-008-0080-1>

Koeppen, A. H. (2000). Basic Neurochemistry: Molecular, Cellular, and Medical Aspects. *Journal of the Neurological Sciences*, 174 (1), 49-50. [https://doi.org/10.1016/S0022-510X\(00\)00257-4](https://doi.org/10.1016/S0022-510X(00)00257-4)

Kovalevich, J., & Langford, D. (2013). Considerations for the use of SH-SY5Y neuroblastoma cells in neurobiology. *Methods in molecular biology (Clifton, N.J.)*, 1078, 9–21. https://doi.org/10.1007/978-1-62703-640-5_2

Kumar, M., Murugan, T. P., Lionel, A. P., Thomas, M. M., Mannam, P., & Yoganathan, S. (2022). Management of Children and Adolescents with Wilson Disease and Neurological Worsening Following D-Penicillamine Therapy: A Single Centre Experience. *Annals of Indian Academy of Neurology*, 25(4), 698–702. https://doi.org/10.4103/aian.aian_519_21

Kume, T., Kawato, Y., Osakada, F., Izumi, Y., Katsuki, H., Nakagawa, T., Kaneko, S., Niidome, T., Takada-Takatori, Y., & Akaike, A. (2008). Dibutyryl cyclic AMP induces differentiation of human neuroblastoma SH-SY5Y cells into a noradrenergic phenotype. *Neuroscience letters*, 443(3), 199–203. <https://doi.org/10.1016/j.neulet.2008.07.079>

Kuperstein, I., Broersen, K., Benilova, I., Rozenski, J., Jonckheere, W., Debulpaep, M., Vandersteen, A., Segers-Nolten, I., Van Der Werf, K., Subramaniam, V., Braeken, D., Callewaert, G., Bartic, C., D'Hooge, R., Martins, I. C., Rousseau, F., Schymkowitz, J., & De Strooper, B. (2010). Neurotoxicity of Alzheimer's disease A β peptides is induced by small changes in the A β 42 to A β 40 ratio. *The EMBO journal*, 29(19), 3408–3420. <https://doi.org/10.1038/emboj.2010.211>

Kweon, G. R., Marks, J. D., Krencik, R., Leung, E. H., Schumacker, P. T., Hyland, K., & Kang, U. J. (2004). Distinct mechanisms of neurodegeneration induced by chronic complex I inhibition in dopaminergic and non-dopaminergic cells. *The Journal of biological chemistry*, 279(50), 51783–51792. <https://doi.org/10.1074/jbc.M407336200>

Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., Wals, P., Zhang, C., Finch, C. E., Krafft, G. A., & Klein, W. L. (1998). Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. *Proceedings of the National Academy of Sciences of the United States of America*, 95(11), 6448–6453. <https://doi.org/10.1073/pnas.95.11.6448>

Lee, H., Lee, M. W., Warren, J. R., & Ferrie, J. (2022). Childhood lead exposure is associated with lower cognitive functioning at older ages. *Science advances*, 8(45), eabn5164. <https://doi.org/10.1126/sciadv.abn5164>

Lee, K. H., Cha, M., & Lee, B. H. (2020). Neuroprotective Effect of Antioxidants in the Brain. *International journal of molecular sciences*, 21(19), 7152. <https://doi.org/10.3390/ijms21197152>

Li, H., Wang, Z., Fu, Z., Yan, M., Wu, N., Wu, H., & Yin, P. (2018). Associations between blood cadmium levels and cognitive function in a cross-sectional study of US adults aged 60 years or older. *BMJ open*, 8(4), e020533. <https://doi.org/10.1136/bmjopen-2017-020533>

- Li, Z., Liu, Y., Wei, R., Yong, V. W., & Xue, M. (2022). The Important Role of Zinc in Neurological Diseases. *Biomolecules*, 13(1), 28. <https://doi.org/10.3390/biom13010028>
- Lin, R., Liang, J., Wang, R., Yan, T., Zhou, Y., Liu, Y., Feng, Q., Sun, F., Li, Y., Li, A., Gong, H., & Luo, M. (2020). The Raphe Dopamine System Controls the Expression of Incentive Memory. *Neuron*, 106(3), 498–514.e8. <https://doi.org/10.1016/j.neuron.2020.02.009>
- Livingston, G., Huntley, J., Liu, K. Y., Costafreda, S. G., Selbæk, G., Alladi, S., Ames, D., Banerjee, S., Burns, A., Brayne, C., Fox, N. C., Ferri, C. P., Gitlin, L. N., Howard, R., Kales, H. C., Kivimäki, M., Larson, E. B., Nakasujja, N., Rockwood, K., Samus, Q., ... Mukadam, N. (2024). Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. *Lancet (London, England)*, 404(10452), 572–628. [https://doi.org/10.1016/S0140-6736\(24\)01296-0](https://doi.org/10.1016/S0140-6736(24)01296-0)
- Looyenga, B. D., Resau, J., & MacKeigan, J. P. (2013). Cytokine receptor-like factor 1 (CRLF1) protects against 6-hydroxydopamine toxicity independent of the gp130/JAK signaling pathway. *PloS one*, 8(6), e66548. <https://doi.org/10.1371/journal.pone.0066548>
- Lovell, M. A., Robertson, J. D., Teesdale, W. J., Campbell, J. L., & Markesbery, W. R. (1998). Copper, iron and zinc in Alzheimer's disease senile plaques. *Journal of the neurological sciences*, 158(1), 47–52. [https://doi.org/10.1016/s0022-510x\(98\)00092-6](https://doi.org/10.1016/s0022-510x(98)00092-6)
- Mann, D. M., Lincoln, J., Yates, P. O., Stamp, J. E., & Toper, S. (1980). Changes in the monoamine containing neurones of the human CNS in senile dementia. *The British journal of psychiatry: the journal of mental science*, 136, 533–541. <https://doi.org/10.1192/bjp.136.6.533>
- Manoharan, S., Guillemin, G. J., Abiramasundari, R. S., Essa, M. M., Akbar, M., & Akbar, M. D. (2016). The Role of Reactive Oxygen Species in the Pathogenesis of Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease: A Mini Review. *Oxidative medicine and cellular longevity*, 2016, 8590578. <https://doi.org/10.1155/2016/8590578>
- Martin, E. R., Gandawijaya, J., & Oguro-Ando, A. (2022). A novel method for generating glutamatergic SH-SY5Y neuron-like cells utilizing B-27 supplement. *Frontiers in pharmacology*, 13, 943627. <https://doi.org/10.3389/fphar.2022.943627>
- Menezes-Filho, J. A., Novaes, C.deO., Moreira, J. C., Sarcinelli, P. N., & Mergler, D. (2011). Elevated manganese and cognitive performance in school-aged children and their mothers. *Environmental research*, 111(1), 156–163. <https://doi.org/10.1016/j.envres.2010.09.006>
- Meyerstein D. (2021). Re-examining Fenton and Fenton-like reactions. *Nature reviews. Chemistry*, 5(9), 595–597. <https://doi.org/10.1038/s41570-021-00310-4>
- Miller, L. M., Wang, Q., Telivala, T. P., Smith, R. J., Lanzirotti, A., & Miklossy, J. (2006). Synchrotron-based infrared and X-ray imaging shows focalized accumulation of Cu and Zn co-localized with beta-amyloid deposits in Alzheimer's disease. *Journal of structural biology*, 155(1), 30–37. <https://doi.org/10.1016/j.jsb.2005.09.004>

- Monnot, A. D., Zheng, G., & Zheng, W. (2012). Mechanism of copper transport at the blood-cerebrospinal fluid barrier: influence of iron deficiency in an in vitro model. *Experimental biology and medicine* (Maywood, N.J.), 237(3), 327–333. <https://doi.org/10.1258/ebm.2011.011170>
- Morais, F. M., Ribeiro, A. M., Moreira, F. A., & Silva, P. V. G. (2021). Systematic review and meta-analysis on the role of mitochondrial cytochrome c oxidase in Alzheimer's disease. *Acta neuropsychiatrica*, 33(2), 55–64. <https://doi.org/10.1017/neu.2020.43>
- Morbelli, S., & Nobili, F. (2014). Cognitive reserve and clinical expression of Alzheimer's disease: evidence and implications for brain PET imaging. *American journal of nuclear medicine and molecular imaging*, 4(3), 239–247. PMCID: [PMC3999404](https://pubmed.ncbi.nlm.nih.gov/PMC3999404/)
- Moreta, M. P., Burgos-Alonso, N., Torrecilla, M., Marco-Contelles, J., & Bruzos-Cidón, C. (2021). Efficacy of Acetylcholinesterase Inhibitors on Cognitive Function in Alzheimer's Disease. Review of Reviews. *Biomedicines*, 9(11), 1689. <https://doi.org/10.3390/biomedicines9111689>
- Motter, R., Vigo-Pelfrey, C., Kholodenko, D., Barbour, R., Johnson-Wood, K., Galasko, D., Chang, L., Miller, B., Clark, C., & Green, R. (1995). Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. *Annals of neurology*, 38(4), 643–648. <https://doi.org/10.1002/ana.410380413>
- Mrdenovic, D., Pieta, I. S., Nowakowski, R., Kutner, W., Lipkowski, J., & Pieta, P. (2022). Amyloid β interaction with model cell membranes - What are the toxicity-defining properties of amyloid β ? *International journal of biological macromolecules*, 200, 520–531. <https://doi.org/10.1016/j.ijbiomac.2022.01.117>
- Mullan, K., Cardwell, C. R., McGuinness, B., Woodside, J. V., & McKay, G. J. (2018). Plasma Antioxidant Status in Patients with Alzheimer's Disease and Cognitively Intact Elderly: A Meta-Analysis of Case-Control Studies. *Journal of Alzheimer's disease: JAD*, 62(1), 305–317. <https://doi.org/10.3233/JAD-170758>
- Murakami, K., Murata, N., Noda, Y., Tahara, S., Kaneko, T., Kinoshita, N., Hatsuta, H., Murayama, S., Barnham, K. J., Irie, K., Shirasawa, T., & Shimizu, T. (2011). SOD1 (copper/zinc superoxide dismutase) deficiency drives amyloid β protein oligomerization and memory loss in mouse model of Alzheimer disease. *The Journal of biological chemistry*, 286(52), 44557–44568. <https://doi.org/10.1074/jbc.M111.279208>
- Nakamura, K., Bindokas, V. P., Kowlessur, D., Elas, M., Milstien, S., Marks, J. D., Halpern, H. J., & Kang, U. J. (2001). Tetrahydrobiopterin scavenges superoxide in dopaminergic neurons. *The Journal of biological chemistry*, 276(37), 34402–34407. <https://doi.org/10.1074/jbc.M103766200>
- Nam, E., Derrick, J. S., Lee, S., Kang, J., Han, J., Lee, S. J. C., Chung, S. W., & Lim, M. H. (2018). Regulatory Activities of Dopamine and Its Derivatives toward Metal-Free and Metal-Induced Amyloid- β Aggregation, Oxidative Stress, and Inflammation in Alzheimer's Disease. *ACS chemical neuroscience*, 9(11), 2655–2666. <https://doi.org/10.1021/acschemneuro.8b00122>

National Library of Medicine. (2011). *Trial of novel zinc cysteine preparation in Alzheimer's disease (CopperProof-2)*. ClinicalTrials.gov (Retrieved July 20, 2025, from <https://clinicaltrials.gov/study/NCT01099332>)

Nitta, Y., & Sugie, A. (2022). Studies of neurodegenerative diseases using *Drosophila* and the development of novel approaches for their analysis. *Fly*, 16(1), 275–298. <https://doi.org/10.1080/19336934.2022.2087484>

Nobili, A., Latagliata, E. C., Viscomi, M. T., Cavallucci, V., Cutuli, D., Giacobazzo, G., Krashia, P., Rizzo, F. R., Marino, R., Federici, M., De Bartolo, P., Aversa, D., Dell'Acqua, M. C., Cordella, A., Sancandi, M., Keller, F., Petrosini, L., Puglisi-Allegra, S., Mercuri, N. B., Coccurello, R., ... D'Amelio, M. (2017). Dopamine neuronal loss contributes to memory and reward dysfunction in a model of Alzheimer's disease. *Nature communications*, 8, 14727. <https://doi.org/10.1038/ncomms14727>

Nordberg, A., Ballard, C., Bullock, R., Darreh-Shori, T., & Somogyi, M. (2013). A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease. *The primary care companion for CNS disorders*, 15(2), PCC.12r01412. <https://doi.org/10.4088/PCC.12r01412>

O'Brien, R. J., & Wong, P. C. (2011). Amyloid precursor protein processing and Alzheimer's disease. *Annual review of neuroscience*, 34, 185–204. <https://doi.org/10.1146/annurev-neuro-061010-113613>

Ohrvik, H., & Thiele, D. J. (2014). How copper traverses cellular membranes through the mammalian copper transporter 1, Ctr1. *Annals of the New York Academy of Sciences*, 1314, 32–41. <https://doi.org/10.1111/nyas.12371>

Opazo, C., Huang, X., Cherny, R. A., Moir, R. D., Roher, A. E., White, A. R., Cappai, R., Masters, C. L., Tanzi, R. E., Inestrosa, N. C., & Bush, A. I. (2002). Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H₂O₂. *The Journal of biological chemistry*, 277(43), 40302–40308. <https://doi.org/10.1074/jbc.M206428200>

Ortiz-Sanz, C., Balantzategi, U., Quintela-López, T., Ruiz, A., Luchena, C., Zuazo-Ibarra, J., Capetillo-Zarate, E., Matute, C., Zugaza, J. L., & Alberdi, E. (2022). Amyloid β / PKC-dependent alterations in NMDA receptor composition are detected in early stages of Alzheimer's disease. *Cell death & disease*, 13(3), 253. <https://doi.org/10.1038/s41419-022-04687-y>

Ott, S., Dziadulewicz, N., & Crowther, D. C. (2015). Iron is a specific cofactor for distinct oxidation- and aggregation-dependent A β toxicity mechanisms in a *Drosophila* model. *Disease models & mechanisms*, 8(7), 657–667. <https://doi.org/10.1242/dmm.019042>

Pan, X., Kaminga, A. C., Wen, S. W., Wu, X., Acheampong, K., & Liu, A. (2019). Dopamine and Dopamine Receptors in Alzheimer's Disease: A Systematic Review and Network Meta-Analysis. *Frontiers in aging neuroscience*, 11, 175. <https://doi.org/10.3389/fnagi.2019.00175>

- Pathak, D., & Sriram, K. (2023). Molecular Mechanisms Underlying Neuroinflammation Elicited by Occupational Injuries and Toxicants. *International journal of molecular sciences*, 24(3), 2272. <https://doi.org/10.3390/ijms24032272>
- Pérez-Grijalba, V., Romero, J., Pesini, P., Sarasa, L., Monleón, I., San-José, I., Arbizu, J., Martínez-Lage, P., Munuera, J., Ruiz, A., Tárraga, L., Boada, M., & Sarasa, M. (2019). Plasma A β 42/40 Ratio Detects Early Stages of Alzheimer's Disease and Correlates with CSF and Neuroimaging Biomarkers in the AB255 Study. *The journal of prevention of Alzheimer's disease*, 6(1), 34–41. <https://doi.org/10.14283/jpad.2018.41>
- Pifferi, A., Chiaino, E., Fernandez-Abascal, J., Bannon, A. C., Davey, G. P., Frosini, M., & Valoti, M. (2024). Exploring the Regulation of Cytochrome P450 in SH-SY5Y Cells: Implications for the Onset of Neurodegenerative Diseases. *International journal of molecular sciences*, 25(13), 7439. <https://doi.org/10.3390/ijms25137439>
- Pignatelli, A., & Belluzzi, O. (2017). Dopaminergic Neurons in the Main Olfactory Bulb: An Overview from an Electrophysiological Perspective. *Frontiers in neuroanatomy*, 11, 7. <https://doi.org/10.3389/fnana.2017.00007>
- Piller C. (2022). Second death linked to potential antibody treatment for Alzheimer's disease. Woman's brain hemorrhage while receiving Eisai's widely heralded lecanemab heightens concerns over its safety. *Science*. <https://doi.org/10.1126/science.adf9701>
- Pingali, U., Kammila, S., Mekala, P., Yareeda, S., & Penugonda, S. (2024). A Study to Evaluate the Effect of Alpha-Lipoic Acid on Neuropathic Symptoms in Diabetic Neuropathy Patients on Gabapentin or Pregabalin. *Cureus*, 16(9), e70299. <https://doi.org/10.7759/cureus.70299>
- Presgraves, S. P., Ahmed, T., Borwege, S., & Joyce, J. N. (2004). Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamine agonists. *Neurotoxicity research*, 5(8), 579–598. <https://doi.org/10.1007/BF03033178>
- Pyatha, S., Kim, H., Lee, D., & Kim, K. (2022). Association between Heavy Metal Exposure and Parkinson's Disease: A Review of the Mechanisms Related to Oxidative Stress. *Antioxidants (Basel, Switzerland)*, 11(12), 2467. <https://doi.org/10.3390/antiox11122467>
- Pyo, H., Jou, I., Jung, S., & Joe, E. (1999). cAMP potentiates beta-amyloid-induced nitric oxide release from microglia. *Neuroreport*, 10(1), 37–40. <https://doi.org/10.1097/00001756-199901180-00007>
- Qu, M., Shi, H., Wang, K., Wang, X., Yu, N., & Guo, B. (2021). The Associations of Plasma/Serum Carotenoids with Alzheimer's Disease: A Systematic Review and Meta-Analysis. *Journal of Alzheimer's disease: JAD*, 82(3), 1055–1066. <https://doi.org/10.3233/JAD-210384>
- Quinn, J. F., Bussiere, J. R., Hammond, R. S., Montine, T. J., Henson, E., Jones, R. E., & Stackman, R. W., Jr (2007). Chronic dietary alpha-lipoic acid reduces deficits in hippocampal memory of aged Tg2576 mice. *Neurobiology of aging*, 28(2), 213–225. <https://doi.org/10.1016/j.neurobiolaging.2005.12.014>

- Rae, T. D., Schmidt, P. J., Pufahl, R. A., Culotta, V. C., & O'Halloran, T. V. (1999). Undetectable intracellular free copper: the requirement of a copper chaperone for superoxide dismutase. *Science (New York, N.Y.)*, 284(5415), 805–808. <https://doi.org/10.1126/science.284.5415.805>
- Rajendran, R., Minqin, R., Ynsa, M. D., Casadesus, G., Smith, M. A., Perry, G., Halliwell, B., & Watt, F. (2009). A novel approach to the identification and quantitative elemental analysis of amyloid deposits--insights into the pathology of Alzheimer's disease. *Biochemical and biophysical research communications*, 382(1), 91–95. <https://doi.org/10.1016/j.bbrc.2009.02.136>
- Reiter, L. T., Potocki, L., Chien, S., Gribskov, M., & Bier, E. (2001). A systematic analysis of human disease-associated gene sequences in *Drosophila melanogaster*. *Genome research*, 11(6), 1114–1125. <https://doi.org/10.1101/gr.169101>
- Religa, D., Strozzyk, D., Cherny, R. A., Volitakis, I., Haroutunian, V., Winblad, B., Naslund, J., & Bush, A. I. (2006). Elevated cortical zinc in Alzheimer disease. *Neurology*, 67(1), 69–75. <https://doi.org/10.1212/01.wnl.0000223644.08653.b5>
- Rinne, J. O., Säkö, E., Paljärvi, L., Mölsä, P. K., & Rinne, U. K. (1988). A comparison of brain choline acetyltransferase activity in Alzheimer's disease, multi-infarct dementia, and combined dementia. *Journal of neural transmission*, 73(2), 121–128. <https://doi.org/10.1007/BF01243383>
- Rischel, E. B., Gejl, M., Brock, B., Rungby, J., & Gjedde, A. (2023). In Alzheimer's disease, amyloid beta accumulation is a protective mechanism that ultimately fails. *Alzheimer's & dementia: the journal of the Alzheimer's Association*, 19(3), 771–783. <https://doi.org/10.1002/alz.12701>
- Ritchie, C. W., Bush, A. I., Mackinnon, A., Macfarlane, S., Mastwyk, M., MacGregor, L., Kiers, L., Cherny, R., Li, Q. X., Tammer, A., Carrington, D., Mavros, C., Volitakis, I., Xilinas, M., Ames, D., Davis, S., Beyreuther, K., Tanzi, R. E., & Masters, C. L. (2003). Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. *Archives of neurology*, 60(12), 1685–1691. <https://doi.org/10.1001/archneur.60.12.1685>
- Rival, T., Page, R. M., Chandraratna, D. S., Sendall, T. J., Ryder, E., Liu, B., Lewis, H., Rosahl, T., Hider, R., Camargo, L. M., Shearman, M. S., Crowther, D. C., & Lomas, D. A. (2009). Fenton chemistry and oxidative stress mediate the toxicity of the beta-amyloid peptide in a *Drosophila* model of Alzheimer's disease. *The European journal of neuroscience*, 29(7), 1335–1347. <https://doi.org/10.1111/j.1460-9568.2009.06701.x>
- Rogers, S. L., & Friedhoff, L. T. (1996). The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group. *Dementia (Basel, Switzerland)*, 7(6), 293–303. <https://doi.org/10.1159/000106895>
- Rosenberg, H.R., Culik, R. (1959). Effect of α -lipoic acid on vitamin C and vitamin E deficiencies. *Archives of Biochemistry and Biophysics*, 80(1), 86-93. [https://doi.org/10.1016/0003-9861\(59\)90345-5](https://doi.org/10.1016/0003-9861(59)90345-5)

Ross, R. A., Spengler, B. A., Domènech, C., Porubcin, M., Rettig, W. J., & Biedler, J. L. (1995). Human neuroblastoma I-type cells are malignant neural crest stem cells. *Cell growth & differentiation: the molecular biology journal of the American Association for Cancer Research*, 6(4), 449–456.

Rowland, E. A., Snowden, C. K., & Cristea, I. M. (2018). Protein lipoylation: an evolutionarily conserved metabolic regulator of health and disease. *Current opinion in chemical biology*, 42, 76–85. <https://doi.org/10.1016/j.cbpa.2017.11.003>

Roy, R. G., Mandal, P. K., & Maroon, J. C. (2023). Oxidative Stress Occurs Prior to Amyloid A β Plaque Formation and Tau Phosphorylation in Alzheimer's Disease: Role of Glutathione and Metal Ions. *ACS chemical neuroscience*, 14(17), 2944–2954. <https://doi.org/10.1021/acscchemneuro.3c00486>

Roy, S., & Lutsenko, S. (2024). Mechanism of Cu entry into the brain: many unanswered questions. *Neural regeneration research*, 19(11), 2421–2429. <https://doi.org/10.4103/1673-5374.393107>

Sagy-Bross, C., Kasianov, K., Solomonov, Y., Braiman, A., Friedman, A., Hadad, N., & Levy, R. (2015). The role of cytosolic phospholipase A2 α in amyloid precursor protein induction by amyloid beta1-42: implication for neurodegeneration. *Journal of neurochemistry*, 132(5), 559–571. <https://doi.org/10.1111/jnc.13012>

Salloway, S., Chalkias, S., Barkhof, F., Burkett, P., Barakos, J., Purcell, D., Suhy, J., Forrestal, F., Tian, Y., Umans, K., Wang, G., Singhal, P., Budd Haeberlein, S., & Smirnakis, K. (2022). Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients with Early Alzheimer Disease. *JAMA neurology*, 79(1), 13–21. <https://doi.org/10.1001/jamaneurol.2021.4161>

Sasahara, K., Morigaki, K., & Shinya, K. (2013). Effects of membrane interaction and aggregation of amyloid β -peptide on lipid mobility and membrane domain structure. *Physical chemistry chemical physics: PCCP*, 15(23), 8929–8939. <https://doi.org/10.1039/c3cp44517h>

Sasaki S. (2018). High prevalence of parkinsonism in patients with MCI or mild Alzheimer's disease. *Alzheimer's & dementia: the journal of the Alzheimer's Association*, 14(12), 1615–1622. <https://doi.org/10.1016/j.jalz.2018.06.3054>

Sawicki, K. T., De Jesus, A., & Ardehali, H. (2023). Iron Metabolism in Cardiovascular Disease: Physiology, Mechanisms, and Therapeutic Targets. *Circulation research*, 132(3), 379–396. <https://doi.org/10.1161/CIRCRESAHA.122.321667>

Schindler, S. E., Bollinger, J. G., Ovod, V., Mawuenyega, K. G., Li, Y., Gordon, B. A., Holtzman, D. M., Morris, J. C., Benzinger, T. L. S., Xiong, C., Fagan, A. M., & Bateman, R. J. (2019). High-precision plasma β -amyloid 42/40 predicts current and future brain amyloidosis. *Neurology*, 93(17), e1647–e1659. <https://doi.org/10.1212/WNL.0000000000008081>

- Scolari Grotto, F., & Glaser, V. (2024). Are high copper levels related to Alzheimer's and Parkinson's diseases? A systematic review and meta-analysis of articles published between 2011 and 2022. *Biometals: an international journal on the role of metal ions in biology, biochemistry, and medicine*, 37(1), 3–22. <https://doi.org/10.1007/s10534-023-00530-9>
- Selkoe D. J. (2001). Alzheimer's disease: genes, proteins, and therapy. *Physiological reviews*, 81(2), 741–766. <https://doi.org/10.1152/physrev.2001.81.2.741>
- Serra, L., Perri, R., Cercignani, M., Spanò, B., Fadda, L., Marra, C., Carlesimo, G. A., Caltagirone, C., & Bozzali, M. (2010). Are the behavioral symptoms of Alzheimer's disease directly associated with neurodegeneration? *Journal of Alzheimer's disease: JAD*, 21(2), 627–639. <https://doi.org/10.3233/JAD-2010-100048>
- Sharma, A. K., Pavlova, S. T., Kim, J., Kim, J., & Mirica, L. M. (2013). The effect of Cu(2+) and Zn(2+) on the A β 42 peptide aggregation and cellular toxicity. *Metallomics: integrated biometal science*, 5(11), 1529–1536. <https://doi.org/10.1039/c3mt00161j>
- Shay, K. P., Moreau, R. F., Smith, E. J., Smith, A. R., & Hagen, T. M. (2009). Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. *Biochimica et biophysica acta*, 1790(10), 1149–1160. <https://doi.org/10.1016/j.bbagen.2009.07.026>
- Sheline, C. T., Behrens, M. M., & Choi, D. W. (2000). Zinc-induced cortical neuronal death: contribution of energy failure attributable to loss of NAD(+) and inhibition of glycolysis. *The Journal of neuroscience: the official journal of the Society for Neuroscience*, 20(9), 3139–3146. <https://doi.org/10.1523/JNEUROSCI.20-09-03139.2000>
- Shinto, L., Quinn, J., Montine, T., Dodge, H. H., Woodward, W., Baldauf-Wagner, S., Waichunas, D., Bumgarner, L., Bourdette, D., Silbert, L., & Kaye, J. (2014). A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer's disease. *Journal of Alzheimers disease: JAD*, 38(1), 111–120. <https://doi.org/10.3233/JAD-130722>
- Shukla, A. K., & Misra, S. (2023). Evidences and therapeutic advantages of donanemab in the treatment of early Alzheimer's disease. *Journal of basic and clinical physiology and pharmacology*, 35(1-2), 25–29. <https://doi.org/10.1515/jbcpp-2023-0176>
- Singh, S. K., Sinha, P., Mishra, L., & Srikrishna, S. (2013). Neuroprotective Role of a Novel Copper Chelator against A β 42 Induced Neurotoxicity. *International journal of Alzheimer's disease*, 2013, 567128. <https://doi.org/10.1155/2013/567128>
- Smirnova, J., Kabin, E., Järving, I., Bragina, O., Tõugu, V., Plitz, T., & Palumaa, P. (2018). Copper(I)-binding properties of de-coppering drugs for the treatment of Wilson disease. α -Lipoic acid as a potential anti-copper agent. *Scientific reports*, 8(1), 1463. <https://doi.org/10.1038/s41598-018-19873-2>
- Smith, M. A., Harris, P. L., Sayre, L. M., & Perry, G. (1997). Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. *Proceedings of the National Academy of Sciences of the United States of America*, 94(18), 9866–9868. <https://doi.org/10.1073/pnas.94.18.9866>

Smith, D. P., Smith, D. G., Curtain, C. C., Boas, J. F., Pilbrow, J. R., Ciccotosto, G. D., Lau, T. L., Tew, D. J., Perez, K., Wade, J. D., Bush, A. I., Drew, S. C., Separovic, F., Masters, C. L., Cappai, R., & Barnham, K. J. (2006). Copper-mediated amyloid-beta toxicity is associated with an intermolecular histidine bridge. *The Journal of biological chemistry*, 281(22), 15145–15154. <https://doi.org/10.1074/jbc.M600417200>

Solomonson, A., & DeBerardinis, R. J. (2018). Lipoic acid metabolism and mitochondrial redox regulation. *The Journal of biological chemistry*, 293(20), 7522–7530. <https://doi.org/10.1074/jbc.TM117.000259>

Southon, A., Greenough, M. A., Ganio, G., Bush, A. I., Burke, R., & Camakaris, J. (2013). Presenilin promotes dietary copper uptake. *PloS one*, 8(5), e62811. <https://doi.org/10.1371/journal.pone.0062811>

Spoletti, E., La Barbera, L., Cauzzi, E., De Paolis, M. L., Saba, L., Marino, R., Sciamanna, G., Di Lazzaro, V., Keller, F., Nobili, A., Krashia, P., & D'Amelio, M. (2024). Dopamine neuron degeneration in the Ventral Tegmental Area causes hippocampal hyperexcitability in experimental Alzheimer's Disease. *Molecular psychiatry*, 29(5), 1265–1280. <https://doi.org/10.1038/s41380-024-02408-9>

Squitti, R., Faller, P., Hureau, C., Granzotto, A., White, A. R., & Kepp, K. P. (2021). Copper Imbalance in Alzheimer's Disease and Its Link with the Amyloid Hypothesis: Towards a Combined Clinical, Chemical, and Genetic Etiology. *Journal of Alzheimer's disease: JAD*, 83(1), 23–41. <https://doi.org/10.3233/JAD-201556>

Squitti, R., Ventriglia, M., Simonelli, I., Bonvicini, C., Costa, A., Perini, G., Binetti, G., Benussi, L., Ghidoni, R., Koch, G., Borroni, B., Albanese, A., Sensi, S. L., & Rongioletti, M. (2021). Copper Imbalance in Alzheimer's Disease: Meta-Analysis of Serum, Plasma, and Brain Specimens, and Replication Study Evaluating *ATP7B* Gene Variants. *Biomolecules*, 11(7), 960. <https://doi.org/10.3390/biom11070960>

Stefaniak, E., & Bal, W. (2019). Cu^{II} Binding Properties of N-Truncated Aβ Peptides: In Search of Biological Function. *Inorganic chemistry*, 58(20), 13561–13577. <https://doi.org/10.1021/acs.inorgchem.9b01399>

Storga, D., Vrecko, K., Birkmayer, J. G., & Reibnegger, G. (1996). Monoaminergic neurotransmitters, their precursors and metabolites in brains of Alzheimer patients. *Neuroscience letters*, 203(1), 29–32. [https://doi.org/10.1016/0304-3940\(95\)12256-7](https://doi.org/10.1016/0304-3940(95)12256-7)

Sturchio, A., Dwivedi, A. K., Malm, T., Wood, M. J. A., Cilia, R., Sharma, J. S., Hill, E. J., Schneider, L. S., Graff-Radford, N. R., Mori, H., Nübling, G., El Andaloussi, S., Svenningsson, P., Ezzat, K., Espay, A. J., & Dominantly Inherited Alzheimer Consortium (DIAN) (2022). High Soluble Amyloid-β42 Predicts Normal Cognition in Amyloid-Positive Individuals with Alzheimer's Disease-Causing Mutations. *Journal of Alzheimer's disease: JAD*, 90(1), 333–348. <https://doi.org/10.3233/JAD-220808>

Takaishi, N., Yoshida, K., Satsu, H., & Shimizu, M. (2007). Transepithelial transport of alpha-lipoic acid across human intestinal Caco-2 cell monolayers. *Journal of agricultural and food chemistry*, 55(13), 5253–5259. <https://doi.org/10.1021/jf063624i>

- Takeda A. (2000). Movement of zinc and its functional significance in the brain. *Brain research. Brain research reviews*, 34(3), 137–148. [https://doi.org/10.1016/s0165-0173\(00\)00044-8](https://doi.org/10.1016/s0165-0173(00)00044-8)
- Tampi, R. R., & van Dyck, C. H. (2007). Memantine: efficacy and safety in mild-to-severe Alzheimer's disease. *Neuropsychiatric disease and treatment*, 3(2), 245–258. <https://doi.org/10.2147/ndt.2007.3.2.245>
- Taniguchi, K., Yamamoto, F., Amano, A., Tamaoka, A., Sanjo, N., Yokota, T., Kametani, F., & Araki, W. (2022). Amyloid- β oligomers interact with NMDA receptors containing GluN2B subunits and metabotropic glutamate receptor 1 in primary cortical neurons: Relevance to the synapse pathology of Alzheimer's disease. *Neuroscience research*, 180, 90–98. <https://doi.org/10.1016/j.neures.2022.03.001>
- Tapia, L., González-Agüero, M., Cisternas, M. F., Suazo, M., Cambiazo, V., Uauy, R., & González, M. (2004). Metallothionein is crucial for safe intracellular copper storage and cell survival at normal and supra-physiological exposure levels. *The Biochemical journal*, 378(Pt 2), 617–624. <https://doi.org/10.1042/BJ20031174>
- Teng, X., Stefaniak, E., Girvan, P., Kotuniak, R., Płonka, D., Bal, W., & Ying, L. (2020). Hierarchical binding of copper^{II} to N-truncated A β ₄₋₁₆ peptide. *Metallomics : integrated biometal science*, 12(4), 470–473. <https://doi.org/10.1039/c9mt00299e>
- Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002). Phases of A beta-deposition in the human brain and its relevance for the development of AD. *Neurology*, 58(12), 1791–1800. <https://doi.org/10.1212/wnl.58.12.1791>
- Tolar, M., Hey, J., Power, A., & Abushakra, S. (2021). Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer's Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression. *International journal of molecular sciences*, 22(12), 6355. <https://doi.org/10.3390/ijms22126355>
- Troutwine, B. R., Hamid, L., Lysaker, C. R., Strobe, T. A., & Wilkins, H. M. (2022). Apolipoprotein E and Alzheimers disease. *Acta pharmaceutica Sinica. B*, 12(2), 496–510. <https://doi.org/10.1016/j.apsb.2021.10.002>
- Tsvetkov, P., Coy, S., Petrova, B., Dreishpoon, M., Verma, A., Abdusamad, M., Rossen, J., Joesch-Cohen, L., Humeidi, R., Spangler, R. D., Eaton, J. K., Frenkel, E., Kocak, M., Corsello, S. M., Lutsenko, S., Kanarek, N., Santagata, S., & Golub, T. R. (2022). Copper induces cell death by targeting lipoylated TCA cycle proteins. *Science (New York, N.Y.)*, 375(6586), 1254–1261. <https://doi.org/10.1126/science.abf0529>
- U.S. Food and Drug Administration. (2023, July 6). *FDA converts novel Alzheimer's disease treatment to traditional approval*. U.S. Food and Drug Administration. Retrieved September 20, 2024, from <https://www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-treatment-traditional-approval>

U.S. Food and Drug Administration. (2025, May 15). *FDA clears first blood test used in diagnosing Alzheimer's disease*. U.S. Department of Health and Human Services. Retrieved May 24, 2025, from <https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease>

U.S. National Library of Medicine. (2017). *A study of Deferiprone in participants with Alzheimer's disease (NCT03234686)*. ClinicalTrials.gov. Retrieved September 15, 2024, from <https://clinicaltrials.gov/study/NCT03234686>

van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., Froelich, L., Katayama, S., Sabbagh, M., Vellas, B., Watson, D., Dhadda, S., Irizarry, M., Kramer, L. D., & Iwatsubo, T. (2023). Lecanemab in Early Alzheimer's Disease. *The New England journal of medicine*, 388(1), 9–21. <https://doi.org/10.1056/NEJMoa2212948>

Vajdi, M., Noshadi, N., Hassanizadeh, S., Bonyadian, A., Seyedhosseini-Ghaheh, H., & Askari, G. (2023). The effects of alpha lipoic acid (ALA) supplementation on blood pressure in adults: a GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials. *Frontiers in cardiovascular medicine*, 10, 1272837. <https://doi.org/10.3389/fcvm.2023.1272837>

Villemagne, V. L., Rowe, C. C., Barnham, K. J., Cherny, R., Woodward, M., Bozinosvski, S., Salvado, O., Bourgeat, P., Perez, K., Fowler, C., Rembach, A., Maruff, P., Ritchie, C., Tanzi, R., & Masters, C. L. (2017). A randomized, exploratory molecular imaging study targeting amyloid β with a novel 8-OH quinoline in Alzheimer's disease: The PBT2-204 IMAGINE study. *Alzheimer's & dementia (New York, N. Y.)*, 3(4), 622–635. <https://doi.org/10.1016/j.trci.2017.10.001>

Volloch, V., & Rits-Volloch, S. (2022). The Amyloid Cascade Hypothesis 2.0: On the Possibility of Once-in-a-Lifetime-Only Treatment for Prevention of Alzheimer's Disease and for Its Potential Cure at Symptomatic Stages. *Journal of Alzheimer's disease reports*, 6(1), 369–399. <https://doi.org/10.3233/ADR-220031>

Volloch, V., & Rits-Volloch, S. (2023). The Amyloid Cascade Hypothesis 2.0: Generalization of the Concept. *Journal of Alzheimer's disease reports*, 7(1), 21–35. <https://doi.org/10.3233/ADR-220079>

Vossel, K. A., Beagle, A. J., Rabinovici, G. D., Shu, H., Lee, S. E., Naasan, G., Hegde, M., Cornes, S. B., Henry, M. L., Nelson, A. B., Seeley, W. W., Geschwind, M. D., Gorno-Tempini, M. L., Shih, T., Kirsch, H. E., Garcia, P. A., Miller, B. L., & Mucke, L. (2013). Seizures and epileptiform activity in the early stages of Alzheimer disease. *JAMA neurology*, 70(9), 1158–1166. <https://doi.org/10.1001/jamaneurol.2013.136>

Wallin, C., Sholts, S. B., Österlund, N., Luo, J., Jarvet, J., Roos, P. M., Ilag, L., Gräslund, A., & Wärmländer, S. K. T. S. (2017). Alzheimer's disease and cigarette smoke components: effects of nicotine, PAHs, and Cd(II), Cr(III), Pb(II), Pb(IV) ions on amyloid- β peptide aggregation. *Scientific reports*, 7(1), 14423. <https://doi.org/10.1038/s41598-017-13759-5>

- Wang, T., Cheng, J., Wang, S., Wang, X., Jiang, H., Yang, Y., Wang, Y., Zhang, C., Liang, W., & Feng, H. (2018). α -Lipoic acid attenuates oxidative stress and neurotoxicity via the ERK/Akt-dependent pathway in the mutant hSOD1 related Drosophila model and the NSC34 cell line of amyotrophic lateral sclerosis. *Brain research bulletin*, 140, 299–310. <https://doi.org/10.1016/j.brainresbull.2018.05.019>
- Wang, Z., Zhu, W., Xing, Y., Jia, J., & Tang, Y. (2022). B vitamins and prevention of cognitive decline and incident dementia: a systematic review and meta-analysis. *Nutrition reviews*, 80(4), 931–949. <https://doi.org/10.1093/nutrit/nuab057>
- Ward, R. J., Zucca, F. A., Duyn, J. H., Crichton, R. R., & Zecca, L. (2014). The role of iron in brain ageing and neurodegenerative disorders. *The Lancet. Neurology*, 13(10), 1045–1060. [https://doi.org/10.1016/S1474-4422\(14\)70117-6](https://doi.org/10.1016/S1474-4422(14)70117-6)
- Wärmländer, S. K. T. S., Österlund, N., Wallin, C., Wu, J., Luo, J., Tiiman, A., Jarvet, J., & Gräslund, A. (2019). Metal binding to the amyloid- β peptides in the presence of biomembranes: potential mechanisms of cell toxicity. *Journal of biological inorganic chemistry: JBIC: a publication of the Society of Biological Inorganic Chemistry*, 24(8), 1189–1196. <https://doi.org/10.1007/s00775-019-01723-9>
- Warren, P. J., Earl, C. J., & Thompson, R. H. (1960). The distribution of copper in human brain. *Brain: a journal of neurology*, 83, 709–717. <https://doi.org/10.1093/brain/83.4.709>
- Willem, M., Tahirovic, S., Busche, M. A., Ovsepian, S. V., Chafai, M., Kootar, S., Hornburg, D., Evans, L. D., Moore, S., Daria, A., Hampel, H., Müller, V., Giudici, C., Nuscher, B., Wenninger-Weinzierl, A., Kremmer, E., Heneka, M. T., Thal, D. R., Giedraitis, V., Lannfelt, L., ... Haass, C. (2015). η -Secretase processing of APP inhibits neuronal activity in the hippocampus. *Nature*, 526(7573), 443–447. <https://doi.org/10.1038/nature14864>
- World Health Organization. (2023, September). *Dementia*. World Health Organization. Retrieved February 8, 2025, from <https://www.who.int/news-room/fact-sheets/detail/dementia>
- Xiao, X., Liu, H., Liu, X., Zhang, W., Zhang, S., & Jiao, B. (2021). APP, PSEN1, and PSEN2 Variants in Alzheimer's Disease: Systematic Re-evaluation According to ACMG Guidelines. *Frontiers in aging neuroscience*, 13, 695808. <https://doi.org/10.3389/fnagi.2021.695808>
- Xu, L., Zhang, W., Liu, X., Zhang, C., Wang, P., & Zhao, X. (2018). Circulatory Levels of Toxic Metals (Aluminum, Cadmium, Mercury, Lead) in Patients with Alzheimer's Disease: A Quantitative Meta-Analysis and Systematic Review. *Journal of Alzheimer's disease: JAD*, 62(1), 361–372. <https://doi.org/10.3233/JAD-170811>
- Yang, Z., Zou, Y., & Wang, L. (2023). Neurotransmitters in Prevention and Treatment of Alzheimer's Disease. *International journal of molecular sciences*, 24(4), 3841. <https://doi.org/10.3390/ijms24043841>
- Yu, W. H., Lukiw, W. J., Bergeron, C., Niznik, H. B., & Fraser, P. E. (2001). Metallothionein III is reduced in Alzheimer's disease. *Brain research*, 894(1), 37–45. [https://doi.org/10.1016/S0006-8993\(00\)03196-6](https://doi.org/10.1016/S0006-8993(00)03196-6)

- Zamberlan, D. C., Halmenschelager, P. T., Silva, L. F. O., & da Rocha, J. B. T. (2020). Copper decreases associative learning and memory in *Drosophila melanogaster*. *The Science of the total environment*, 710, 135306. <https://doi.org/10.1016/j.scitotenv.2019.135306>
- Zarow, C., Lyness, S. A., Mortimer, J. A., & Chui, H. C. (2003). Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. *Archives of neurology*, 60(3), 337–341. <https://doi.org/10.1001/archneur.60.3.337>
- Zatta, P., Drago, D., Zambenedetti, P., Bolognin, S., Nogara, E., Peruffo, A., & Cozzi, B. (2008). Accumulation of copper and other metal ions, and metallothionein I/II expression in the bovine brain as a function of aging. *Journal of chemical neuroanatomy*, 36(1), 1–5. <https://doi.org/10.1016/j.jchemneu.2008.02.008>
- Zehnpfennig, B., Wiriyaermskul, P., Carlson, D. A., & Quick, M. (2015). Interaction of α -Lipoic Acid with the Human Na⁺/Multivitamin Transporter (hSMVT). *The Journal of biological chemistry*, 290(26), 16372–16382. <https://doi.org/10.1074/jbc.M114.622555>
- Zhang, X. X., Wang, H. R., Meng-Wei, Hu, Y. Z., Sun, H. M., Feng, Y. X., & Jia, J. J. (2024). Association of Vitamin D Levels with Risk of Cognitive Impairment and Dementia: A Systematic Review and Meta-Analysis of Prospective Studies. *Journal of Alzheimer's disease: JAD*, 98(2), 373–385. <https://doi.org/10.3233/JAD-231381>
- Zhang, X., Li, Y., Xu, H., & Zhang, Y. W. (2014). The γ -secretase complex: from structure to function. *Frontiers in cellular neuroscience*, 8, 427. <https://doi.org/10.3389/fncel.2014.00427>
- Zhang, Z., Song, M., Liu, X., Su Kang, S., Duong, D. M., Seyfried, N. T., Cao, X., Cheng, L., Sun, Y. E., Ping Yu, S., Jia, J., Levey, A. I., & Ye, K. (2015). Delta-secretase cleaves amyloid precursor protein and regulates the pathogenesis in Alzheimer's disease. *Nature communications*, 6, 8762. <https://doi.org/10.1038/ncomms9762>
- Ziegler, D., Nowak, H., Kempler, P., Vargha, P., & Low, P. A. (2004). Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. *Diabetic medicine: a journal of the British Diabetic Association*, 21(2), 114–121. <https://doi.org/10.1111/j.1464-5491.2004.01109.x>

Acknowledgements

I would like to acknowledge and thank my supervisors Professor Peep Palumaa and Adjunct Professor Vello Tõugu for their valuable support and good advice throughout my studies.

Great science is teamwork. Therefore, I am thankful for all my colleagues and co-authors, thanks to whom all the experiments and articles have been completed.

I would like to thank my dear fellow student Laura, with whom I started my bachelor's studies and with whom I now share the doctoral journey, even though we have completed the same path partly at different times. She has been a wonderful companion throughout this journey, sharing both joys and challenges along the way.

I must also express my deep gratitude to my dear little son, whose presence gave me the strength and motivation to finish writing my doctoral thesis after a long break.

I am also grateful to all the funding agencies that have supported our work including Estonian Research Council and Estonian Science Foundation.

Abstract

Toxicity of amyloid beta peptides and the effect of α -lipoic acid in Cellular and Fruit Fly Models of Alzheimer's Disease

Alzheimer's disease is the most common form of dementia, with devastating economic and social impacts. The neuropathological features of the disease – amyloid plaques and neurofibrillary tangles – have long been considered central to its aetiology. Although amyloid plaques, composed of amyloid beta peptides and neurofibrillary tangles, formed by hyperphosphorylated tau protein, are frequently observed in the brains of AD patients, the precise role these features play in the initiation and progression of the disease remains unclear. Recently, there has been an increased focus on the processes preceding amyloid accumulation, and it has been found that dysregulation of metal ions plays a role in the development of the disease. The association of metal ions with AD has also led to the investigation of various metal-binding compounds as potential therapeutic agents.

Cellular models, including immortalized cell lines, have become essential tools for investigating the molecular and cellular mechanisms underlying AD in a cost-effective and reproducible manner. One of the most widely used immortalized cell lines in AD research is the human neuroblastoma SH-SY5Y cell line. Most research has used these cells in their undifferentiated form, but they have the ability to differentiate into multiple neuronal phenotypes, including cholinergic, dopaminergic, and noradrenergic cells, which resemble neurons found in the human brain. It is known that various neurotransmitter systems are implicated in AD and a better understanding of these systems helps personalize treatment approaches, which is crucial for managing the complex nature of AD. In this thesis, human neuroblastoma SH-SY5Y cells were differentiated into cholinergic, noradrenergic, and dopaminergic phenotypes, and their sensitivities to A β 42 were compared. Cell viability measurements and cell membrane permeability assays showed that noradrenergic and cholinergic cells were susceptible to A β 42 toxicity, whereas dopaminergic cells were resistant. Using cholinergic SH-SY5Y cells, A β 42 was shown to induce apoptotic cell death. A β can exist in multiple assembly states, and the most toxic form has long been debated. Our results showed that cellular toxicity was raised during the fibrillization process, as mature fibrils were not toxic to the cells.

Since it is known that copper is misdistributed in the brains of AD patients, and that the natural compound α -lipoic acid (α -LA) has previously been found to have copper-binding properties, it was investigated whether α -LA could help to restore copper homeostasis. Using undifferentiated and cholinergic SH-SY5Y cells, ICP-MS measurements showed that α -LA was able to promote translocation of copper from the extracellular space into the cells. The effect of α -LA was also studied *in vivo*, and negative geotaxis locomotor experiments with *Drosophila melanogaster* demonstrated that it protected AD model flies from developing AD-like phenotype. SEM experiments further showed that α -LA alleviated copper-induced eye defects in AD model flies.

In conclusion, differentiated SH-SY5Y cells represent a valuable model for investigating various aspects of AD and for supporting the development of novel therapeutic strategies. Furthermore, the natural compound α -LA shows promise in modulating copper metabolism and may be beneficial in the prevention or early stages of AD.

Lühikokkuvõte

Amüloid beeta peptiidide toksilisus ning α -lipoehappe mõju Alzheimeri tõve rakulistes ja äädikakärbsse mudelites

Alzheimeri tõbi (AT) on neurodegeneratiivne haigus, mida iseloomustavad ajurakkude degeneratsioon ning kognitiivsete funktsioonide järk-järguline halvenemine. Haiguse täpseid molekulaarseid mehhanisme ei ole siiani täielikult mõistetud. AT neuropatoloogilised tunnused – amüloidsed naastud ja neurofibrillaarsed kämbud – on pikka aega olnud haiguse etioloogia keskseks osaks. Kuigi amüloidsed naastud, mis koosnevad amüloid-beeta ($A\beta$) peptiididest ja neurofibrillaarsed kämbud, mis moodustuvad hüperfosforüleeritud tau valgust, esinevad sageli AT patsientide ajus, on nende täpne roll haiguse tekkes ja arengus endiselt ebaselge. Seetõttu on hakatud viimastel aastatel rohkem tähelepanu pöörama amüloidide kogunemisele eelnevatele protsessidele ning on leitud, et metallioonide regulatsiooni häired mängivad haiguse arengus olulist rolli. Metallioonide seos AT-ga on viinud ka erinevate metalle-siduvate ühendite uurimiseni, mida oleks võimalik kasutada potentsiaalsete terapeutiliste agentidena.

AT molekulaarsete ja rakuliste mehhanismide uurimisel on erinevad rakumudelid muutunud olulisteks tööriistadeks. Üks enim kasutatavaid rakuliine AT uurimisel on inimese neuroblastoomi SH-SY5Y rakuliin. Enamik teadusuuringutest on kasutanud neid rakke nende diferentseerimata vormis, kuid neil on ka võime diferentseeruda erinevateks neuronisarnasteks fenotüüpideks, sealhulgas koliinergilisteks, dopamiinergilisteks ja noradrenergilisteks, mis meenutavad neuroneid. Käesolevas doktoritöös diferentseeriti inimese neuroblastoomi SH-SY5Y rakud koliinergilisteks, noradrenergilisteks ja dopamiinergilisteks fenotüüpideks ning võrreldi nende tundlikkust $A\beta$ 42 suhtes. Rakkude elulemuse mõõtmised WST-1 testiga ning rakumembraani läbilaskvuse katsed propiidiumiiodiidiga näitasid, et noradrenergilised ja koliinergilised rakud olid $A\beta$ 42 toksilisuse suhtes tundlikud, samas kui dopamiinergilised rakud olid resistentsed. See on kooskõlas varasema leiuga, et AT ajus on just koliinergilised ning noradrenergilised neuronid need, mis esimestena hukuvad. Koliinergiliste SH-SY5Y rakkudega näidati, et $A\beta$ 42 põhjustas apoptootilist rakusurma, $A\beta$ 40 aga rakkudele toksiline ei olnud. $A\beta$ võib esineda erinevates molekulaarsetes vormides ning kõige toksilisema vormi üle on pikka aega arutletud. Antud töö tulemused näitasid, et toksilisus tekkis $A\beta$ fibrillisatsiooni protsessi käigus ning küpsed $A\beta$ fibrillid rakkudele toksilised ei olnud.

On leitud, et vask on AT-ga patsientide ajus valesti jaotunud – rakust väljaspool on seda liiga palju ning raku sees liiga vähe, jättes olulised vaskensüümid vase puudusesse. Kuna varasematest uuringutest on teada, et looduslik ühend α -lipoehape (α -LH) on vaske-siduvate omadustega, uuriti, kas α -LH võiks aidata normaliseerida vase homöostaasi. Nii diferentseerimata kui ka koliinergiliste SH-SY5Y rakkudega tehtud ICP-MS mõõtmised näitasid, et α -LH suudab viia vase ekstratsellulaarsest ruumist rakkudesse kontsentratsioonist-sõltuval viisil, samas kui kaks Wilsoni tõves kasutatavat ravimit trientiin ja D-penisillamiin sellist efekti ei omanud. Kõrgematel kontsentratsioonidel muutus D-penisillamiin vase juuresolekul hoopis toksiliseks. α -LH mõju uuriti edasi ka *in vivo* tingimustes kasutades selleks äädikakärbsed. Äädikakärbestega tehtud negatiivse geotaksise katsetes näidati, et α -LH manustamine omas ennetavat mõju, kaitses AT mudelkärbsed AT-sarnase fenotüübi tekkimise eest. SEM-katsed näitasid, et α -LH leevendas ka vase põhjustatud silmakahjustusi AT mudelkärbestel.

Kokkuvõttes võib öelda, et diferentseeritud kujul pakuvad SH-SY5Y rakud sobilikku mudelit erinevate AT-ga seotud aspektide uurimiseks ning on abiks uute ravimeetodite väljatöötamiseks. Lisaks omab looduslik ühend α -LH potentsiaali vase metabolismi reguleerimiseks ning sellest võiks eelkõige kasu olla AT ennetusel või varajases staadiumis.

Appendix 1

Publication I

Krishtal, J., Bragina, O., Metsla, K., Palumaa, P., & Tõugu, V. (2017). In situ fibrillizing amyloid-beta 1-42 induces neurite degeneration and apoptosis of differentiated SH-SY5Y cells. *PloS one*, 12(10), e0186636. <https://doi.org/10.1371/journal.pone.0186636>

RESEARCH ARTICLE

In situ fibrillizing amyloid-beta 1-42 induces neurite degeneration and apoptosis of differentiated SH-SY5Y cells

Jekaterina Krishtal*, Olga Bragina, Kristel Metsla, Peep Palumaa, Vello Tõugu

Department of Chemistry and Biotechnology, Tallinn University of Technology, Tallinn, Estonia

* katerina.kristall@gmail.com



Abstract

The progression of Alzheimer's disease is causatively linked to the accumulation of amyloid- β aggregates in the brain, however, it is not clear how the amyloid aggregates initiate the death of neuronal cells. The *in vitro* toxic effects of amyloid peptides are most commonly examined using the human neuroblastoma derived SH-SY5Y cell line and here we show that differentiated neuron-like SH-SY5Y cells are more sensitive to amyloid peptides than non-differentiated cells, because the latter lack long neurites. Exogenous soluble amyloid- β 1–42 covered cell bodies and whole neurites in differentiated cells with dense fibrils, causing neurite beading and fragmentation, whereas preformed amyloid- β 1–42 fibrils had no toxic effects. Importantly, spontaneously fibrillizing amyloid- β 1–42 peptide exhibited substantially higher cellular toxicity than amyloid- β 1–40, which did not form fibrils under the experimental conditions. These results support the hypothesis that peptide toxicity is related to the active fibrillization process in the incubation mixture.

OPEN ACCESS

Citation: Krishtal J, Bragina O, Metsla K, Palumaa P, Tõugu V (2017) In situ fibrillizing amyloid-beta 1-42 induces neurite degeneration and apoptosis of differentiated SH-SY5Y cells. PLoS ONE 12(10): e0186636. <https://doi.org/10.1371/journal.pone.0186636>

Editor: Stephen D Ginsberg, Nathan S Kline Institute, UNITED STATES

Received: March 27, 2017

Accepted: October 4, 2017

Published: October 24, 2017

Copyright: © 2017 Krishtal et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: This work was supported by the Estonian Research Council (grant IUT 19-8) to PP and Estonian Science Foundation grant 9318 to VT.

Competing interests: No competing financial interests exist.

Abbreviations: AD, Alzheimer's disease; APP, amyloid precursor protein; ATCC, American Type

Introduction

Alzheimer's disease (AD), a complex neurodegenerative disorder, is the most prevalent cause of dementia worldwide. Although the disease was first described more than 100 years ago, the etiology of AD is still elusive. Amyloid plaques in the patient's brain are the primary hallmark of AD and the evidence for the central role of amyloid beta ($A\beta$) peptides—the main component of amyloid plaques—in the pathogenesis of AD is very strong [1, 2]. For more than twenty years, the amyloid cascade hypothesis has served as the dominant framework for AD studies, however, a clear understanding and description of the molecular events leading to neurodegeneration is still missing and several alternative explanations for disease progression are under discussion [3–6]. It has been shown that various aggregated forms of $A\beta$ peptides are neurotoxic in animal models, primary neuronal cultures and immortalized cell lines [7–9]. However, the results of $A\beta$ toxicity studies are often controversial and have not yet provided a clear understanding of the disease mechanism or the molecular events underlying $A\beta$ toxicity. Since mainly neuronal cells die during neurodegeneration, it is likely that $A\beta$ acts via a specific mechanism to induce neuronal cell death. Previous studies on primary neurons have shown

Culture Collection; A β , amyloid beta; BDNF, brain derived neurotrophic factor; CalceinAM, calcein-acetoxymethyl ester; DAPI, 4',6-diamidino-2-phenylindole; DIC, differential interference contrast; DMEM, Dulbecco's modified Eagle's medium; DMSO, dimethyl sulfoxide; EDTA, Ethylenediaminetetraacetic acid; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; HFIP, 1,1,1,3,3,3-hexafluoro-2-propanol; LSM, laser scanning microscope; MALDI-MS, matrix-assisted laser desorption ionization mass spectrometry; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; RA, retinoic acid; ROS, reactive oxygen species; SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis; Sy, Synaptophysin1; TUJ-1, beta III tubulin; WST, water soluble tetrazolium.

that A β causes neuritic abnormalities in neuronal cultures [10, 11], which are also initial signs of dying neurons in AD. Therefore, it is important to use relevant cellular models for the study of the neuron-specific effects of A β peptides. The human SH-SY5Y cell line is widely used as a model for different neurodegenerative diseases including AD [12]. The phenotype of SH-SY5Y cells can be manipulated by inducing different programs of neural differentiation, however, in most (81.5%) publications non-differentiated cells are used [12]. Due to their dopaminergic character, SH-SY5Y cells are generally considered as a model for Parkinson's disease, however, they can be differentiated to dominantly cholinergic phenotype suitable for AD studies by treatment with retinoic acid (RA) and brain-derived neurotrophic factor (BDNF) [13]. A β toxicity on SH-SY5Y cells has been determined in a large number of studies, however, there are only a few examples examining A β -induced toxicity in SH-SY5Y cells where cell proliferation has been suppressed and preliminary differentiation initiated by RA [14–16]. Additionally to the best of our knowledge, there are currently no available data investigating whether A β is toxic for RA/BDNF differentiated SH-SY5Y cells.

Another important yet understudied area within the framework of the amyloid hypothesis concerns the exact nature of the toxic form(s) of A β . In the AD brain, the “extra” amyloid in developing plaques is in the form of amyloid fibrils. The fibrillation is an autocatalytic process—once the fibrils are formed they start to grow by trapping monomers. Due to the relatively low toxicity of A β monomers and preformed A β fibrils for cell cultures, the pathogenic entities of the peptide are intensively searched for and the toxic effects have been attributed to a wide variety of species, including oligomers, intermediate aggregates and peptide-copper complexes [17–20]. In many cases the peptide formulations have been pretreated in conditions entirely different from those that can occur in living organisms. For instance, a popular oligomerization procedure involves fast dilution of concentrated peptide solutions in an organic solvent to form a supersaturated solution [21, 22]. In 1994 Lambert and colleagues demonstrated the toxic effect of A β 42 on RA pretreated SH-SY5Y cells and attributed this effect to the peptide oligomers (DMSO-induced) [23]. Recent studies have demonstrated that the toxic entities of the peptide can be the metastable particles that form during the natural fibrillization of A β [20, 24], and serve to highlight that these more natural fibrils should be preferred over artificially generated oligomers.

Here we used RA and BDNF differentiated human neuroblastoma SH-SY5Y cells, a simple model suggested for neuronal screening [25–27], to study the effects of A β -peptides. The differentiation of SH-SY5Y cells increased their susceptibility to A β and allowed the description and quantification of pathological changes associated with primary neuronal cultures and patients with AD [28]. The obtained results support the hypothesis that neuron-specific A β toxicity may be caused by the intermediate amyloid aggregates that form during the fibrillization of A β -peptides [29]. In our opinion, further study of the differentiated SH-SY5Y cells will aid our understanding of the molecular mechanisms responsible for the pathological processes induced by amyloid peptides in cells of human origin.

Materials and methods

Chemicals and reagents

Cell culture associated reagents were purchased from Gibco, Thermo Fisher: Dulbecco's Modified Eagle's Medium (DMEM), 0.25% Trypsin-EDTA solution. Penicillin/Streptomycin solution was from PAA, Cambridge, UK. Brain derived neurotrophic factor was obtained from Alomone Labs, Jerusalem, Israel. Recombinant human A β 40 and A β 42 peptides (TFA salts, purity >97%) were from rPeptide, Bogart, GA 30622, USA. Tween-20 (Ferak, Berlin, Germany) WST-1 cell viability assay was purchased from Roche, Switzerland, and the Caspase-

Glo assay kit from Promega Co, Madison, WI, USA. 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), poly-L-lysine, retinoic acid, CalceinAM (calcein-acetoxymethyl ester), sodium chloride; goat serum; staurosporine, 4',6-diamidino-2-phenylindole (DAPI), PBS were obtained from Sigma Aldrich.

Antibodies against a microtubule component β III-tubulin TUJ-1 were obtained from Abcam, Cambridge, UK; anti-APP/A β antibody—from Millipore, Darmstadt, Germany. Guinea pig anti-Synaptophysin1 was from Synaptic Systems, Goettingen, Germany. Secondary antibodies were Alexa-488 and Alexa-568 from Invitrogen.

Cell culture

SH-SY5Y cells (ATCC, VA 20110, USA) were cultured in DMEM without Phenol Red and supplemented with 10% FBS and 1X Penicillin/Streptomycin solution at 37°C and 5% CO₂, to allow fluorescence measurements (Gibco, Thermo Fisher). The medium was changed every 2–3 days and cells were split using 0.25% Trypsin-EDTA solution.

SH-SY5Y differentiation

A differentiation protocol from Ref. [25, 26] with several changes was applied. The cells were seeded onto microtiter plates (Greiner Bio-one) coated with poly-L-lysine to allow neurite outgrowth and differentiation. Cells were grown for 1 day prior to differentiation. The next day, 10 μ M RA in DMEM with 10% FBS was applied; the medium with RA was changed every day. After a 4-day incubation with RA, BDNF at the final concentration of 50 ng/ml was applied in DMEM without serum for 2 days. After 6 days of differentiation the cells were used for the experiments. (S1 Fig).

Preparation of amyloid- β peptide solutions

Lyophilized A β 40 and A β 42 peptides were dissolved in HFIP to get a homogeneously monomeric preparation, vortexed briefly and incubated for 1 hour at room temperature. Next, defibrillized peptide solutions were aliquoted and dried in a vacuum desiccator overnight. Peptide aliquots were stored at -80°C until usage. Peptide quality was assessed by ¹H NMR, MALDI-MS and SDS-PAGE (S2 Fig). For experiments, A β 40 and A β 42 aliquots were dissolved in 20 mM HEPES buffer containing 100 mM NaCl at pH 7.3 to the final concentration of 160 μ M and vortexed for 10 sec. The prepared peptide solution was immediately applied to the serum free cell culture. Preformed fibrils were prepared as described in Ref. [30].

Evaluation of neurite degeneration

Cells were grown in 6 cm cell culture plates on 47 mm glass coverslips coated with poly-L-lysine and differentiated as described above. Photomicrographs of at least 12 random areas of neurites were taken using a Zeiss Duo 510 META microscope with a 20X objective or a 63X objective with oil immersion. Neurites were stained with CalceinAM for the analysis. General morphology of neurites was obtained with the differential interference contrast (aperture DIC2) technique. All microscopy experiments were performed in an incubation chamber at 37°C in the presence of 5% CO₂.

Photomicrographs of neurites in randomly selected areas were stored and processed using LSM Image Browser software. The method to evaluate neurite degeneration was adopted from Ref. [31] with small modifications. The number of beads per total length of measured neurites was counted. Medium or thin neurites in captured regions were chosen for this purpose. The number of beadings/50 μ m length was counted and averaged over at least 8 neurites for each

area. The proportion of fragmented neurites was counted for each area and expressed as a percentage of the total amount of counted neurites longer than 100 μm (S3 Fig). The procedures were repeated on three different samples (vehicle, A β 40 and A β 42). The results of three independent experiments were averaged and presented with SEM without normalization. The photomicrographs were coded for the evaluator by random codes.

Immunofluorescence

The neuronal phenotype of differentiated SH-SY5Y was established by immunocytochemical staining with antibodies against a microtubule component β III-tubulin TUJ-1 (1:2000). For the determination of A β location in the cell culture, the cells were stained with anti-APP/A β antibody (1:2000) and guinea pig anti-Synaptophysin1 (1:2000). Samples were fixed for 15 min at 4°C in methanol (for microtubule visualization) or 4% paraformaldehyde (anti-APP/A β staining). Blocking was performed with 3% goat serum. The samples were washed with PBS to remove excess protein before incubation with primary monoclonal antibodies in 0.25% Tween-20 solution 1:2000 at 4°C overnight. Samples were washed with PBS for 5 min before incubation with secondary Alexa-488 or Alexa-568 conjugated goat anti-mouse antibody 1:2000 or goat anti-guinea pig antibody 1:2000 in PBS for 1 hour at room temperature. Nuclei were stained with DAPI for 5 min at room temperature. Cells were investigated using a confocal Zeiss Duo 510 META microscope with a 20X objective or a 63X objective with Zeiss oil immersion.

Cell cytotoxicity assays

The effects of peptides on the cells were determined using the WST-1 cell viability assay and the membrane permeability assay with propidium iodide (PI). 20 mM HEPES buffer containing 100 mM NaCl at pH 7.3 was used as a negative control (hereafter Vehicle) added to serum-free medium in equal amounts with the peptide sample. 5 μl /well of WST-1 reagent was added to 100 μl cell culture medium, incubated at 37°C for 2 h and the absorbance measured at 450 nm. PI in PBS (0.5 mM) was added to 100 μl cell culture 1.5 μl /well and incubated for 2 h at 37°C. Fluorescence was measured using a TECAN Genios Pro microplate reader (Tecan, Switzerland) (excitation 540 nm, emission 612 nm). Data from at least three independent experiments, all experimental points in triplicates, were normalized taking Vehicle as 100%.

Measurement of caspase activity

The differentiated SH-SY5Y cells were plated in 96-well plates. The activity of caspase-3/7 was measured using a Caspase-Glo assay kit. In this kit a substrate for luciferase is released when the colorimetric substrate, containing the tetrapeptide sequence DEVD, is cleaved by caspase-3/7. After cell treatment with the buffer (the vehicle), staurosporine or A β (20 μM), Caspase Glo-3/7 reagent was added to the culture medium and incubated at room temperature for 1 h. The intensity of the chemiluminescence was measured using a TECAN Genios Pro microplate reader.

Statistical analysis

The differential significance of the results obtained was determined by one-way ANOVA followed by a Bonferroni's multiple comparisons test at the 0.05 level. All values are presented with means $\pm$ SEM, except where otherwise indicated. Raw data values can be seen in S1–S7 Tables. The number of experiments is represented by *n*. *p*-values of post-hoc test are




Fig 1. RA/BDNF differentiated cells establish a neuron-like phenotype with long neurites. (A) Immunocytochemistry of non-differentiated and RA/BDNF differentiated SH-SY5Y cells for DAPI (blue; left), anti-TUJ-1 (green; middle). Scale bar 50 μ m.

<https://doi.org/10.1371/journal.pone.0186636.g001>

denoted by asterisks (* $p \leq 0.01$; ** $p \leq 0.005$). Statistical analysis was carried out using Graph-Pad Prism 6.

Results

RA/BDNF differentiation increases the susceptibility of SH-SY5Y cells towards A β toxicity

Neuron-like SH-SY5Y human neuroblastoma cells were generated using a differentiation procedure modified from previously described protocols [25–27]. The cells were pre-treated for 4 days with 10 μ M *all-trans* RA to induce the expression of TrkB receptors and increase their biological responsiveness to neurotrophic factor treatment [32]. After the sequential treatment with RA and BDNF, the cells developed long beta III tubulin (TUJ-1)-positive neurites that formed networks characteristic to neurons (Fig 1A).

A β -peptides had a small effect on the viability of undifferentiated SH-SY5Y cells in serum-free DMEM. The influence of serum withdrawal on cell viability during 3 days was not significant (S4 Fig). In the presence of A β 42 the cell viability decreased to $84 \pm 5\%$, after a 48-hour incubation, whereas A β 40 tended to increase the viability ($111 \pm 2\%$) (Fig 2A, left panels; S1 and S2 Tables). No changes in cell viability according to the WST-1 test were detected after a 72 h incubation with either peptide at a concentration of 20 μ M. At the same time, the membrane permeability test with PI showed a statistically significant increase in cell death after a 72 h incubation with A β 42 ($130 \pm 6\%$). A β 40 also increased cell death, however, the results varied remarkably between independent repeats ($124 \pm 16\%$) and the effect was statistically insignificant. Thus, both the cell viability and the membrane permeability tests showed that the toxic




Fig 2. Aβ reduces viability and activates caspases-3/7 in differentiated SH-SY5Y cells. (A) Cell viability was measured with the WST-1 test and membrane integrity was measured using propidium iodide 48h and 72h after incubation with 20μM peptides. The figure displays the mean± SEM; at least $n = 3$ independent experiments in case of Aβ42 and $n = 5$ experiments in case of Aβ40; ** $p \leq 0.005$; * $p \leq 0.01$; (B) Effect of Aβ42 on the activity of caspase-3 and/or 7. Caspase activity was determined by measuring DEVD-AFC hydrolysis in lysates from SH-SY5Y cells treated with 20μM Aβ42 for 48h. The figure displays the mean ± SD; $n = 5$; ** $p \leq 0.005$. One-way ANOVA followed by a Bonferroni's multiple comparisons test at the 0.05 level was used to determine the difference between the conditions.

<https://doi.org/10.1371/journal.pone.0186636.g002>

influence of Aβ-peptides on non-differentiated SH-SY5Y cells is relatively small. Aβ-peptides could eventually affect a small subpopulation of non-differentiated SH-SY5Y cells (S5 Fig), however the majority of the cells continued to proliferate, which complicates the interpretation of viability measurements. Nevertheless, the non-differentiated SH-SY5Y cells with a low sensitivity to Aβ and heterogeneous RA-differentiated cells cannot be used as a reliable model for the study of the toxic effects of native Aβ.

Aβ-peptides were more toxic to the RA/BDNF neuronally differentiated SH-SY5Y cells according to both the WST-1 and the PI tests (Fig 2A, right panels; S3 and S4 Tables). In the WST-1 test, cell viability started to decline after a 48-hour incubation ($81 \pm 5\%$ for Aβ40 and $78 \pm 9\%$ for Aβ42), however, statistically significant effects ($70 \pm 3\%$ and to $57.3 \pm 1.3\%$) in the presence of Aβ40 and Aβ42, respectively, were observed after 72 h. A statistically significant increase in the membrane permeability was observed after 72 h only in the case of Aβ42 ($150 \pm 6\%$). The PI fluorescence also slightly increased after a 72 h incubation with Aβ40 ($129 \pm 12\%$) and after 48 h with Aβ42 ($131 \pm 15\%$). The neuron-like RA/BDNF differentiated SH-SY5Y cells appeared to be more susceptible to Aβ-peptides than the non-differentiated SH-SY5Y cells.

Aβ42, but not Aβ40, induces apoptosis of differentiated SH-SY5Y

To prove the apoptotic nature of Aβ-induced cell death, we examined the activation of caspase-3/7. After a 48 h incubation, Aβ42 significantly increased caspase-3/7 activity ($160 \pm 14\%$) compared to that of the vehicle (Fig 2B; S5 Table). Staurosporine (a positive control for the induction of apoptosis) increased the activation of caspases-3/7 by $199 \pm 19\%$. Incubation with Aβ40, which only slightly increased the number of PI-permeable cells, had no effect on caspase activity ($103 \pm 14\%$). We can conclude that Aβ42, but not Aβ40, induced apoptotic cell death.

Aβ peptides induce pathological changes in neurite morphology

For the detection of Aβ-induced abnormalities in differentiated SH-SY5Y cells, the culture was stained with a CalceinAM dye that reveals viable cells and their extensions [33]. The morphological changes in neurites after incubation with Aβ peptides (Fig 3A) appeared considerably earlier than the Aβ mediated decrease in cell viability (Fig 2A). Aβ peptides induced beading and the subsequent fragmentation of neurites (Fig 3A, red arrows), whereas no CalceinAM signal was detected in fragmented neurites (Fig 3B). Quantitative analysis of the morphological changes in neurites showed that both peptides induced beading and fragmentation, but the influence of Aβ42 were considerably stronger than that of Aβ40 (Fig 3C; S6 and S7 Tables). The analysis of the early signs of microtubule disruption indicated that Aβ42 significantly induced bead formation. The amount of beads in the presence of Aβ42 per 50 μm of neurite length increased to 1.12 ± 0.08 compared to the vehicle 0.40 ± 0.03 . Aβ40 did not induce statistically significant beading: 0.78 ± 0.11 beads per 50 μm neurite length. Both peptides caused a substantial increase in the neurite fragmentation: $22.4 \pm 1.0\%$ and $37.6 \pm 0.4\%$ of neurites were fragmented in the presence of Aβ40 and Aβ42 respectively, whereas the fragmentation was not significant ($0.57 \pm 0.57\%$) in the absence of the peptides.

Aβ42 aggregates cover cell bodies and neurites

Since highly amyloidogenic Aβ-peptides can form fibrils on the cell surface in cell cultures [34–36], we studied the distribution of Aβ40 and Aβ42 using an anti-APP/Aβ antibody (Fig 4A). Panels presenting “Vehicle” demonstrate the endogenous APP/Aβ pattern in RA/BDNF differentiated cells. When cells were incubated with 20 μM peptide (lower panels) the presence of large extracellular Aβ aggregates appeared, which almost overshadowed the endogenous signals in the case of Aβ42. Three-dimensional reconstruction (Fig 4B) demonstrated that the cell bodies and neurites were fully covered with Aβ42 aggregates after 24 hours of incubation (Fig 4B, medium panels), whereas the less amyloidogenic Aβ40 did not cover the neurites and only random aggregates were present near and on the cell bodies after 48h (Fig 4B, right panels). Furthermore, this is in accordance with the fact that only Aβ42 induces caspase3/7 activation (Fig 2C). It could also be concluded that covering of neurites does not cause rapid cell death since a significant decrease in viability was observed only after incubation for 72 hours (Fig 2A). The non-differentiated cells were only partially covered with Aβ42 after 24h (Fig 4B, left panels). These results indicate that the Aβ42-induced toxic effects are related to the “Aβ cover” of neurites, because the non-differentiated cells lack long neuron-like extensions.

The presence of fibrillar aggregates in the cell medium containing Aβ42 after 48 hours of incubation was confirmed by TEM (S6 Fig), whereas no fibrils were detected in the medium containing Aβ40 under similar conditions. The fibrils formed in the cell culture were comparable to those previously generated in a test tube using peptides obtained from the same source [37]. Thioflavin T test showed that the aggregation of Aβ42 in serum free cell medium was completed within 24h (S7 Fig). In contrast to the significant toxic effect of Aβ42 fibrillizing in the solution surrounding the cells, the matured Aβ42 fibrils (preformed according to the




Fig 3. Aβ40 and Aβ42 induce pathological changes in neurite morphology after 72 h. (A) RA/BDNF differentiated live cell imaging for differential interference contrast (right), CalceinAM fluorescence (green; middle). Red arrows indicate fragmented neurites. Scale bar 20 μm. (B) Greater magnification of a neurite with beads versus a fragmented neurite. Scale bar 5 μm. (C) Quantification of pathological changes in RA/BDNF differentiated cell culture. The figure displays the mean ± SEM; at least $n = 3$ independent experiments; ** $p \leq 0.005$; * $p \leq 0.05$, One-way ANOVA followed by a Bonferroni's multiple comparisons test at the 0.05 level was used to determine differences between the conditions.

<https://doi.org/10.1371/journal.pone.0186636.g003>




Fig 4. A β 42 covers cell bodies and neurites. (A) Immunocytochemistry of non-differentiated and RA/BDNF differentiated SH-SY5Y cells after a 24h (A β 42) and a 48h incubation (Vehicle; A β 40) for DAPI (blue; left), anti-APP/A β (green; left middle), anti-Synaptophysin1 (red; right middle). Scale bar 20 μ m. (B) Three-dimensional reconstruction of differentiated cells incubated with 20 μ M A β 40 and A β 42 for 48h, and non-differentiated cells incubated with 20 μ M A β 42 for 24h, stained for DAPI, anti-APP/A β , anti-Synaptophysin1. Confocal microscope images were obtained with optical section separation (z-interval) of 0.303 μ m. Upper

panels represent the virtually generated volume of chromophores and the lower panels represent the surface. Scale bar 20 μ m.

<https://doi.org/10.1371/journal.pone.0186636.g004>

protocol in Ref [38]) added to the culture medium had no toxic effect on the differentiated SH-SY5Y cells (S8 Fig). These data support the hypothesis that the toxic amyloid species may form during the fibrillization process [39].

Discussion

During the last decades, when the amyloid hypothesis has been the prevailing concept in AD, research scientists have used various cellular and animal models to establish the toxic effects of A β -peptides and to search for possible “antidotes” [18, 40, 41]. Despite multiple promising candidates proposed as the result of these studies, none of the drug candidates have proved to be useful for AD patients. Although multiple examples of high A β toxicity can be found in the literature [15, 42–44], the toxicity of biologically more common peptide forms, e.g., monomers and fibrils, is often too low for use in test systems. The high toxicity values appear only under particular experimental conditions and are sometimes observed only when using particular test methods. For instance, A β peptides show high toxicity when cell viability is estimated by the MTT test. However, A β peptides have been shown to interfere with the MTT test, as the decrease in optical density is considerably larger than the decrease in the number of viable cells in the presence of A β [45–47]. Generating supersaturated A β solutions using organic solvents also enhance the peptide toxicity [21, 48, 49], however, this process has no analogue in living organisms. A β 25–35 peptide, a fragment of A β consisting of amino acid residues only present in the non-amyloidogenic P3 peptide, also shows higher toxicity on cells than A β 42. A β 25–35 has not been found in the brains of AD patients and its high toxicity is related to the methionine in its C-terminal: the peptide variant with an additional amino acid in C-terminus is practically nontoxic under the same conditions [50]. Thus, A β 25–35 is not a relevant substitution for A β -peptides in AD related studies [50]. It is desirable to use native peptides and biologically relevant procedures for the preparation of potentially toxic biomolecules in toxicological studies. A β peptides showed very low toxicity on non-differentiated SH-SY5Y cells, however the subsequent RA and BDNF treatment increased the susceptibility of the resulting neuron-like cells to the level applicable for toxicity studies and screening of putative protecting agents.

The most debatable topic in the amyloid hypothesis is which aggregation form of A β is toxic. Originally the amyloid fibrils were considered the neurotoxic species [23, 51]. Later on, interest concentrated on the more toxic A β oligomers generated by fast dilution of supersaturated A β solutions [22, 52]. Recently it has been proposed that the toxicity is related to the active fibrillization process: most likely the cells are affected by some metastable particles forming during the fibrillization [53]. In our experiments, only A β 1–42 added in a predominantly monomeric form and fibrillizing in the cellular medium, induced apoptotic cell death. Both peptides A β 1–40 and A β 1–42 fibrillize within a half of an hour when the solution is vigorously agitated, whereas under quiescent conditions the fibrillization can take days to begin [54]. Once the fibrillization is initiated by adding fibrillary seeds or by agitation, A β 1–42 retains a high fibrillization rate under non-agitated conditions, whereas the fibrillization rates of A β 40 decrease substantially [55]. In our experiment, only A β 42 that fibrillized within 24 hours in cellular medium was toxic for the cells, thus, relating the toxicity of amyloid to a myriad of dynamic intermediates present in the solution during the fibrillization. According to the relatively new concept that secondary nucleation mechanisms prevail in amyloidogenesis, the growing fibrils are partially converted to small amyloid species, which are considered to be

toxic and also responsible for propagation of plaques [39]. Our results support the general idea of this hypothesis, because pre-formed mature fibrils were not toxic for the cells.

Matsuzaki et al. demonstrated that amyloid fibrils growing on cells cause membrane deformation [35]. In our experiments A β 1–42, but not A β 1–40, covered the cell neurites and cell bodies with a dense fibrillary coating, which lead to a significant increase in membrane permeability as demonstrated by the PI test. The mechanism of how the intermediate A β 1–42 aggregates induce apoptosis is not clear, for instance, they could form pores in cell membranes [56]. It is important to note that the non-differentiated cells are also partially covered with A β 1–42, however, their viability was not significantly affected. The non-differentiated cells lack long neurites that have an especially tight amyloid cover and have a smaller surface area, thus, their contact area with A β is substantially smaller. Recently it was demonstrated that small fibrillary aggregates of A β consisting of 50–70 monomers are always present in A β 1–42, but not in A β 1–40 solutions right after the dilution [55]. This data can be invaluable in understanding the peptide toxicity—only the longer peptide containing fibrillary seeds and capable of forming fibrils in the cell culture medium had a substantial toxic effect on the cells.

RA/BDNF-differentiated SH-SY5Y cells with neuron-like morphology were more susceptible to A β than the non-differentiated cells. We demonstrated that A β 1–42 impairs neurites and this is followed by apoptotic cell death. Similar results were obtained with primary cultures [10, 11], supporting the suggestion that RA/BDNF-differentiated SH-SY5Y cells are an appropriate model for studying the effects of amyloids on neuronal cells. The peptides showed relatively low toxicity on the RA/BDNF-differentiated cells *in vitro*, which is in agreement with the slow progression of AD, however, a question may arise about the biological relevance of the effects observed at extremely high concentrations of these effectors. Considering that in the AD brain neurons nearby the plaques are dying [57], it is the contact with peptide aggregate and not the bulk peptide concentration that is the trigger for cell death. The high concentration used in cell experiments ensures that all cells are influenced by the toxic entity—growing fibrils. The main plaque component A β 42 was more toxic on the differentiated SH-SY5Y cells than its less malignant counterpart A β 40, most likely because of its stronger ability to form fibrils and cover neurites with a dense coating. Taken together, our findings show that amyloid fibrils, formed *in situ* in the cell culture, induce beading and neurite fragmentation in differentiated human neuron-like SH-SY5Y cells. The RA/BDNF-differentiated SH-SY5Y cells can be used in further detailed studies of the A β toxicity on neuronal cells and *in vitro* screening of putative drugs that suppress the A β toxicity [58, 59].

Conclusion

The current study showed that the RA/BDNF-differentiated human SH-SY5Y cell line is substantially more sensitive to amyloid peptides than non-differentiated cells. A β 42 fibrils forming spontaneously in the culture had clear toxic effect on the cells and caused neuritic abnormalities and caspase activation similar to the processes in the brain of patients with neurodegeneration, whereas A β 40 was non-toxic. It can be concluded that the RA/BDNF-differentiated SH-SY5Y cells can serve as a reasonably good *in vitro* model for the study of neuronal death in AD. Further studies are needed to describe the putative mechanism of pathology in this model.

Supporting information

S1 Fig. Representative photograph of non-differentiated and RA/BDNF differentiated cells in phase contrast.
(PDF)

S2 Fig. Amyloid beta quality control by NMR, MALDI-MS and SDS-PAGE.
(PDF)

S3 Fig. Representative snapshot of the process of the evaluation of neurite degeneration.
(PDF)

S4 Fig. WST-1 test results on non-differentiated cells without serum.
(PDF)

S5 Fig. Representative photograph of RA-differentiated SH-SY5Y cells.
(PDF)

S6 Fig. Transmission electron microscopy of cell medium after a 48 h incubation with amyloid peptides.
(PDF)

S7 Fig. Detection of amyloid aggregation by Thioflavin T in the cell medium.
(PDF)

S8 Fig. Cell viability after a 72 h incubation with 20 μ M previously formed fibrils measured with the WST-1 test and membrane integrity counted with the propidium iodide permeabilization tests.
(PDF)

S1 Table. Non-differentiated SH-SY5Y cells, cell viability WST-1 test.
(PDF)

S2 Table. Non-differentiated SH-SY5Y cells, propidium iodide test.
(PDF)

S3 Table. RA/BDNF-differentiated SH-SY5Y cells, cell viability WST-1 test.
(PDF)

S4 Table. RA/BDNF-differentiated SH-SY5Y cells, propidium iodide test.
(PDF)

S5 Table. Effect of A β 42 on the activities of caspase-3 and/or 7 on RA/BDNF differentiated cells.
(PDF)

S6 Table. The number of beads per 50 μ M of neurite length after 72 h with 20 μ M peptide.
(PDF)

S7 Table. Proportion of fragmented neurites per area after 72 h with 20 μ M peptide.
(PDF)

Acknowledgments

This work was supported by the Estonian Research Council (grant IUT 19–8) to PP and Estonian Science Foundation grant 9318 to VT. Authors thank Dr. Urmas Arumäe for his valuable comments on the manuscript, Dr. Jüri Jarvet and Dr. Jasper Adamson for taking and interpreting the ^1H NMR spectra of peptides and Ms. Merlin Friedemann for the quality checks of the peptides by using MALDI-MS and SDS-PAGE techniques. The authors thank Lewis Taylor for academic writing support.

Author Contributions

Conceptualization: Jekaterina Krishtal, Olga Bragina, Peep Palumaa, Vello Tõugu.

Data curation: Jekaterina Krishtal, Olga Bragina, Vello Tõugu.

Formal analysis: Jekaterina Krishtal, Olga Bragina, Kristel Metsla.

Funding acquisition: Peep Palumaa, Vello Tõugu.

Investigation: Jekaterina Krishtal, Kristel Metsla.

Methodology: Jekaterina Krishtal.

Project administration: Olga Bragina, Peep Palumaa, Vello Tõugu.

Resources: Vello Tõugu.

Software: Jekaterina Krishtal.

Supervision: Peep Palumaa, Vello Tõugu.

Validation: Jekaterina Krishtal, Kristel Metsla.

Visualization: Jekaterina Krishtal, Kristel Metsla.

Writing – original draft: Jekaterina Krishtal.

Writing – review & editing: Jekaterina Krishtal, Olga Bragina, Kristel Metsla, Peep Palumaa, Vello Tõugu.

References

1. Musiek ES, Holtzman DM. Three dimensions of the amyloid hypothesis: time, space and 'wingmen'. *Nat Neurosci*. 2015; 18(6):800–6. <https://doi.org/10.1038/nn.4018> PMID: 26007213
2. Selkoe DJ. Alzheimer's disease. *Cold Spring Harb Perspect Biol*. 2011; 3(7):a004457. Epub 2011/05/18. <https://doi.org/10.1101/cshperspect.a004457> PMID: 21576255.
3. Funderburk SF, Marcellino BK, Yue Z. Cell "self-eating" (autophagy) mechanism in Alzheimer's disease. *Mt Sinai J Med*. 2010; 77(1):59–68. Epub 2010/01/27. <https://doi.org/10.1002/msj.20161> PMID: 20101724.
4. Morris GP, Clark IA, Vissel B. Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease. *Acta Neuropathol Commun*. 2014; 2:135. <https://doi.org/10.1186/s40478-014-0135-5> PMID: 25231068.
5. Endres K, Reinhardt S. ER-stress in Alzheimer's disease: turning the scale? *Am J Neurodegener Dis*. 2013; 2(4):247–65. PMID: 24319643.
6. Swerdlow RH, Burns JM, Khan SM. The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives. *Biochim Biophys Acta*. 2014; 1842(8):1219–31. <https://doi.org/10.1016/j.bbadis.2013.09.010> PMID: 24071439.
7. LaFerla FM, Green KN. Animal models of Alzheimer disease. *Cold Spring Harb Perspect Med*. 2012; 2(11). <https://doi.org/10.1101/cshperspect.a006320> PMID: 23002015.
8. Choi SH, Kim YH, Hebisch M, Sliwinski C, Lee S, D'Avanzo C, et al. A three-dimensional human neural cell culture model of Alzheimer's disease. *Nature*. 2014; 515(7526):274–8. <https://doi.org/10.1038/nature13800> PMID: 25307057.
9. Dorostkar MM, Zou C, Blazquez-Llorca L, Herms J. Analyzing dendritic spine pathology in Alzheimer's disease: problems and opportunities. *Acta Neuropathol*. 2015; 130(1):1–19. <https://doi.org/10.1007/s00401-015-1449-5> PMID: 26063233.
10. Olah J, Vincze O, Virok D, Simon D, Bozso Z, Tokesi N, et al. Interactions of pathological hallmark proteins: tubulin polymerization promoting protein/p25, beta-amyloid, and alpha-synuclein. *J Biol Chem*. 2011; 286(39):34088–100. <https://doi.org/10.1074/jbc.M111.243907> PMID: 21832049.
11. Song MS, Saavedra L, de Chaves EI. Apoptosis is secondary to non-apoptotic axonal degeneration in neurons exposed to Abeta in distal axons. *Neurobiol Aging*. 2006; 27(9):1224–38. <https://doi.org/10.1016/j.neurobiolaging.2005.06.007> PMID: 16122841.

12. Xicoy H, Wieringa B, Martens GJ. The SH-SY5Y cell line in Parkinson's disease research: a systematic review. *Mol Neurodegener.* 2017; 12(1):10. <https://doi.org/10.1186/s13024-017-0149-0> PMID: 28118852.
13. Edsjo A, Lavenius E, Nilsson H, Hoehner JC, Simonsson P, Culp LA, et al. Expression of trkB in human neuroblastoma in relation to MYCN expression and retinoic acid treatment. *Lab Invest.* 2003; 83(6):813–23. PMID: 12808116.
14. Datki Z, Juhasz A, Galfi M, Soos K, Papp R, Zadori D, et al. Method for measuring neurotoxicity of aggregating polypeptides with the MTT assay on differentiated neuroblastoma cells. *Brain Res Bull.* 2003; 62(3):223–9. PMID: 14698355.
15. Milton NG, Chilumuri A, Rocha-Ferreira E, Nercessian AN, Ashioti M. Kisspeptin prevention of amyloid-beta peptide neurotoxicity in vitro. *ACS Chem Neurosci.* 2012; 3(9):706–19. <https://doi.org/10.1021/cn300045d> PMID: 23019497.
16. Amijee H, Bate C, Williams A, Virdee J, Jeggo R, Spanswick D, et al. The N-methylated peptide SEN304 powerfully inhibits Abeta(1–42) toxicity by perturbing oligomer formation. *Biochemistry.* 2012; 51(42):8338–52. <https://doi.org/10.1021/bi300415v> PMID: 23025847.
17. Benilova I, Karran E, De Strooper B. The toxic Abeta oligomer and Alzheimer's disease: an emperor in need of clothes. *Nat Neurosci.* 2012; 15(3):349–57. <https://doi.org/10.1038/nn.3028> PMID: 22286176.
18. Marshall KE, Marchante R, Xue WF, Serpell LC. The relationship between amyloid structure and cytotoxicity. *Prion.* 2014; 8(2). <https://doi.org/10.4161/pri.28860> PMID: 24819071.
19. Tõugu V, Tiiman A, Palumaa P. Interactions of Zn(II) and Cu(II) ions with Alzheimer's amyloid-beta peptide. Metal ion binding, contribution to fibrillization and toxicity. *Metallomics.* 2011; 3(3):250–61. Epub 2011/03/02. <https://doi.org/10.1039/c0mt00073f> PMID: 21359283.
20. Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PT Jr. Neurodegenerative disease: amyloid pores from pathogenic mutations. *Nature.* 2002; 418(6895):291. <https://doi.org/10.1038/418291a> PMID: 12124613.
21. Stine WB Jr., Dahlgren KN, Krafft GA, LaDu MJ. In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. *J Biol Chem.* 2003; 278(13):11612–22. <https://doi.org/10.1074/jbc.M210207200> PMID: 12499373.
22. Walsh DM, Selkoe DJ. A beta oligomers—a decade of discovery. *J Neurochem.* 2007; 101(5):1172–84. <https://doi.org/10.1111/j.1471-4159.2006.04426.x> PMID: 17286590.
23. Lambert MP, Stevens G, Sabo S, Barber K, Wang G, Wade W, et al. Beta/A4-evoked degeneration of differentiated SH-SY5Y human neuroblastoma cells. *J Neurosci Res.* 1994; 39(4):377–85. <https://doi.org/10.1002/jnr.490390404> PMID: 7533843.
24. Ferrone FA. Secondary nucleation wears the BRICHOS in this family. *Nat Struct Mol Biol.* 2015; 22(3):180–1. Epub 2015/03/05. <https://doi.org/10.1038/nsmb.2980> PMID: 25736087.
25. Encinas M, Iglesias M, Liu Y, Wang H, Muhaisen A, Cena V, et al. Sequential treatment of SH-SY5Y cells with retinoic acid and brain-derived neurotrophic factor gives rise to fully differentiated, neurotrophic factor-dependent, human neuron-like cells. *J Neurochem.* 2000; 75(3):991–1003. PMID: 10936180.
26. Agholme L, Lindstrom T, Kagedal K, Marcusson J, Hallbeck M. An in vitro model for neuroscience: differentiation of SH-SY5Y cells into cells with morphological and biochemical characteristics of mature neurons. *J Alzheimers Dis.* 2010; 20(4):1069–82. <https://doi.org/10.3233/JAD-2010-091363> PMID: 20413890.
27. Forster JI, Koglsberger S, Trefois C, Boyd O, Baumratov AS, Buck L, et al. Characterization of Differentiated SH-SY5Y as Neuronal Screening Model Reveals Increased Oxidative Vulnerability. *J Biomol Screen.* 2016. Epub 2016/01/08. <https://doi.org/10.1177/1087057115625190> PMID: 26738520.
28. Gurry T, Stultz CM. Mechanism of amyloid-beta fibril elongation. *Biochemistry.* 2014; 53(44):6981–91. <https://doi.org/10.1021/bi500695g> PMID: 25330398.
29. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. *Cold Spring Harb Perspect Med.* 2011; 1(1):a006189. <https://doi.org/10.1101/cshperspect.a006189> PMID: 22229116.
30. Zovo K, Helk E, Karafin A, Tõugu V, Palumaa P. Label-free high-throughput screening assay for inhibitors of Alzheimer's amyloid-beta peptide aggregation based on MALDI MS. *Anal Chem.* 2010; 82(20):8558–65. Epub 2010/09/23. <https://doi.org/10.1021/ac101583q> PMID: 20857910.
31. Kawataki T, Osafune K, Suzuki M, Koike T. Neuronal maturation-associated resistance of neurite degeneration caused by trophic factor deprivation or microtubule-disrupting agents. *Brain Res.* 2008; 1230:37–49. <https://doi.org/10.1016/j.brainres.2008.06.075> PMID: 18621035.
32. Kaplan DR, Matsumoto K, Lucarelli E, Thiele CJ. Induction of TrkB by retinoic acid mediates biologic responsiveness to BDNF and differentiation of human neuroblastoma cells. *Eukaryotic Signal Transduction Group. Neuron.* 1993; 11(2):321–31. PMID: 8394722.

33. Ikegami K, Koike T. Non-apoptotic neurite degeneration in apoptotic neuronal death: pivotal role of mitochondrial function in neurites. *Neuroscience*. 2003; 122(3):617–26. PMID: [14622905](#).
34. Wakabayashi M, Matsuzaki K. Formation of Amyloids by Abeta-(1–42) on NGF-differentiated PC12 Cells: Roles of Gangliosides and Cholesterol. *J Mol Biol*. 2007; 371(4):924–33. <https://doi.org/10.1016/j.jmb.2007.06.008> PMID: [17597153](#).
35. Matsuzaki K. Formation of Toxic Amyloid Fibrils by Amyloid beta-Protein on Ganglioside Clusters. *Int J Alzheimers Dis*. 2011; 2011:956104. Epub 2011/02/15. <https://doi.org/10.4061/2011/956104> PMID: [21318142](#).
36. Takahashi RH, Almeida CG, Kearney PF, Yu F, Lin MT, Milner TA, et al. Oligomerization of Alzheimer's beta-amyloid within processes and synapses of cultured neurons and brain. *J Neurosci*. 2004; 24(14):3592–9. <https://doi.org/10.1523/JNEUROSCI.5167-03.2004> PMID: [15071107](#).
37. Constantinescu R, Constantinescu AT, Reichmann H, Janetzky B. Neuronal differentiation and long-term culture of the human neuroblastoma line SH-SY5Y. *J Neural Transm Suppl*. 2007; (72):17–28. PMID: [17982873](#).
38. Zovo K, Helk E, Karafin A, Tougu V, Palumaa P. Label-free high-throughput screening assay for inhibitors of Alzheimer's amyloid-beta peptide aggregation based on MALDI MS. *Anal Chem*. 2010; 82(20):8558–65. <https://doi.org/10.1021/ac101583q> PMID: [20857910](#).
39. Cohen SI, Linse S, Luheshi LM, Hellstrand E, White DA, Rajah L, et al. Proliferation of amyloid-beta42 aggregates occurs through a secondary nucleation mechanism. *Proc Natl Acad Sci U S A*. 2013; 110(24):9758–63. <https://doi.org/10.1073/pnas.1218402110> PMID: [23703910](#).
40. Sengupta U, Nilson AN, Kaye R. The Role of Amyloid-beta Oligomers in Toxicity, Propagation, and Immunotherapy. *EBioMedicine*. 2016; 6:42–9. <https://doi.org/10.1016/j.ebiom.2016.03.035> PMID: [27211547](#).
41. Munter LM. How many amyloid-beta peptides can a neuron bind before it dies? *J Neurochem*. 2016; 136(3):437–9. <https://doi.org/10.1111/jnc.13502> PMID: [26786571](#).
42. Xiao Z, Huang C, Wu J, Sun L, Hao W, Leung LK, et al. The neuroprotective effects of ipriflavone against H (2)O (2) and amyloid beta induced toxicity in human neuroblastoma SH-SY5Y cells. *Eur J Pharmacol*. 2013; 721(1–3):286–93. <https://doi.org/10.1016/j.ejphar.2013.09.023> PMID: [24084576](#).
43. Silva-Alvarez C, Arrazola MS, Godoy JA, Ordenes D, Inestrosa NC. Canonical Wnt signaling protects hippocampal neurons from Abeta oligomers: role of non-canonical Wnt-5a/Ca(2+) in mitochondrial dynamics. *Front Cell Neurosci*. 2013; 7:97. <https://doi.org/10.3389/fncel.2013.00097> PMID: [23805073](#).
44. Chen YS, Chen SD, Wu CL, Huang SS, Yang DI. Induction of sestrin2 as an endogenous protective mechanism against amyloid beta-peptide neurotoxicity in primary cortical culture. *Exp Neurol*. 2014; 253:63–71. <https://doi.org/10.1016/j.expneurol.2013.12.009> PMID: [24368194](#).
45. Lu L, Zhang L, Wai MS, Yew DT, Xu J. Exocytosis of MTT formazan could exacerbate cell injury. *Toxicol In Vitro*. 2012; 26(4):636–44. <https://doi.org/10.1016/j.tiv.2012.02.006> PMID: [22401948](#).
46. Isobe I, Michikawa M, Yanagisawa K. Enhancement of MTT, a tetrazolium salt, exocytosis by amyloid beta-protein and chloroquine in cultured rat astrocytes. *Neurosci Lett*. 1999; 266(2):129–32. PMID: [10353344](#).
47. Liu Y. Understanding the biological activity of amyloid proteins in vitro: from inhibited cellular MTT reduction to altered cellular cholesterol homeostasis. *Prog Neuropsychopharmacol Biol Psychiatry*. 1999; 23(3):377–95. PMID: [10378224](#).
48. Yuan C, Gao J, Guo J, Bai L, Marshall C, Cai Z, et al. Dimethyl sulfoxide damages mitochondrial integrity and membrane potential in cultured astrocytes. *PLoS One*. 2014; 9(9):e107447. <https://doi.org/10.1371/journal.pone.0107447> PMID: [25238609](#).
49. Julien C, Marcouiller F, Bretteville A, El Khoury NB, Baillargeon J, Hebert SS, et al. Dimethyl sulfoxide induces both direct and indirect tau hyperphosphorylation. *PLoS One*. 2012; 7(6):e40020. <https://doi.org/10.1371/journal.pone.0040020> PMID: [22768202](#).
50. Varadarajan S, Kanski J, Aksanova M, Lauderback C, Butterfield DA. Different mechanisms of oxidative stress and neurotoxicity for Alzheimer's A beta(1–42) and A beta(25–35). *J Am Chem Soc*. 2001; 123(24):5625–31. PMID: [11403592](#).
51. Pike CJ, Burdick D, Walencewicz AJ, Glabe CG, Cotman CW. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. *J Neurosci*. 1993; 13(4):1676–87. PMID: [8463843](#).
52. Picone P, Carotta R, Montana G, Nobile MR, San Biagio PL, Di Carlo M. Abeta oligomers and fibrillar aggregates induce different apoptotic pathways in LAN5 neuroblastoma cell cultures. *Biophys J*. 2009; 96(10):4200–11. <https://doi.org/10.1016/j.bpj.2008.11.056> PMID: [19450490](#).

53. Jan A, Adolfsson O, Allaman I, Buccarello AL, Magistretti PJ, Pfeifer A, et al. Abeta42 neurotoxicity is mediated by ongoing nucleated polymerization process rather than by discrete Abeta42 species. *J Biol Chem*. 2011; 286(10):8585–96. <https://doi.org/10.1074/jbc.M110.172411> PMID: 21156804.
54. Tiiman A, Noormagi A, Friedemann M, Krishtal J, Palumaa P, Tougu V. Effect of agitation on the peptide fibrillization: Alzheimer's amyloid-beta peptide 1–42 but not amylin and insulin fibrils can grow under quiescent conditions. *J Pept Sci*. 2013; 19(6):386–91. <https://doi.org/10.1002/psc.2513> PMID: 23609985.
55. Tiiman A, Jarvet J, Graslund A, Vukojevic V. Heterogeneity and Turnover of Intermediates during Amyloid-beta (Abeta) Peptide Aggregation Studied by Fluorescence Correlation Spectroscopy. *Biochemistry*. 2015; 54(49):7203–11. <https://doi.org/10.1021/acs.biochem.5b00976> PMID: 26574169.
56. Di Scala C, Yahi N, Boutemour S, Flores A, Rodriguez L, Chahinian H, et al. Common molecular mechanism of amyloid pore formation by Alzheimer's beta-amyloid peptide and alpha-synuclein. *Sci Rep*. 2016; 6:28781. <https://doi.org/10.1038/srep28781> PMID: 27352802.
57. Fiala JC. Mechanisms of amyloid plaque pathogenesis. *Acta Neuropathol*. 2007; 114(6):551–71. <https://doi.org/10.1007/s00401-007-0284-8> PMID: 17805553.
58. Ramsey A, Lord S, Torrey J, Marsch L, Lardiere M. Paving the Way to Successful Implementation: Identifying Key Barriers to Use of Technology-Based Therapeutic Tools for Behavioral Health Care. *J Behav Health Serv Res*. 2016; 43(1):54–70. <https://doi.org/10.1007/s11414-014-9436-5> PMID: 25192755.
59. Jankowska A, Wesolowska A, Pawlowski M, Chlon-Rzepa G. Multi-Target-Directed Ligands Affecting Serotonergic Neurotransmission for Alzheimer's Disease Therapy: Advances in Chemical and Biological Research. *Curr Med Chem*. 2017. <https://doi.org/10.2174/0929867324666170529122802> PMID: 28554324.

Appendix 2

Publication II

Krishtal, J., Metsla, K., Bragina, O., Tõugu, V., & Palumaa, P. (2019). Toxicity of Amyloid- β Peptides Varies Depending on Differentiation Route of SH-SY5Y Cells. *Journal of Alzheimer's disease: JAD*, 71(3), 879–887. <https://doi.org/10.3233/JAD-190705>

Toxicity of Amyloid- β Peptides Varies Depending on Differentiation Route of SH-SY5Y Cells

Jekaterina Krishtal*, Kristel Metsla, Olga Bragina, Vello Tõugu and Peep Palumaa
Department of Chemistry and Biotechnology, Tallinn University of Technology, Tallinn, Estonia

Accepted 19 July 2019

Abstract. Alzheimer's disease (AD) is a currently incurable neurodegenerative disorder being the major form of dementia worldwide. AD pathology is initiated by cerebral aggregation of amyloid- β (A β) peptides in the form of amyloid plaques; however, the mechanism how A β peptide aggregates participate in the disease progression and neurodegeneration is still under debate. Human neuroblastoma cell line SH-SY5Y is a convenient cellular model, which is widely used in biochemical and toxicological studies of neurodegenerative diseases. This model can be further improved by differentiation of the cells toward more neuron-like culture using different protocols. In the current study, dbcAMP, retinoic acid with TPA, or BDNF were used for differentiation of SH-SY5Y cells, and the resulting cultures were tested for the toxicity toward the A β ₄₂ peptide. The toxicity of A β ₄₂ peptide depended on the type of differentiated cells: RA and TPA- differentiated cells were most resistant, whereas dbcAMP and RA/BDNF- differentiated cells were more sensitive to A β toxicity as compared with non-differentiated cells. The differentiated cultures provide more appropriate cellular models of human origin that can be used for studies of the mechanism of A β pathogenesis and for a screening of compounds antagonistic to the toxicity of A β peptides.

Keywords: Alzheimer's disease, amyloid- β , differentiation, SH-SY5Y, toxicity

INTRODUCTION

Alzheimer's disease (AD) is a progressive neurodegenerative disease that is responsible for up to 75% of all dementia cases [1]. Brains of AD patients are characterized by the presence of amyloid plaques, consisting of amyloid- β (A β) peptides, and neurofibrillary tangles consisting of hyperphosphorylated tau proteins. A β peptide aggregates accumulate in the brain long before the onset of neurological symptoms and play a significant role in the neurodegeneration. Toxicity of A β is intensively studied in cellular models, which can shed light on the mechanisms of disease progression at cellular level. In

these studies, a variety of *in vitro* cellular models, which include primary rodent neuronal cultures, neuroblastoma cell lines (mouse Neuro-2A, rat PC12, human SH-SY5Y cells), and human induced pluripotent stem cells (iPSCs), are widely used [2, 3]. Each model has its own advantages and disadvantages; however, human origin, price advantage, and accessibility make human neuroblastoma cell line SH-SY5Y the most popular cellular model in toxicological and biochemical studies of AD. Unfortunately, SH-SY5Y cells in the non-differentiated state lack several essential features of neurons specifically affected in AD. Most importantly, they expose several morphological subtypes with rounded cell bodies and only few short neurites [4] and moreover, they proliferate rapidly. Cancerous cell line-based models can be further improved by application of specific agents, which induce differentiation toward neuron-like

*Correspondence to: Jekaterina Krishtal, Department of Chemistry and Biotechnology, Tallinn University of Technology, Akadeemia tee 15, Tallinn 12816, Tallinn, Estonia. Tel.: +372 620 4411; E-mail: jekaterina.kristal@taltech.ee.

morphology, expression of neuron-specific proteins, and inhibition of proliferation.

It is known that differentiation of SH-SY5Y cells can be induced by various agents including retinoic acid (RA), brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), tetradecanoylphorbol acetate (TPA), 17 beta-Estradiol (E_2), 3 β -hydroxy-5-cholestene (cholesterol), N(6),2'-O-dibutyryl adenosine 3':5' cyclic monophosphate (dbcAMP), insulin-like growth factor 1 (IGF-1), and several others [5–9].

RA treatment enhances the outgrowth of neurites [10] and leads to increase of the survival of SH-SY5Y cells through the upregulation of BCL-2 protein [11] and changes in cellular sodium homeostasis [12]. Treatment with RA makes SH-SY5Y cells responsive to neurotrophins including BDNF and sensitive to further differentiation. Sequential treatment of SH-SY5Y cells with RA and BDNF leads to outgrowth of neurites, synaptogenesis, and modulates the cellular survival. At the molecular level, treatment leads to increased expression of VACHT and ChAT, and to increased activity of AChE, suggesting differentiation toward the cholinergic neuronal phenotype [13, 14].

Differentiation of SH-SY5Y cells with dbcAMP also induces morphological changes in cells toward a neuron-like phenotype with neurite outgrowth and branching, exposing noradrenergic phenotype [9]. DbcAMP is degraded by intracellular esterases to butyrate and monobutyl cAMP (mbcAMP), which activates protein kinase A (PKA). It was shown that both the butyrate and the activation of PKA play an important role in dbcAMP mediated differentiation of SH-SY5Y cells [9]. Several studies have demonstrated that dbcAMP increases the expression of amyloid- β protein precursor (A β PP), the precursor molecule for A β peptides [15, 16].

12-O-tetradecanoylphorbol-13-acetate (TPA) is a biologically active phorbol ester affecting cell growth and differentiation via protein kinase C (PKC) [13]. During differentiation by TPA, SH-SY5Y cells undergo morphological changes, discontinue replication, and reach a stable cell population. It has been previously shown that sequential exposure of SH-SY5Y cells to RA and TPA induces 3-fold increase in TH, 4-fold increase in DAT, 3-fold increase in D2 and 6-fold increase in D3 receptor levels as compared to undifferentiated cells, characteristic for a dopaminergic cellular phenotype [7, 17].

We have differentiated SH-SY5Y cells by using three protocols: RA/BDNF, RA/TPA, and dbcAMP,

which all induced differentiation toward more neuron-like phenotype characterized by dense neurite network. The cultures were tested against toxicity of A β_{42} peptide by using different viability tests as well as microscopy and immunocytochemistry. After 48 h exposure to A β_{42} , all differentiated cells and neurites were covered with A β layer and neurite fragmentation was observed. However, cells exhibited different sensitivity toward A β_{42} peptide in viability tests: dbcAMP treatment and RA/BDNF treatment increased the sensitivity whereas RA/TPA-differentiated cells were the most resistant toward A β toxicity.

MATERIALS AND METHODS

Cell culture

SH-SY5Y human neuroblastoma cells (ATCC, Europe) were cultured in Dulbecco's Modified Eagle's Medium (DMEM, Gibco) supplemented with 10% fetal bovine serum (FBS, Gibco) and 50 U/ml penicillin, 50 μ g/ml streptomycin solution (Gibco) in an incubator at 37°C and 5% CO₂. The medium was changed every 2-3 days and cells were split using Trypsin-EDTA solution (Gibco). Cells were seeded in poly-L-lysine (PLL) (Sigma) coated (dbcAMP) or uncoated (RA/TPA and RA/BDNF) white clear bottom 96-well plates (Greiner Bio-One) for toxicity experiments or 24-well plates (Greiner Bio-One) for microscopy experiments. Prior to the application of differentiating agents, cells were allowed to adhere for 24 h.

Obtained cells were treated according to the following differentiation protocols: cells were pre-differentiated with RA (10 μ M; Sigma Aldrich) in full media for 4 days and then treated with BDNF (50 ng/mL; Alomone Labs) in serum free media for 2 days or with 80 nM TPA (Sigma Aldrich) in serum free media for 3 days; dbcAMP (Sigma Aldrich) treatment was conducted with 2 mM dbcAMP in full media for 2 days and subsequently in serum-free media containing 2 mM dbcAMP for an additional day.

Cells were visualized with Zeiss Axiovert 200 M, AxioCam MRC5 with 20x A-Plan with Ph2 and 20x Plan NeoFluo objectives.

Cell viability measured by WST-1

The effects of A β_{42} on the viability of cells were determined using the cell viability assay WST-1 (Roche). WST-1 allows colorimetric measurement of

cell viability due to reduction of tetrazolium salts to water-soluble formazan by viable cells. The amount of formed formazan dye correlates with the number of viable cells. The measurements were completed 48 h after cells treatment with A β ₄₂. 1 μ M staurosporine (Santa Cruz) added to serum-free control group was used as a positive control to induce apoptosis during 48 h. The experiments with HEPES buffer were used as a negative control. 5 μ l/well of WST-1 reagent was added to 100 μ l cell culture medium, incubated at 37°C for 2 h and absorbance was measured at 450 nm using TECAN Genios Pro microplate reader.

Propidium iodide assay

Propidium iodide (PI) is a red-fluorescent DNA-binding dye used to detect nonviable cells with disrupted cell membranes as it cannot cross intact cell membranes. 0.5 mM PI in phosphate buffered saline (PBS, Sigma) was added to 100 μ l cell culture 0.5 μ l/well and incubated for 10 min at 37°C. Fluorescence was measured using TECAN Genios Pro microplate reader (excitation 540 nm, emission 612 nm). Results are presented as the fold increase from control islets.

Peptide preparation

Lyophilized amyloid- β 1–42 peptide (A β ₄₂) (rPeptide) was dissolved in 1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP) (Sigma) to disaggregate the peptide oligomeric and fibrillar assemblies, vortexed and incubated for 1 h at room temperature, divided into aliquots and dried overnight in a vacuum desiccator. The aliquots were stored at –80°C. One day before experiments, the aliquots were treated with HFIP again as described before. Defibrillized A β ₄₂ aliquot was dissolved in 10 mM NaOH and incubated on ice for 10 min. Next, equal amount of 40 mM HEPES buffer containing 200 mM NaCl (pH 7.3) was added to a final peptide concentration of 400 μ M. Prepared peptide solution was immediately applied to the serum-free differentiated cell culture at final concentration of 10 μ M and 20 μ M.

Immunocytochemistry

Cells were seeded on glass coverslips in 24-well plates. After differentiation, culture media was removed and cells were washed twice with PBS. Cells were fixed using 4% PFA (for TUJ antibody - methanol for 15 min at 4°C) for 20 min

at room temperature, washed twice with PBS and blocked with 3% goat serum diluted in PBS for 20 min at room temperature to avoid non-specific staining. Cells were washed twice with PBS and primary antibodies diluted in 0.2% Tween solution were applied for incubation overnight at 4°C. Primary antibodies - anti-Synaptophysin 1 (1:2000) (Synaptic Systems), anti- β III tubulin (1:2000), anti-A β PP/ β -Amyloid (1:2000) NAB228 (antigen is 1–11aa from A β) were used (Cell Signaling Technology).

Samples were washed three times for 5 min with PBS and incubated with secondary antibodies diluted in PBS for 1 h at room temperature in dark. Secondary antibodies, Alexa Fluor 488 goat anti-mouse and Alexa Fluor 568 goat anti guinea pig (1:2000) (Thermo Fisher Scientific), were used.

Samples were washed three times for 5 min each with PBS, and nuclei were counterstained with DAPI for 5 min. Coverslips were rinsed once with PBS and once with water and applied onto the microscope slides mounted with a drop of ProLong® Diamond antifade reagent (Life Technologies). Cells were visualized using a confocal microscope Zeiss Duo 510 META with 63X oil immersion objective.

Statistical analysis

Statistical analysis was performed by using one-way analysis of variance (ANOVA) with the *post hoc* Dunnett's multiple comparison test. The graphs represent data from at least three independent experiments, all performed in triplicates as mean $\pm$ standard error of the mean (SEM). In the cell viability assay, positive cells were normalized to 100% in negative control (HEPES buffer). In the PI assay, results are presented as the fold increase from control islets. Statistical significance of $p < 0.05$ is represented as *, $p < 0.002$ as **, $p < 0.0002$ as ***, $p < 0.0001$ as ****. Statistical analyses were performed with GraphPad Prism 7.

RESULTS

Morphology of differentiated SH-SY5Y cells

Treatment of SH-SY5Y cells with differentiating agents used induces neurite outgrowth with elongated neurites that form connections with surrounding




Fig. 1. Visualization of the differentiated SH-SY5Y cells. Phase contrast (left column) images obtained with Zeiss Axiovert 200M, Axiocam MRc5 with 20x A-Plan with Ph2. Scale bar 50 μ m. Immunohistochemistry for Tuj1 (right column) with counterstained nuclei (DAPI) were visualized with the confocal microscope Zeiss Duo 510 META and 63x oil immersion objective. Stack layers with z-interval of 320 nm are presented in sum intensity projection. Brightness and contrast were increased for clarity. Images were edited by using Fiji software. Scale bar 20 μ m.

cells comparing to non-differentiated cells (Fig. 1). RA/BDNF resulted in almost homogeneous cell population whereas small populations of undifferentiated cells were present in dbcAMP and RA/TPA differentiated cell cultures. The success of differentiation was also visualized using immunostaining with an early neuronal marker beta III tubulin (Fig. 1, right column).

Toxicity of $A\beta_{42}$ on non-differentiated SH-SY5Y cells

The toxicity of $A\beta$ on non-differentiated SH-SY5Y cells was determined, which served as a reference for comparison of the effects of differentiation (Fig. 2A, B). The results showed that after 48 h, 10 μ M $A\beta_{42}$ was not toxic in viability (WST-1) test ($100.2 \pm 3.4\%$ compared with negative control) as well as in cell permeability (PI) tests (1.1 ± 0.1 fold increase over control). In contrast, 20 μ M $A\beta_{42}$ exposed significant toxicity by reducing viability to $57.4 \pm 8.7\%$, and increasing PI uptake was 1.8 ± 0.2 fold over control.

Toxicity of $A\beta_{42}$ on dbcAMP differentiated cells

Incubation with $A\beta_{42}$ had a statistically significant effect on the viability of dbcAMP differentiated cells after 48 h incubation period as measured with WST-1 assay (Fig. 2C). 10 μ M and 20 μ M $A\beta_{42}$ induced respectively a $51.3 \pm 4.2\%$ and $37.2 \pm 1.7\%$ decrease in the cell viability, which was in both cases statistically significant ($p < 0.0001$).

PI assay revealed that 20 μ M $A\beta_{42}$ induced a significant ($p < 0.0002$), almost 2-fold increase in number of permeabilized cells (1.94 ± 0.1 fold increase over control) (Fig. 2D), incubation with 10 μ M $A\beta_{42}$ caused 1.37 ± 0.1 fold increase, which was also statistically significant ($p < 0.04$).

Toxicity of $A\beta_{42}$ on RA/BDNF differentiated cells

RA/BDNF differentiated cells were also susceptible to $A\beta$ toxicity; however, 10 μ M $A\beta_{42}$ led to a slightly lower relative viability ($59.4 \pm 5.3\%$, $p < 0.0002$) as compared to the effect of 20 μ M $A\beta_{42}$ ($77.2 \pm 6.8\%$, $p < 0.0021$) after 48 h incubation (Fig. 2E).

Similarly, treated cells exhibited also increase in amount of permeabilized cells, measured by PI test (Fig. 2F). In case of 10 μ M $A\beta_{42}$, there was a 1.8 ± 0.2 fold increase over control, whereas 20 μ M $A\beta_{42}$ displayed lower 1.6 ± 0.2 fold increase over control.

Toxicity of $A\beta_{42}$ on RA/TPA differentiated cells

RA/TPA differentiated cells were not sensitive to $A\beta_{42}$ toxicity. In the WST-1 assay, both peptide concentrations induced only minor changes in relative viability of the cells (Fig. 2G), being $85.7 \pm 3.7\%$ in




Fig. 2. Quantitation of viable and dead cells after 48 h incubation with Aβ₄₂. WST-1 viability test results are on panels A, C, E and G. PI uptake estimation results are on panels B, D, F and H. Negative control: HEPES buffer; positive control: staurosporine. The figure displays the mean ± SEM; *n* = 4 for non-differentiated cells; *n* = 4 for dbcAMP cells; *n* = 10 for RA/BDNF cells; *n* = 6 for RA/TPA cells. **** *p* < 0.0001; *** *p* < 0.0002; ** *p* < 0.0021; * *p* < 0.0489. One-way ANOVA followed by a Dunnett's multiple comparisons test at the 0.05 level was used for statistical analysis.

the case of 10 μM $\text{A}\beta_{42}$ and $102.6 \pm 5.3\%$ in the case of 20 μM $\text{A}\beta_{42}$. Viability of staurosporine-treated cells as a positive control was decreased significantly to $26.4 \pm 4.1\%$ ($p < 0.0001$) from control.

Quantification of PI-positive cells also did not expose statistically significant toxic effects of $\text{A}\beta_{42}$ on RA/TPA differentiated cells after 48 h incubation (Fig. 2H). In case of 10 μM $\text{A}\beta_{42}$, the number of permeabilized cells was increased 1.3 ± 0.1 fold over control, and in the case of 20 μM $\text{A}\beta_{42}$, a 1.4 ± 0.1 fold increase was observed. The positive control, staurosporine, induced nearly two-fold increase in PI-positive cell count (2.0 ± 0.2).

Pathological changes in cell culture and coverage with $\text{A}\beta$ peptide

Pathological changes were detected in all differentiated cultures after 48 h incubation with 10 μM $\text{A}\beta_{42}$ peptide; however, the signs of pathology were completely different from the effects of staurosporine (Supplementary Figure 1). DbcAMP differentiated cells lost all neurites after 48 h incubation even with 10 μM $\text{A}\beta_{42}$ (Supplementary Figure 1F, J). In the case of RA/TPA differentiated cells, which were most resistant to amyloid, we observed a relatively small increase in the amount of dead cells after 48 h incubation even with 20 μM $\text{A}\beta_{42}$; regardless, neurite fragmentation was seen in the case of both 10 and 20 μM $\text{A}\beta_{42}$ as compared with the negative control (Supplementary Figure 1H, L). Both effects were substantially larger in the case of RA/BDNF differentiated cells (Supplementary Figure 1G, K). It is known that $\text{A}\beta$ interacts with the plasma membrane and there is also evidence for localization of $\text{A}\beta_{42}$ on the cell membranes in the brain of AD patients [18]. As distinct differentiation methods revealed different sensitivities to $\text{A}\beta_{42}$, the next step was to evaluate the differences in the distribution of the $\text{A}\beta_{42}$ peptide in the cell cultures. For these experiments, cells were stained for $\text{A}\beta\text{PP}/\text{A}\beta$ and synaptophysin 1 after the treatment with 10 μM $\text{A}\beta_{42}$ for 24 h. Synaptophysin 1 is a major synaptic vesicle membrane protein, whose expression is a broad-range marker of neural and neuroendocrine cells including neuroblastoma cells [19]. By means of ICC, we detected that in case of all cell types studied (non-differentiated cells and three differentiated cell cultures), the cell bodies and neurites were too large extent covered with the $\text{A}\beta_{42}$ peptide aggregates (Fig. 3), whereas $\text{A}\beta$ aggregates were also present in the intracellular space (Fig. 3B, G, L, Q, white arrows).

DISCUSSION

To expand our understanding of the neurotoxicity of amyloid peptides in AD, we compared the effects of $\text{A}\beta_{42}$ on human neuroblastoma cell line SH-SY5Y differentiated toward more neuron-like morphology, exposing different biochemical phenotypes [20]. Three different treatments included: 1) dbcAMP, 2) RA followed by BDNF, and 3) RA followed by TPA, which supposedly induce noradrenergic [9], cholinergic [14], and dopaminergic [7] phenotypes, respectively. In all cases, differentiation induced the outgrowth of $\beta\text{III-tubulin}$ positive networked neurites.

One of the most important factors in $\text{A}\beta$ toxicity studies is peptide pre-treatment and preparation for cell culture experiments. It has been shown that the origin of the $\text{A}\beta$ peptide [21] as well as the protocol of the preparation of the peptide before applying it to the cells can affect the results [22, 23]. Therefore, comparative studies of $\text{A}\beta$ toxicity should be performed using strictly standardized protocols of peptide preparation. In the current study, we used freshly HFIP-treated and alkali-solubilized recombinant $\text{A}\beta_{42}$, which minimizes the amount of preformed fibrillary seeds present in the initial solution. In our previous study with RA/BDNF differentiated SH-SY5Y cells, we used a slightly different $\text{A}\beta$ dissolving protocol solubilizing the HFIP-pretreated peptide at neutral pH and observed a lower toxic effect, especially in PI assay [24]. In many studies, amyloid peptide is pre-treated with organic solvents before toxicity experiments in order to get oligomers [25, 26] or protofibrils [27, 28] with enhanced toxicity. However, since an increasing amount of evidence points to the decisive role of intermediate fibrillization species in the cellular toxicity [22], we suggest that toxicity of the peptide in the state of active fibrillization can be better model for the *in vivo* toxicity of the peptide than artificially generated formulations.

By comparing the toxicity of similarly pre-treated $\text{A}\beta_{42}$ peptide toward differently prepared SH-SY5Y cells, we established that dbcAMP treatment toward noradrenergic phenotype and RA/BDNF treatment toward cholinergic phenotype increase the susceptibility of cells to the toxicity of $\text{A}\beta_{42}$ (Tables 1 and 2). In the study with rat primary neuronal cell cultures, it has been demonstrated that $\text{A}\beta$ is more toxic to noradrenergic neurons in comparison with cholinergic neurons [29], similarly to our results with human derived cell line. It can also be speculated that the higher susceptibility to $\text{A}\beta_{42}$ peptide might be caused




Fig. 3. Distribution of A β in cell cultures after 24 h incubation. Immunocytochemistry of 10 μ M A β ₄₂-treated SH-SY5Y cells for APP/A β (panels D, I, N, and S) and Sy (panels E, J, O, and T) with DAPI counterstained nuclei (panels C, H, M, and R) visualized with the confocal microscope Zeiss Duo 510 META and 63x oil immersion objective. White arrows (panels B, G, L, and Q) indicate the aggregates in the intracellular space. Stack layers with z-interval of 320 nm presented in sum intensity projection. Three-dimensional reconstruction of stacks (panels A, F, K, and P) generated with Imaris software. Brightness and contrast were increased for clarity. Images were edited by using Fiji software. Scale bar 20 μ m.

by the dbcAMP-induced overexpression of A β PP [15], which proteolytic processing yields A β peptides and may enhance the toxic effects endogenously. Surprisingly, in the case of RA/BDNF differentiated cells the A β ₄₂ peptide at 10 μ M concentration was more toxic than at 20 μ M level. The reason for this unordinary concentration dependence is not clear; however, it can be hypothesized that as 20 μ M peptide fibrillizes faster, then the exposure time of cells to the toxic intermediate species crucial for A β -induced neurotoxicity [22, 24] is shorter. Significant sensitivity of RA/BDNF cells toward amyloid can also be enhanced by increased expression of A β PP, showed by Holback et al [30], similarly to dbcAMP- differentiated cells; however, the irregular concentration effect on this type of cells need further investiga-

tion. RA/TPA differentiated dopaminergic SH-SY5Y cells were almost resistant to A β ₄₂ toxicity. Such cells are also more resistant to other toxic compounds like 6-OHDA [17], which is used to destroy dopaminergic neurons by different mechanisms as compared to A β . Moreover, TPA treatment had protective effect against A β toxicity also in case of hippocampal primary neurons, which is assumingly mediated by activation of protein kinase C [31], known to support cell survival [32]. Thus, RA/TPA differentiated SH-SY5Y culture is characterized by high resistance against A β -mediated toxicity applicable for studies of the underlying mechanisms of tolerance.

In parallel with toxicological studies, we also monitored distribution of extracellularly applied A β ₄₂ in cell cultures by ICC. The visualized pattern of peptide

Table 1
Comparative table of cell viability WST-1 test results

Differentiation type	10 μ M A β_{42}	20 μ M A β_{42}	Staurosporine
Non-differentiated	100.20 $\pm$ 3.45	57.36 $\pm$ 8.71	31.58 $\pm$ 3.60
dbcAMP	51.34 $\pm$ 4.23	37.19 $\pm$ 1.73	21.36 $\pm$ 1.74
RA/BDNF	59.44 $\pm$ 5.30	77.20 $\pm$ 6.83	15.59 $\pm$ 1.31
RA/TPA	85.75 $\pm$ 4.37	102.60 $\pm$ 5.26	26.45 $\pm$ 4.15

The table displays the mean $\pm$ SEM; n = 4 for non-differentiated cells; n = 4 for dbcAMP cells; n = 10 for RA/BDNF cells; n = 6 for RA/TPA cells.

Table 2
Comparative table of PI test results

Differentiation type	10 μ M A β_{42}	20 μ M A β_{42}	Staurosporine
Non-differentiated	1.08 $\pm$ 0.05	1.81 $\pm$ 0.17	2.16 $\pm$ 0.14
dbcAMP	1.37 $\pm$ 0.10	1.94 $\pm$ 0.08	2.11 $\pm$ 0.13
RA/BDNF	1.84 $\pm$ 0.17	1.61 $\pm$ 0.20	2.88 $\pm$ 0.31
RA/TPA	1.28 $\pm$ 0.06	1.36 $\pm$ 0.11	1.98 $\pm$ 0.25

The table displays the mean $\pm$ SEM; n = 4 for non-differentiated cells; n = 4 for dbcAMP cells; n = 10 for RA/BDNF cells; n = 6 for RA/TPA cells.

distribution on cell bodies and neurites in different cultures was generally similar. We expected that the increased resistance of RA/TPA-differentiated cells toward A β might be associated with decreased peptide association with cell membranes, which composition might differ from other cells studied. It is known that the composition of cell membranes is crucial for seeding of A β peptide aggregation [33, 34] and involved also in cell death signaling [35]. However, our assumption was not confirmed, as we did not find any correlations between the extent of A β distribution in the studied cell cultures and the peptide toxicity, which indicates that the reasons of RA/TPA-differentiated cell resistance toward A β toxicity need further clarification.

To conclude, we have generated three neuron-like cellular models of human origin by differentiation of SH-SY5Y cells according to different prescribed protocols, which possess several advantages over non-differentiated cell line model, and compared the toxic effects of A β_{42} peptide on these systems. We have found that RA/TPA differentiated cells SH-SY5Y cells were almost resistant against toxicity of A β . DbcAMP-differentiated and RA-BDNF-differentiated SH-SY5Y cells might be useful for further studies of the mechanisms of A β toxicity as well as in the screening of compounds protecting the neuronal cells from the toxic effects of A β . DbcAMP differentiation should be preferred because of the normal concentration dependence; RA/TPA

differentiated cells can be used for unravelling the mechanisms of A β tolerance, which might contribute to better understanding of the neurodegeneration and neuroprotection in case of AD.

ACKNOWLEDGMENTS

This work was supported by the Estonian Ministry of Education and Research (grant IUT 19-8) to PP.

Authors' disclosures available online (<https://www.j-alz.com/manuscript-disclosures/19-0705>).

SUPPLEMENTARY MATERIAL

The supplementary material is available in the electronic version of this article: <http://dx.doi.org/10.3233/JAD-190705>.

REFERENCES

- [1] Anand R, Gill KD, Mahdi AA (2014) Therapeutics of Alzheimer's disease: Past, present and future. *Neuropharmacology* **76 Pt A**, 27-50.
- [2] Schlachetzki JC, Saliba SW, Oliveira AC (2013) Studying neurodegenerative diseases in culture models. *Rev Bras Psiquiatr* **35**(Suppl 2), S92-S100.
- [3] Alhibshi AH, Odawara A, Suzuki I (2019) Neuroprotective efficacy of thymoquinone against amyloid beta-induced neurotoxicity in human induced pluripotent stem cell-derived cholinergic neurons. *Biochem Biophys Res* **17**, 122-126.
- [4] Yusuf M, Leung K, Morris KJ, Volpi EV (2013) Comprehensive cytogenomic profile of the in vitro neuronal model SH-SY5Y. *Neurogenetics* **14**, 63-70.
- [5] Agholme L, Lindstrom T, Kagedal K, Marcusson J, Hallbeck M (2010) An in vitro model for neuroscience: Differentiation of SH-SY5Y cells into cells with morphological and biochemical characteristics of mature neurons. *J Alzheimers Dis* **20**, 1069-1082.
- [6] Dwane S, Durack E, Kiely PA (2013) Optimising parameters for the differentiation of SH-SY5Y cells to study cell adhesion and cell migration. *BMC Res Notes* **6**, 366.
- [7] Presgraves SP, Ahmed T, Borwege S, Joyce JN (2004) Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamine agonists. *Neurotox Res* **5**, 579-598.
- [8] Teppola H, Sarkanen JR, Jalonen TO, Linne ML (2016) Morphological differentiation towards neuronal phenotype of SH-SY5Y neuroblastoma cells by estradiol, retinoic acid and cholesterol. *Neurochem Res* **41**, 731-747.
- [9] Kume T, Kawato Y, Osakada F, Izumi Y, Katsuki H, Nakagawa T, Kaneko S, Niidome T, Takada-Takatori Y, Akaike A (2008) Dibutyryl cyclic AMP induces differentiation of human neuroblastoma SH-SY5Y cells into a noradrenergic phenotype. *Neurosci Lett* **443**, 199-203.
- [10] Cheung YT, Lau WK, Yu MS, Lai CS, Yeung SC, So KF, Chang RC (2009) Effects of all-trans-retinoic acid on human SH-SY5Y neuroblastoma as in vitro model in neurotoxicity research. *Neurotoxicology* **30**, 127-135.

- [11] Itano Y, Ito A, Uehara T, Nomura Y (1996) Regulation of Bcl-2 protein expression in human neuroblastoma SH-SY5Y cells: Positive and negative effects of protein kinases C and A, respectively. *J Neurochem* **67**, 131-137.
- [12] Toselli M, Tosetti P, Taglietti V (1996) Functional changes in sodium conductances in the human neuroblastoma cell line SH-SY5Y during in vitro differentiation. *J Neurophysiol* **76**, 3920-3927.
- [13] Encinas M, Iglesias M, Liu Y, Wang H, Muhaisen A, Cena V, Gallego C, Comella JX (2000) Sequential treatment of SH-SY5Y cells with retinoic acid and brain-derived neurotrophic factor gives rise to fully differentiated, neurotrophic factor-dependent, human neuron-like cells. *J Neurochem* **75**, 991-1003.
- [14] Goldie BJ, Barnett MM, Cairns MJ (2014) BDNF and the maturation of posttranscriptional regulatory networks in human SH-SY5Y neuroblast differentiation. *Front Cell Neurosci* **8**, 325.
- [15] Shekarabi M, Bourbonniere M, Dagenais A, Nalbantoglu J (1997) Transcriptional regulation of amyloid precursor protein during dibutyryl cyclic AMP-induced differentiation of NG108-15 cells. *J Neurochem* **68**, 970-978.
- [16] Sagy-Bross C, Kasianov K, Solomonov Y, Braiman A, Friedman A, Hadad N, Levy R (2015) The role of cytosolic phospholipase A2 alpha in amyloid precursor protein induction by amyloid beta1-42: Implication for neurodegeneration. *J Neurochem* **132**, 559-571.
- [17] Looyenga BD, Resau J, MacKeigan JP (2013) Cytokine receptor-like factor 1 (CRLF1) protects against 6-hydroxydopamine toxicity independent of the gp130/JAK signaling pathway. *PLoS One* **8**, e66548.
- [18] Gibson Wood W, Eckert GP, Igabovoa U, Muller WE (2003) Amyloid beta-protein interactions with membranes and cholesterol: Causes or casualties of Alzheimer's disease. *Biochim Biophys Acta* **1610**, 281-290.
- [19] Miettinen M, Rapola J (1987) Synaptophysin—an immunohistochemical marker for childhood neuroblastoma. *Acta Pathol Microbiol Immunol Scand A* **95**, 167-170.
- [20] Shipley MM, Mangold CA, Szpara ML (2016) Differentiation of the SH-SY5Y human neuroblastoma cell line. *J Vis Exp*, 53193.
- [21] Finder VH, Vodopivec I, Nitsch RM, Glockshuber R (2010) The recombinant amyloid-beta peptide Abeta1-42 aggregates faster and is more neurotoxic than synthetic Abeta1-42. *J Mol Biol* **396**, 9-18.
- [22] Cohen SI, Linse S, Luheshi LM, Hellstrand E, White DA, Rajah L, Otzen DE, Vendruscolo M, Dobson CM, Knowles TP (2013) Proliferation of amyloid-beta42 aggregates occurs through a secondary nucleation mechanism. *Proc Natl Acad Sci U S A* **110**, 9758-9763.
- [23] Stine WB, Jungbauer L, Yu C, LaDu MJ (2011) Preparing synthetic Abeta in different aggregation states. *Methods Mol Biol* **670**, 13-32.
- [24] Krishtal J, Bragina O, Metsla K, Palumaa P, Tõugu V (2017) In situ fibrillizing amyloid-beta 1-42 induces neurite degeneration and apoptosis of differentiated SH-SY5Y cells. *PLoS One* **12**, e0186636.
- [25] Omar SH, Scott CJ, Hamlin AS, Obied HK (2018) Olive bio-phenols reduces Alzheimer's pathology in SH-SY5Y cells and APPswe mice. *Int J Mol Sci* **20**, E125.
- [26] Mokhtar SH, Kim MJ, Magee KA, Aui PM, Thomas S, Bakhuraysah MM, Alrehaili AA, Lee JY, Steer DL, Kenny R, McLean C, Azari MF, Birpanagos A, Lipiec E, Heraud P, Wood B, Petratsos S (2018) Amyloid-beta-dependent phosphorylation of collapsin response mediator protein-2 dissociates kinesin in Alzheimer's disease. *Neural Regen Res* **13**, 1066-1080.
- [27] Ni J, Wu Z, Meng J, Zhu A, Zhong X, Wu S, Nakanishi H (2017) The neuroprotective effects of Brazilian green propolis on neurodegenerative damage in human neuronal SH-SY5Y cells. *Oxid Med Cell Longev* **2017**, 7984327.
- [28] De Lorenzi E, Chiari M, Colombo R, Cretich M, Sola L, Vanna R, Gagni P, Bisceglia F, Morasso C, Lin JS, Lee M, McGeer PL, Barron AE (2017) Evidence that the human innate immune peptide LL-37 may be a binding partner of amyloid-beta and inhibitor of fibril assembly. *J Alzheimers Dis* **59**, 1213-1226.
- [29] Gonzalo-Ruiz A, Gonzalez I, Sanz-Anquela JM (2003) Effects of beta-amyloid protein on serotonergic, noradrenergic, and cholinergic markers in neurons of the pontomesencephalic tegmentum in the rat. *J Chem Neuroanat* **26**, 153-169.
- [30] Holback S, Adlerz L, Iverfeldt K (2005) Increased processing of APLP2 and APP with concomitant formation of APP intracellular domains in BDNF and retinoic acid-differentiated human neuroblastoma cells. *J Neurochem* **95**, 1059-1068.
- [31] Han YS, Zheng WH, Bastianetto S, Chabot JG, Quirion R (2004) Neuroprotective effects of resveratrol against beta-amyloid-induced neurotoxicity in rat hippocampal neurons: Involvement of protein kinase C. *Br J Pharmacol* **141**, 997-1005.
- [32] Lucke-Wold BP, Turner RC, Logsdon AF, Simpkins JW, Alkon DL, Smith KE, Chen YW, Tan Z, Huber JD, Rosen CL (2015) Common mechanisms of Alzheimer's disease and ischemic stroke: The role of protein kinase C in the progression of age-related neurodegeneration. *J Alzheimers Dis* **43**, 711-724.
- [33] Matsuzaki K (2010) Ganglioside cluster-mediated aggregation and cytotoxicity of amyloid beta-peptide: Molecular mechanism and inhibition. *Yakugaku Zasshi* **130**, 511-515.
- [34] Ogawa M, Tsukuda M, Yamaguchi T, Ikeda K, Okada T, Yano Y, Hoshino M, Matsuzaki K (2011) Ganglioside-mediated aggregation of amyloid beta-proteins (Abeta): Comparison between Abeta-(1-42) and Abeta-(1-40). *J Neurochem* **116**, 851-857.
- [35] Lau TL, Gehman JD, Wade JD, Perez K, Masters CL, Barnham KJ, Separovic F (2007) Membrane interactions and the effect of metal ions of the amyloidogenic fragment Abeta(25-35) in comparison to Abeta(1-42). *Biochim Biophys Acta* **1768**, 2400-2408.

Appendix 3

Publication III

Metsla, K. *, Kirss, S. *, Laks, K., Sildnik, G., Palgi, M., Palumaa, T., Tõugu, V., & Palumaa, P. (2022). α -Lipoic Acid Has the Potential to Normalize Copper Metabolism, Which Is Dysregulated in Alzheimer's Disease. *Journal of Alzheimer's disease: JAD*, 85(2), 715–728. <https://doi.org/10.3233/JAD-215026>

α -Lipoic Acid Has the Potential to Normalize Copper Metabolism, Which Is Dysregulated in Alzheimer's Disease

Kristel Metsla^{a,1}, Sigrid Kirss^{a,1}, Katrina Laks^a, Gertrud Sildnik^a, Mari Palgi^a, Teele Palumaa^b, Vello Tõugu^a and Peep Palumaa^{a,*}

^aDepartment of Chemistry and Biotechnology, Tallinn University of Technology, Tallinn, Estonia

^bEast Tallinn Central Hospital Eye Clinic, Tallinn, Estonia

Handling Associate Editor: Colin Masters

Accepted 20 October 2021

Pre-press 30 November 2021

Abstract.

Background: Alzheimer's disease (AD) is an age-dependent progressive neurodegenerative disorder and the most common cause of dementia. The treatment and prevention of AD present immense yet unmet needs. One of the hallmarks of AD is the formation of extracellular amyloid plaques in the brain, composed of amyloid- β (A β) peptides. Besides major amyloid-targeting approach there is the necessity to focus also on alternative therapeutic strategies. One factor contributing to the development of AD is dysregulated copper metabolism, reflected in the intracellular copper deficit and excess of extracellular copper.

Objective: In the current study, we follow the widely accepted hypothesis that the normalization of copper metabolism leads to the prevention or slowing of the disease and search for new copper-regulating ligands.

Methods: We used cell culture, ICP MS, and *Drosophila melanogaster* models of AD.

Results: We demonstrate that the natural intracellular copper chelator, α -lipoic acid (LA) translocates copper from extracellular to intracellular space in an SH-SY5Y-based neuronal cell model and is thus suitable to alleviate the intracellular copper deficit characteristic of AD neurons. Furthermore, we show that supplementation with LA protects the *Drosophila melanogaster* models of AD from developing AD phenotype by improving locomotor activity of fruit fly with overexpression of human A β with Iowa mutation in the fly brain. In addition, LA slightly weakens copper-induced smooth eye phenotype when amyloid- β protein precursor (A β PP) and beta-site A β PP cleaving enzyme 1 (BACE1) are overexpressed in eye photoreceptor cells.

Conclusion: Collectively, these results provide evidence that LA has the potential to normalize copper metabolism in AD.

Keywords: Alzheimer's disease, copper metabolism, metalloneurochemistry, α -lipoic acid

INTRODUCTION

Alzheimer's disease (AD) is characterized by the occurrence of amyloid plaques and neurofibrillary

tangles in the brain, which results in neurodegeneration and clinical diagnosis of dementia [1]. AD is an age-dependent disease affecting approximately 50 million people worldwide, and this number is expected to increase dramatically because of the population aging [2]. AD is the costliest disease for the developed countries as there is no cure and the patients require long-term support [3, 4]. It is universally accepted that the prevention and treatment of

¹These authors contributed equally to this work.

*Correspondence to: Peep Palumaa, Department of Chemistry and Biotechnology, Tallinn University of Technology, Akadeemia tee 15, 12618 Tallinn, Estonia. Tel.: +372 6204410; E-mail: peep.palumaa@ttu.ee.

AD is one of the major current medical problems and the development of effective treatment and prevention strategies will considerably decrease the global healthcare burden [2].

According to the prevalent amyloid cascade hypothesis [5, 6], the formation of amyloid plaques, consisting of amyloid- β ($A\beta$) peptides, and the consequent appearance of neurofibrillary tangles, composed of aggregated hyperphosphorylated tau proteins ultimately lead to neurodegeneration in AD. $A\beta$ peptides are produced through proteolytic cleavage of amyloid- β protein precursor ($A\beta$ PP) by beta-site $A\beta$ PP cleaving enzyme 1 (BACE1) and gamma secretase. Most therapeutic approaches to AD have focused on targeting $A\beta$ and tau, but unfortunately, many of them have failed in clinical trials [7–9]. However, one $A\beta$ -targeting antibody, Aducanumab, was recently approved by FDA [10]. Currently there is conflicting evidence about the clinical benefit of the costly Aducanumab treatment [11]. Therefore, there is still the need to investigate alternative treatment options.

It has been confirmed that copper metabolism is dysregulated in AD [12, 13], which may trigger the development of AD. Copper is an essential redox cofactor for more than twenty enzymes with crucial roles in cellular energy production (cytochrome c oxidase), antioxidative defense (Cu,Zn-superoxide dismutase-1), oxidative metabolism (lysyl oxidase, tyrosinase, dopamine β -monooxygenase, peptidyl-glycine α -amidating monooxygenase, etc.), and metabolism of iron (ceruloplasmin). However, “free” or weakly complexed copper ions interact with oxygen metabolites, generating reactive oxygen species, including highly toxic hydroxyl radicals [14]. This double-faceted nature of copper ions dictates the requirement for their tight control [15, 16]. Dysregulation of copper metabolism, such as deficiency, misdistribution, or excessive accumulation is detrimental and leads to various diseases [17]. Classical examples of excessive accumulation and deficiency of copper are Wilson’s disease (WD) and Menkes disease, caused by loss-of-function mutations in copper transporters ATP7B [18] and ATP7A [19], respectively. Importantly WD and Menkes disease can be treated by correcting the abnormal copper metabolism by using copper chelators [20] or copper supplements [21], accordingly.

Disturbance of copper metabolism in AD is characterized by copper misdistribution. AD is accompanied by substantially elevated levels of copper in extracellular space, e.g., blood serum and

cerebrospinal fluid (CSF) [22–26] and simultaneous copper deficiency in brain tissue [22, 27, 28]. These changes result in decoppering of cellular copper proteins and can hypothetically be detrimental to neurons. Similar changes on a smaller scale also occur during the normal aging process [29, 30]. Recently, a new CuAD hypothesis has been proposed [22]: it theorizes a copper imbalance in AD among the contributing early drivers of this multifactorial condition. This hypothesis posits an age aggravated gradual shift from copper from the pool bound to proteins, with both loss of energy production and antioxidant function, to pools of loosely bound copper ions that increase in the extracellular space and in general circulation and facilitate oxidative stress. According to such a scenario, dysregulation of copper metabolism is an early event in AD pathology and its normalization may be an effective strategy for the prevention and/or treatment of AD.

Attempts to regulate copper metabolism in AD have thus far been unsuccessful. In our opinion, the failures have been caused by several reasons. Generally, so far, the attempts have been largely trial and error cases and were not based on a comprehensive understanding of the copper-binding properties of the ligands in comparison with organismal copper proteins and peculiarities of copper metabolism in healthy and AD brains. Second, synthetic Cu(II) chelators [31–33] have been used, which are known to induce undesirable decoppering of the organism [34–36]. Third, application of synthetic copper ionophores such as clioquinol leads in contrary to an abnormal increase of cellular copper [37, 38] which becomes toxic [39]. A more detailed analysis of copper links with AD and copper-focused therapeutic strategies is presented in the Discussion.

In the current study, we propose molecular tools to normalize copper metabolism in AD based on systematic knowledge about the metal-binding properties of potential AD drug candidates, which have the potential to normalize distorted copper metabolism in AD. Our lead compound is α -lipoic acid (LA). Earlier work from our group has shown that the reduced dihydro-LA (DHLA) form has a substantial Cu(I)-binding affinity [40]. Its affinity for Cu(I) is higher than glutathione but lower than intracellular copper chaperones and enzymes (Fig. 1) [40, 41]. LA acts as Cu(I) chelator only in the intracellular space, where it exists in reduced DHLA form and may shift the copper equilibrium from extracellular to intracellular.

LA is an extensively studied natural ligand that is synthesized enzymatically in the mitochondrion

Cu(I)-BINDING AFFINITIES




Fig. 1. Copper(I)-binding affinities of intracellular Cu(I) proteins and copper chelators according to [41] and [40].

from octanoic acid [42] and is functioning primarily as a cofactor covalently linked to mitochondrial α -ketoacid dehydrogenases [43, 44]. LA is also absorbed from dietary sources and elicits a unique set of biochemical activities [42]. Thus far, the biological effects of LA have been explained mainly by its antioxidant action, however, its potential in detoxification of heavy metals has also been recognized [45].

LA has been also studied in the context of AD and aging. For example, LA improves the memory of aged nontransgenic (NMRI) mice [46] as well as transgenic AD (Tg2576) mice [47]. Moreover, supplementation with LA extends the lifespan of immunosuppressed mice [48] and also of *Drosophila melanogaster* [49]. LA has a clinically proven therapeutic value in the treatment of diabetic polyneuropathy [50]. Most importantly, LA has been tested in AD clinical trials. A daily dose of 600 mg showed a positive effect by slowing the progression of cognitive impairment in patients with mild AD (43 patients, trial duration 48 months) [51, 52] and in patients with mild to moderate AD with and without insulin resistance (126 patients, trial duration 16 months) [53]. Despite these promising results, clinical trials with LA have not been taken forward. The therapeutic effect of LA in these trials has mainly been attributed to its antioxidative and anti-inflammatory

effects [43], whereas its copper regulating properties have not been considered or studied.

In this study, we tested the potential of LA to regulate the cellular copper metabolism in a way necessary for the treatment of AD. We demonstrate that supplementation with LA promotes the influx of copper into SH-SY5Y cells in a dose-dependent manner. In addition, by using *Drosophila melanogaster* models of AD, we show that LA can alleviate the disease phenotype reflected in a negative geotaxis experiment of fruit flies overexpressing A β Iowa mutation in the fly brain and weakened the development of copper-induced smooth eye phenotype when BACE1 and A β PP were overexpressed in photoreceptor cells. These results, together with surplus data from literature support the hypothesis that LA may be suitable for the normalization of copper distribution, which is disrupted in AD.

MATERIALS AND METHODS

Cell culture experiments

Human SH-SY5Y neuroblastoma cells (ATCC) were grown in Dulbecco's Modified Eagle Medium (Gibco) supplemented with 10% fetal bovine serum (Gibco) and 1% penicillin and streptomycin (Gibco) at 37°C in a humidified atmosphere containing 5%

CO₂. The culture medium was changed every 2 to 3 days and the cells were split every 5 to 7 days using 0.25% Trypsin-EDTA (Gibco), up to 20 times. Cells were plated with a density of 2×10^5 cells/ml into white clear-bottom 6-well plates (Greiner Bio-One) 2 ml per well for inductively coupled plasma mass spectrometry (ICP-MS) experiments. SH-SY5Y cells were differentiated in cell culture plates, using the following differentiation protocol: cells were pre-differentiated with 10 μ M retinoic acid in full medium for 4 days, followed by differentiation with 50 ng/mL brain-derived neurotrophic factor (Alomone Labs) in serum-free medium for 2 days [54]. Phase-contrast images of cells were taken using Zeiss Axiovert 200M microscope with 20x objective. For cell count measurement, 10 μ l of cell suspension was mixed with an equal volume of trypan blue stain, pipetted into Countless cell counting chamber slide, and inserted into the Countess Automated Cell Counter (Invitrogen). To measure copper content, non-differentiated and differentiated SH-SY5Y cells were treated for 24 h with 5 or 10 μ M CuCl₂ (Sigma-Aldrich) in the presence of 5–50 μ M LA (Sigma-Aldrich), 5–200 μ M D-penicillamine (D-PA) (Sigma-Aldrich), and 5–200 μ M triethylenetetramine hydrochloride (TETA) (Sigma-Aldrich). For toxicity experiments, cells were grown and differentiated in white clear bottom 96-well plates. Differentiated SH-SY5Y cells were treated for 24 h with different concentrations of D-PA, TETA, and LA in the presence of 10 μ M CuCl₂ (Sigma-Aldrich). For the assessment of cell viability with propidium iodide (PI), 0.5 mM PI in phosphate buffered saline (PBS, Sigma) was added to 100 μ l cell culture 0.5 μ l/well and incubated for 10 min at 37°C. TECAN Genios Pro microplate reader was used to measure fluorescence (excitation 540 nm, emission 612 nm) [54]. Cells on the plate were imaged with Zeiss Axiovert 200 M microscope.

ICP-MS analysis

Differentiated SH-SY5Y cells were collected from 6-well plate wells into acid-washed 2 ml tubes and centrifuged for 1 min at 10,000 $\times$ g to separate the medium from cells. Cells were washed twice in 500 μ l PBS (Sigma Aldrich), and a sample of 10 μ l from cell suspension sample was taken to measure cell count with Countess Automated Cell Counter as previously described. Cells in PBS were centrifuged for 3 min at 10 000 $\times$ g to separate cells from PBS. PBS was discarded and the obtained cell samples were

stored at –20°C until the ICP-MS analysis. One day before ICP-MS analysis, 100 μ l of 68% HNO₃ was added to the cell samples. Acidified samples were incubated for 24 h at room temperature. For ICP-MS analysis, samples were diluted to 2% HNO₃. Ultrapure Milli-Q water with a resistivity of 18.2 M Ω /cm, produced by a Merck Millipore Direct-Q & Direct-Q UV water purification system (Merck KGaA, Darmstadt, Germany), was used for all sample preparations.

ICP-MS analyses for Cu-63 were performed on an Agilent 7800 series ICP-MS instrument (Agilent Technologies, Santa Clara, USA) and Agilent SPS-4 autosampler was used for sample introduction. For instrument control and data acquisition, ICP-MS MassHunter 4.4 software Version C.01.04 from Agilent was used. ICP-MS analysis was performed in peak-hopping mode, 6 points per peak, 100 scans per replicate, 3 replicates per sample, and the instrument was operated under general matrix working mode under the following conditions: RF power 1550 W, nebulizer gas flow 1.05 l/min, the plasma gas flow 15 l/min, nebulizer type: MicroMist. Elements monitored: Sc-45 (internal standard) and Cu-63. The ICP-MS apparatus was calibrated using multielement calibration standard 2A in 2% HNO₃ (Agilent Technologies, USA) containing Ag, Al, As, Ba, Be, Ca, Cd, Co, Cr, Cs, Cu, Fe, Ga, K, Li, Mg, Mn, Na, Ni, Pb, Rb, Se, Sr, Ti, U, V, and Zn at levels 0.5, 1, 5, 10, and 25 ppb with Sc-45 (ICP-MS internal standard mix 1 μ g/mL in 2% HNO₃, Agilent Technologies) as the internal standard for Cu-63.

Drosophila melanogaster experiments

Used stocks, maintenance, and husbandry of Drosophila melanogaster

The following stocks were used for the experiments: driver lines *30Y-Gal4* (a gift from Mark Fortini) [55] and *ninaE^{GMR}-Gal4* [56] (Bloomington Drosophila Stock Center (BDSC) #1104), responder lines UAS-APP.A β 42.D694N.VTR (Iowa flies) (Vitruvian; BDSC #33779) and UAS-APP695-N-myc, UAS-BACE1/ TM6B (A β PP/BACE1 flies), (Vitruvian; BDSC #33797). Fly stocks were maintained at 25°C (12 h:12 h light: dark cycle; 60–70% humidity) on malt-semolina based food prepared from 6.5 g agar, 38 g semolina, 70.5 g malt flour, 17.5 g dry yeast, 5.9 ml nipagin (Tegosept 30%; 30 g/100 ml 94% EtOH; Dutcher Scientific), and 6.8 ml propionic acid (Sigma) per 1000 ml water. *Drosophila* crosses were performed at 29°C to obtain a higher

activity of *Gal4-UAS* system. By crossing *30Y-Gal4* and Iowa flies, the offspring (AD Iowa flies) have A β ₄₂ Iowa mutant D23N overexpression driven by *30Y-Gal4* pattern in the fruit fly brain. For controls we used the pure UAS-APP.A β ₄₂.D694N.VTR line inactive in the absence of Gal4. For overexpression in the eye photoreceptors (AD BACE1/A β PP flies), *ninaE^{GMR}-Gal4* flies were crossed to A β PP/BACE1 flies, where *ninaE^{GMR}-Gal4/+; TM6B/+* flies were serving as a control.

LA feeding regimen

To study the effect of LA on the locomotor activity of AD flies, dietary supplementation with LA was performed. For negative geotaxis assay, LA was dissolved in 96% ethanol to obtain a 200 mM stock solution and added into the previously described food at a final concentration of 2 mM (LA-food). Control food (food) contained the same amount of ethanol that was used to produce LA-food. Adult male and female flies were separated and added to LA-food and food within 24 h after eclosion and aged at 29°C for 7 days before the experiments. To study the effect of LA on the developed AD phenotype, separated male and female flies were maintained on regular food for 7 days and transferred to LA-food and food for further 7 days.

For the eye phenotype experiment, CuCl₂ was dissolved in 0.5% HCl for a 1 M stock solution and added to the food at a final concentration of 500 μ M (Cu-food). In addition, to measure the effect of LA, food was supplemented with both 500 μ M CuCl₂ and 2 mM LA (Cu/LA-food). Transgenic flies were kept on food and Cu-food from the egg-laying stage. Adult female and male flies were separated and added to food, LA-food, Cu-food, and Cu/LA-food within 24 h after eclosion and aged at 29°C for 5 days before the experiments. Images from eyes were obtained with the scanning electron microscope Carl Zeiss EVO LS15 (SEM).

In all experiments, flies were transferred to fresh food every 2 days.

Negative geotaxis assay for *Drosophila melanogaster*

A negative geotaxis assay for *Drosophila melanogaster* was performed as described earlier in [57]. Before the test, 7–10 flies of each group were transferred into empty 15 ml vials, covered with another upside-down vial, and vials were sealed together with transparent tape. Obtained vials were placed in front of a 20 cm high background that was

divided into 10 equal spaces. For the measurement, flies were knocked to the bottom of the vial three times, and photos were taken after 10 s. The climbing height of each fly was registered, and the average climbing distance score for each vial of flies was calculated.

Statistical analyses

Statistical analyses were performed using Graph-Pad Prism 8. Data of PI assay and ICP-MS were analyzed using a one-way analysis of variance (ANOVA) with the *posthoc* Dunnett's multiple comparison test. Negative geotaxis scores were averaged per vial (5–20 flies per vial) and the mean score of each vial was treated as an individual replicate for further analysis. Two-way ANOVA with Sidak's multiple comparison correction was used to compare the scores of different experimental groups. Data on graphs are presented as mean $\pm$ standard error of the mean (SEM) and a *p* value of ≤ 0.05 was considered as statistically significant. Statistical significance is represented as **p* ≤ 0.05 , ***p* ≤ 0.01 , ****p* ≤ 0.001 , and *****p* ≤ 0.0001 .

RESULTS

Toxicity of metal chelating agents in the presence of copper ions on differentiated SH-SY5Y cells

As *in vitro* cellular model, we used human neuroblastoma cell line SH-SY5Y, which is a widely used cellular model in neuroscience in the non-differentiated and differentiated form [58]. In the current study, we differentiated SH-SY5Y cells with retinoic acid and brain-derived neurotrophic factor, which induces neuronal phenotype of cells reflected in the outgrowth of long neurites and formation of neuronal network [59] (Fig. 2A, B). To exclude the toxic effect of LA in the presence of copper ions PI assay was performed on differentiated SH-SY5Y cells. Two copper chelators, used in the treatment of WD, were also included in the test. After a 24 h incubation period, all agents and Cu(II) ions were individually nontoxic (Supplementary Figure 1A, C, E). LA and TETA were also nontoxic in a presence of 10 μ M CuCl₂ (Supplementary Figure 1B, D); however, D-PA at higher concentrations was toxic in a presence of 10 μ M CuCl₂ as PI uptake doubled at 100 μ M D-PA concentration (Supplementary Figure 1F). The phase-contrast image and fluorescent microscopy confirmed the presence of a substantial number of dead cells (Supplementary Figure 2D).




Fig. 2. Effect of LA on the distribution of copper between medium and cells. Phase contrast images showing the morphology of non-differentiated (A) and differentiated SH-SY5Y cells (B). Non-differentiated (C) and differentiated (D) SHSY-5Y cells were treated with 5–50 μ M LA in the presence of 5 μ M CuCl_2 ; The columns display the mean $\pm$ SEM; $n = 8$ –11. One-way ANOVA followed by a Dunnett's multiple comparisons test at the 0.05 level was used for statistical analysis. Main effect of treatment **** $p < 0.0001$; * $p < 0.05$; n.s., not significant.

The effect of LA, DPA, and TETA on the distribution of copper ions in cell culture

To study whether LA and other copper chelators DPA and TETA can redistribute copper from extracellular to intracellular environment, we used differentiated and non-differentiated SH-SY5Y cells. Both types of cells were treated with 5–50 μ M LA in the presence of 5 μ M CuCl_2 . The results demonstrate that LA promotes the translocation of copper ions from the extracellular environment into cells in a concentration-dependent manner (Fig. 2C, D). The effect was evident already at a low micromolar concentration of LA and was more pronounced in the case of differentiated SH-SY5Y cells (Fig. 2C, D). DPA did not increase intracellular copper concentration and in the presence of TETA the intracellular copper concentration decreased (Supplementary Figure 3).

The effect of LA on the phenotype of Drosophila melanogaster AD model

To model AD in fruit flies, we used two fly responder lines: Iowa flies and $\text{A}\beta\text{PP}/\text{BACE1}$ flies, overexpressing $\text{A}\beta$ peptide with an Iowa mutation D23N and human $\text{A}\beta\text{PP}/\text{BACE1}$ respectively (reviewed by

[60]). For the ectopic overexpression in Drosophila, the two-component Gal4-upstream activating sequence (UAS) system is widely exploited [61]. We used also two driver lines - *30Y-Gal4* and *ninaE^{GMR}-Gal4* with specific expression in the Drosophila mushroom body previously shown to affect also the negative geotaxis [57] and in the eye photoreceptor cells, which models neurodegeneration.

The offspring of AD Iowa flies and control flies were provided with standard food (food) and food with LA added (LA-food) after hatching. After 7 days of incubation, the control flies kept on food and LA-food did not display any difference in the climbing score determined by the negative geotaxis experiment (Fig. 3B). The climbing score of AD Iowa flies incubated on food declined compared to control flies (Fig. 3B), whereas AD flies kept on LA-food showed a lower decline, indicating that LA protects AD Iowa flies from developing AD phenotype. Analysis of male and female flies separately demonstrated that the effect of LA was statistically significant in both sexes (Fig. 3C).

We also studied the effect of LA on flies that had already developed the AD phenotype. In this experiment, AD flies were grown on food for 7 days and half of the flies were thereafter transferred to food+LA




Fig. 3. Effect of LA on the climbing ability of Control versus AD flies. The crossing of RE (regulatory element 30Y) driven Gal4 flies with flies containing UAS in tandem with A β ₄₂ gene containing Iowa mutation (D23N) (A). AD flies were incubated for 7 days on food or food+LA before a negative geotaxis assay (B, C). AD flies were incubated on food for 7 days and food or food+LA for the next 7 days (D). The climbing score displays the mean $\pm$ SEM of climbing distance for $n=32-57$ in groups, each consisting of 7–10 flies. Two-way ANOVA with Sidak's multiple comparison correction was used to compare the scores of different experimental groups. Main effect of treatment **** $p<0.0001$; n.s., not significant.

for the subsequent 7 days. We discovered that the supplementation of LA did not affect the results of the negative geotaxis assay in male and female flies (Fig. 3D). These results suggest that in fly model LA is not able to rescue the AD phenotype that has already been developed.

The offspring of AD A β PP/BACE1 flies and control flies were kept on food and Cu-food starting from the egg laying stage. After hatching male and female flies were separated onto food, LA-food, Cu-food, and Cu/LA-food. After 5 days of incubation, the fly eyes were examined using SEM. AD A β PP/BACE1 flies on the food and LA-food had visible neurodegenerative phenotype with degenerated eye size and smooth external eye surface (Fig. 4E, F). Cu-food had a slightly more severe effect on the eye phenotype,

where dark deposits were observed (marked with asterisks in Figure 4G) and had a smoother external eye surface, compared to control flies (Fig. 4E). Eyes of flies on Cu/LA-food exposed slightly more visible ommatidia (marked with asterisks in Fig. 4H), which indicates that LA weakened the effect of copper.

DISCUSSION

In this study, we investigated the molecular tools to normalize copper metabolism, which is dysregulated in AD. Quantitative meta-analyses of numerous independent studies conducted on AD patients have revealed that AD is accompanied by substantially




Fig. 4. Effect of LA on the eye phenotype of AD A β PP/BACE1 flies. SEM images showing the eye morphology of *nina^{EGMR}-Gal4/+; TM6B/+* flies as control and AD A β PP/BACE1 5-day old flies grown on food (A and E), food supplemented with 2 mM LA (B and F), food supplemented with 500 μ M CuCl₂ (C and G), or food supplemented with 500 μ M CuCl₂ and 2 mM LA (D, H). Asterisks show the presence of dark precipitate on (G) or photoreceptor cells on (H).

elevated copper levels in serum [22–25] as well as in the CSF [26] and simultaneous copper deficiency in the brain tissue [23, 27, 28]. The more precise analysis shows that in the serum and CSF of AD patients mainly non-ceruloplasmin (CP)-bound fraction of copper is increased [23, 25, 62, 63] and in AD brain copper deficiency affects the hippocampus (average decrease 35%), amygdala (average decrease 41%), frontal cortex (average decrease 20%) and several other areas of the cerebral cortex, which are the most damaged in the AD pathology, whereas the average copper deficiency in AD brain is 24% [22].

The molecular and genetic background of disturbed copper metabolism has also been extensively studied in the context of AD. Genetically, a higher probability of having AD has been associated with certain variants of *ATP7B*, the copper transporter defective in WD [64]. Furthermore, copper affects several cellular aspects of AD pathology. First, A β PP, a central molecule in AD pathology, the proteolysis of which produces A β peptides [65], is a copper-binding protein [66, 67] and its expression [68], oligomeric state [69], cellular localization [70, 71], and proteolysis [72, 73] are copper-regulated. Therefore, the misbalance of copper metabolism may shift the proteolysis of A β PP towards the amyloidogenic pathway, leading to increased production of A β peptides or more amyloidogenic peptide A β ₄₂, which plays a crucial role in initiating and perpetuating the AD pathologic cascade [6]. Second, copper ions bind with relatively high affinity to full-length and truncated A β peptides [74–76], accelerating their aggregation [77, 78]. Third, copper ions are enriched in A β fibrils *in vivo* in AD brains [79] as well as *in vitro* [80] and cause oxidative stress, which is neurotoxic

and can cause neurodegeneration [81, 82]. Listed evidence indicates that normalizing copper metabolism provides an attractive avenue for the treatment and prevention of AD.

Because of the connection between copper metabolism and AD, several attempts have been made to treat AD by modifying copper metabolism. Three different strategies: copper supplementation, chelation, and redistribution have all been tested in laboratory experiments as well as in clinical trials. Copper supplementation was attempted with copper orotate [83, 84], chelation with D-PA [36] and copper redistribution with clioquinol (CQ, 5-Chloro-8-hydroxy-7-iodoquinoline) and its derivative PBT2 (5,7-dichloro-8-hydroxy-2-[(dimethylamino)methyl]quinoline) [85, 86]. In clinical trials, copper supplementation showed no effect on the progression of AD phenotype over a 12-month treatment period [83]. D-PA promoted decoppering and reduced serum oxidative stress, but did not affect the clinical progression of the disease in a 6-month trial [36]. CQ was also tested in a phase II clinical trial with 36 patients [87]. There was no statistically significant difference in cognition between the treatment and placebo groups at 36 weeks [87, 88]. The drug, however, has been withdrawn from development due to safety concerns as a mutagenic ingredient “di-iodo” CQ that could not be reduced to an acceptable level [88]. PBT2, an improved version of CQ, was tested in two clinical trials [89]. PBT2 showed a favorable safety profile [87] and did reduce A β ₄₂ concentration in CSF compared with those treated with placebo [90]. In the initial publication, it was concluded that BTP2 did not improve the cognitive function of AD patients [90]; however, in later

analysis of the results, some improvement of cognition was detected [89, 91]. The second trial of PBT2 was more rigorously conducted and showed that after 12 weeks this compound appeared to be safe and well-tolerated in people with mild AD; however, larger trials are required for reliable demonstration of cognitive efficacy [87].

In addition to clinically tested compounds, numerous other synthetic Cu(II)-binding ligands [31–33, 92–95], including TETA [96], an FDA-approved WD drug, as well as zinc treatment [97] have been proposed for the treatment of AD. TETA and all other this type of drugs as well as zinc treatment result in a decoppering of an organism [98, 99], which may further decrease the copper levels in the brain.

Therefore, in our opinion the treatments, which lead to decoppering of the organism are not suitable for the normalization of copper dysmetabolism in AD. Rather, substances with the ability to translocate excessive extracellular copper to the intracellular space in the brain are needed. We aimed to normalize copper metabolism by using Cu(I)-binding ligand, which acts only in intracellular space and can shift the equilibrium of copper distribution from extracellular to intracellular location. We established that dihydro-LA has substantial Cu(I)-binding affinity owing to its two closely located SH groups [40]. SH groups of LA are reduced inside the cell and oxidized to a disulfide bond in the extracellular environment thus enabling selective intracellular Cu(I) binding and shifting of equilibrium of copper distribution towards intracellular space through a direct or indirect mode of action.

There are numerous benefits of LA over other synthetic compounds in drug development as well as in further therapeutic use. LA has been approved for the treatment of diabetic polyneuropathy [50] and could be repurposed for therapeutic application in AD [100]. The known toxicology and pharmacodynamic profiles of repurposed drugs significantly accelerate the drug development process, decrease the related costs, and increase the probability of success. By using the PI test, we demonstrated that LA and synthetic compounds, such as D-PA and TETA are individually non-toxic in differentiated SH-SY5Y cell culture. However, when cells were treated with chelating agents in the presence of 10 μ M Cu(II) ions, LA and TETA were non-toxic, whereas D-PA in the presence of copper ions was toxic. It is known, that D-PA treatment in WD worsens neurological symptoms in the early phase of treatment [101], which may be caused by neurotoxicity of D-PA in the presence of copper, demonstrated in our study.

We demonstrated that supplementation with LA significantly increases the intracellular copper level of SH-SY5Y cells in a dose-dependent manner. An increase of intracellular copper occurred already at 5 μ M concentration of LA and the increase was moderate, which is similar to the decrease of copper level in AD brain tissue [23]. The mechanism of LA action in promoting copper redistribution remains to be established. The effect may involve a direct interaction of DHLA with copper ions in the intracellular environment, which shifts the equilibrium of copper distribution towards the intracellular compartment. Alternatively, LA may affect the regulation of copper metabolism indirectly by enhancing or suppressing the synthesis of some proteins. In direct action, LA has to compete with extracellular human serum albumin (HSA), which has a high (picomolar) affinity Cu(II) binding site [102] and is present in CSF at 3 μ M concentration [103]. HSA did not hinder copper translocation by LA in experiments with non-differentiated SH-SY5Y cells where the culture media contained 75 μ M of HSA, which demonstrates that intracellular LA outcompetes extracellular HSA. In addition, indirect or even pleiotropic action of LA is not excluded [43]. It is known that LA increases cellular glutathione levels [104] and functions as an antioxidant by promoting mitochondrial functioning [105]. The mechanism of LA action in promoting copper intake needs further elucidation.

Furthermore, we tested the effect of LA in two transgenic AD *Drosophila melanogaster* models. The first model was AD Iowa flies overexpressing human A β with an Iowa mutation D23N in mushroom bodies. We showed that early supplementation with LA prevents the development of AD phenotype in AD Iowa flies in a negative geotaxis experiment; however, LA cannot alleviate the already developed phenotype in AD flies. Although the expression of A β peptides is not directly connected with copper metabolism, there is evidence that the phenotype of these flies is affected by copper metabolism. For example, the phenotype of A β ₄₂ expressing flies is ameliorated through the inhibition of high-affinity copper influx transporter Ctr1 orthologues in the fly nervous system [106]. The second model was AD A β PP/BACE1 flies overexpressing human A β PP and BACE1 in the eye photoreceptors. In this model, the strongest smooth eye phenotype with dark deposits came up after the addition of 500 μ M CuCl₂ to the food. This effect was slightly weakened by the addition of 2 mM LA to the food, which indicates that LA may have a protective effect on the neurotoxicity of A β ₄₂ in the presence of

KEY EVENTS IN ALZHEIMER'S DISEASE PATHOLOGY




Fig. 5. Key events in Alzheimer's disease pathology. Disturbance of copper metabolism is an early event before initiation of amyloid cascade composed from formation of amyloid plaques, formation of NFTs and following neurodegeneration. According to our hypothesis LA can correct extra- and intracellular copper distribution (1), suppress amyloidogenic processing of A β PP (2), and reverse decoupling of cellular copper proteins leading to neurodegeneration (3) characteristic of AD. A β , amyloid- β ; A β PP, amyloid- β protein precursor; Apo-CP, apoceruloplasmin; CCO, cytochrome c oxidase; CSF, cerebrospinal fluid; Cu,Zn-SOC-1, Cu,Zn-superoxide dismutase-1; NFTs, neurofibrillary tangles

Cu(II) ions. Our data agree with the previous report showing that the phenotype of flies expressing A β_{42} in their eyes is changed by adding Cu(II) ions to the food and these changes could be reversed by copper chelators [107]. In addition, the phenotype of flies expressing A β_{42} specifically in their eyes is changed after mutations in copper transporter ATP7 [108], which highlights the link between A β toxicity and copper metabolism in AD model flies. Therefore, the beneficial effect of LA on AD Iowa flies may also be connected with the normalization of copper metabolism; however, it has to be confirmed in follow-up studies. Moreover, LA might act through an anti-amyloid mechanism different from the regulation of copper since LA protected cultured rat primary neurons against A β toxicity [109].

In conclusion, we propose a hypothetical role of LA in key events of AD, which is presented in Fig. 5. According to our hypothesis, LA can avoid or inhibit the following processes in AD pathology: 1) an increase of extracellular copper levels during aging; 2) malfunctioning of A β PP and its amyloidogenic proteolytic cleavage into amyloid peptides; 3) demetallation of essential copper proteins (Fig. 5).

Disturbed copper metabolism may lead to further downstream processes such as increase of oxidative

stress, depletion of cellular energy reserves, phosphorylation of tau proteins and formation of neurofibrillary tangles leading ultimately to neurodegeneration. Disturbance of copper metabolism is an early event before initiation of amyloid cascade where there are 5–10 years periods between the formation of amyloid plaques and formation of neurofibrillary tangles as well as between formation of neurofibrillary tangles and neurodegeneration/appearance of symptoms (Fig. 5). The proposed mechanism of LA ion waits for verification in further animal experiments and human clinical trials.

ACKNOWLEDGMENTS

This work was supported by the Tallinn University of Technology and by the Estonian Research Council grant (PRG 1289).

Authors' disclosures available online (<https://www.j-alz.com/manuscript-disclosures/21-5026r2>).

SUPPLEMENTARY MATERIAL

The supplementary material is available in the electronic version of this article: <https://dx.doi.org/10.3233/JAD-215026>.

REFERENCES

- [1] Alzheimer A (1906) Über einen eigenartigen schweren Erkrankungsprozeß der Hirnrinde. *Neurologisches Centralblatt* **23**, 1129-1136.
- [2] (2019) Alzheimer's Disease International, <https://www.alz.co.uk/research/WorldAlzheimerReport2019.pdf>
- [3] Hurd MD, Martorell P, Delavande A, Mullen KJ, Langa KM (2013) Monetary costs of dementia in the United States. *N Engl J Med* **368**, 1326-1334.
- [4] Wimo A, Jonsson L, Bond J, Prince M, Winblad B, Int AD (2013) The worldwide economic impact of dementia 2010. *Alzheimers Dement* **9**, 1-11.
- [5] Hardy JA, Higgins GA (1992) Alzheimer's disease: the amyloid cascade hypothesis. *Science* **256**, 184-185.
- [6] Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer's disease at 25 years. *EMBO Mol Med* **8**, 595-608.
- [7] van Dyck CH (2018) Anti-amyloid-beta monoclonal antibodies for Alzheimer's disease: pitfalls and promise. *Biol Psychiatry* **83**, 311-319.
- [8] Servick K (2019) Another major drug candidate targeting the brain plaques of Alzheimer's disease has failed. What's left? *Scienceinsider*, <https://www.science.org/content/article/another-major-drug-candidate-targeting-brain-plaques-alzheimer-s-disease-has-failed>
- [9] Mullard A (2021) Failure of first anti-tau antibody in Alzheimer disease highlights risks of history repeating. *Nat Rev Drug Discov* **20**, 3-5.
- [10] Mullard A (2021) Landmark Alzheimer's drug approval confounds research community. *Nature* **594**, 309-310.
- [11] Selkoe DJ (2021) Treatments for Alzheimer's disease emerge. *Science* **373**, 624-626.
- [12] Bagheri S, Squitti R, Haertle T, Siotto M, Saboury AA (2017) Role of copper in the onset of Alzheimer's disease compared to other metals. *Front Aging Neurosci* **9**, 446.
- [13] Squitti R, Salustri C, Rongioletti M, Siotto M (2017) Commentary: The case for abandoning therapeutic chelation of copper ions in Alzheimer's disease. *Front Neurol* **8**, 503.
- [14] Sies H, Berndt C, Jones DP (2017) Oxidative stress. *Annu Rev Biochem* **86**, 715-748.
- [15] Gaetke LM, Chow-Johnson HS, Chow CK (2014) Copper: toxicological relevance and mechanisms. *Arch Toxicol* **88**, 1929-1938.
- [16] Blockhuys S, Celauro E, Hildesjo C, Feizi A, Stal O, Fierro-Gonzalez JC, Wittung-Stafshede P (2017) Defining the human copper proteome and analysis of its expression variation in cancers. *Metallomics* **9**, 112-123.
- [17] Balsano C, Porcu C, Sideri S (2018) Is copper a new target to counteract the progression of chronic diseases? *Metallomics* **10**, 1712-1722.
- [18] Bull PC, Thomas GR, Rommens JM, Forbes JR, Cox DW (1993) The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. *Nat Genet* **5**, 327-337.
- [19] Tanzi RE, Petrukhin K, Chernov I, Pellequer JL, Wasco W, Ross B, Romano DM, Parano E, Pavone L, Brzustowicz LM, et al. (1993) The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. *Nat Genet* **5**, 344-350.
- [20] Litwin T, Dziezyc K, Czlonkowska A (2019) Wilson disease-treatment perspectives. *Ann Transl Med* **7**, S68.
- [21] Vairo FPE, Chwal BC, Perini S, Ferreira MAP, de Freitas Lopes AC, Saute JAM (2019) A systematic review and evidence-based guideline for diagnosis and treatment of Menkes disease. *Mol Genet Metab* **126**, 6-13.
- [22] Squitti R, Fallor P, Hureau C, Granzotto A, White AR, Kepp KP (2021) Copper imbalance in Alzheimer's disease and its link with the amyloid hypothesis: Towards a combined clinical, chemical, and genetic etiology. *J Alzheimers Dis* **83**, 23-41.
- [23] Squitti R, Ventriglia M, Simonelli I, Bonvicini C, Costa A, Perini G, Binetti G, Benussi L, Ghidoni R, Koch G, Borroni B, Albanese A, Sensi SL, Rongioletti M (2021) Copper imbalance in Alzheimer's disease: meta-analysis of serum, plasma, and brain specimens, and replication study evaluating ATP7B gene variants. *Biomolecules* **11**, 960.
- [24] Li DD, Zhang W, Wang ZY, Zhao P (2017) Serum copper, zinc, and iron levels in patients with Alzheimer's disease: a meta-analysis of case-control studies. *Front Aging Neurosci* **9**, 300.
- [25] Sensi SL, Granzotto A, Siotto M, Squitti R (2018) Copper and zinc dysregulation in Alzheimer's disease. *Trends Pharmacol Sci* **39**, 1049-1063.
- [26] Hozumi I, Hasegawa T, Honda A, Ozawa K, Hayashi Y, Hashimoto K, Yamada M, Koumura A, Sakurai T, Kimura A, Tanaka Y, Satoh M, Inuzuka T (2011) Patterns of levels of biological metals in CSF differ among neurodegenerative diseases. *J Neurol Sci* **303**, 95-99.
- [27] Schrag M, Mueller C, Oyoyo U, Smith MA, Kirsch WM (2011) Iron, zinc and copper in the Alzheimer's disease brain: a quantitative meta-analysis. Some insight on the influence of citation bias on scientific opinion. *Prog Neurobiol* **94**, 296-306.
- [28] Xu J, Church SJ, Patassini S, Begley P, Waldvogel HJ, Curtis MA, Faull RLM, Unwin RD, Cooper GJS (2017) Evidence for widespread, severe brain copper deficiency in Alzheimer's dementia. *Metallomics* **9**, 1106-1119.
- [29] Madaric A, Ginter E, Kadrabova J (1994) Serum copper, zinc and copper/zinc ratio in males: influence of aging. *Physiol Res* **43**, 107-111.
- [30] Bonilla E, Salazar E, Villasmil JJ, Villalobos R, Gonzalez M, Davila JO (1984) Copper distribution in the normal human brain. *Neurochem Res* **9**, 1543-1548.
- [31] Robert A, Liu Y, Nguyen M, Meunier B (2015) Regulation of copper and iron homeostasis by metal chelators: a possible chemotherapy for Alzheimer's disease. *Acc Chem Res* **48**, 1332-1339.
- [32] Liu Y, Nguyen M, Robert A, Meunier B (2019) Metal ions in Alzheimer's disease: a key role or not? *Accounts Chem Res* **52**, 2026-2035.
- [33] Esmieu C, Guettas D, Conte-Daban A, Sabater L, Fallor P, Hureau C (2019) Copper-targeting approaches in Alzheimer's disease: how to improve the fallouts obtained from *in vitro* studies. *Inorg Chem* **58**, 13509-13527.
- [34] Walshe JM (1982) Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride. *Lancet* **1**, 643-647.
- [35] Roberts EA, Schilsky ML (2008) Diagnosis and treatment of Wilson disease: an update. *Hepatology* **47**, 2089-2111.
- [36] Squitti R, Rossini PM, Cassetta E, Moffa F, Pasqualetti P, Cortesi M, Colloca A, Rossi L, Finazzi-Agro A (2002) d-penicillamine reduces serum oxidative stress in Alzheimer's disease patients. *Eur J Clin Invest* **32**, 51-59.
- [37] Treiber C, Simons A, Strauss M, Hafner M, Cappai R, Bayer TA, Multhaup G (2004) Clioquinol mediates copper uptake and counteracts copper efflux activities of the

- amyloid precursor protein of Alzheimer's disease. *J Biol Chem* **279**, 51958-51964.
- [38] White AR, Du T, Laughton KM, Volitakis I, Sharples RA, Xilinas ME, Hoke DE, Holsinger RM, Evin G, Cherny RA, Hill AF, Barnham KJ, Li QX, Bush AI, Masters CL (2006) Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity. *J Biol Chem* **281**, 17670-17680.
- [39] Kawamura K, Kuroda Y, Sogo M, Fujimoto M, Inui T, Mitsui T (2014) Superoxide dismutase as a target of clioquinol-induced neurotoxicity. *Biochem Biophys Res Commun* **452**, 181-185.
- [40] Smirnova J, Kabin E, Jarving I, Bragina O, Tõugu V, Plitz T, Palumaa P (2018) Copper(I)-binding properties of de-coppering drugs for the treatment of Wilson disease. α -Lipoic acid as a potential anti-copper agent. *Sci Rep* **8**, 1463.
- [41] Banci L, Bertini I, Ciofi-Baffoni S, Kozyreva T, Zovo K, Palumaa P (2010) Affinity gradients drive copper to cellular destinations. *Nature* **465**, 645-648.
- [42] Shay KP, Moreau RF, Smith EJ, Smith AR, Hagen TM (2009) Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. *Biochim Biophys Acta* **1790**, 1149-1160.
- [43] Theodosis-Nobelos P, Papagiouvannis G, Tziona P, Rekka EA (2021) Lipoic acid. Kinetics and pluripotent biological properties and derivatives. *Mol Biol Rep* **48**, 6539-6550.
- [44] Tymoczko JL, Berg JM, Stryer L (2013) *Biochemistry. A short course*, W. H. Freeman and Company, New York.
- [45] Bjorklund G, Aaseth J, Crisponi G, Rahman MM, Chirumbolo S (2019) Insights on alpha lipoic and dihydrolipoic acids as promising scavengers of oxidative stress and possible chelators in mercury toxicology. *J Inorg Biochem* **195**, 111-119.
- [46] Stoll S, Hartmann H, Cohen SA, Muller WE (1993) The potent free radical scavenger alpha-lipoic acid improves memory in aged mice: putative relationship to NMDA receptor deficits. *Pharmacol Biochem Behav* **46**, 799-805.
- [47] Quinn JF, Bussiere JR, Hammond RS, Montine TJ, Henson E, Jones RE, Stackman RW (2007) Chronic dietary alpha-lipoic acid reduces deficits in hippocampal memory of aged Tg2576 mice. *Neurobiol Aging* **28**, 213-225.
- [48] Freisleben HJ, Neeb A, Lehr F, Ackermann H (1997) Influence of selegiline and lipoic acid on the life expectancy of immunosuppressed mice. *Arzneimittelforschung* **47**, 776-780.
- [49] Bauer JH, Goupil S, Garber GB, Helfand SL (2004) An accelerated assay for the identification of lifespan-extending interventions in *Drosophila melanogaster*. *Proc Natl Acad Sci U S A* **101**, 12980-12985.
- [50] Mijnhout GS, Kollen BJ, Alkhalaf A, Kleefstra N, Bilo HJ (2012) Alpha lipoic Acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials. *Int J Endocrinol* **2012**, 456279.
- [51] Hager K, Kenkies M, McAfoose J, Engel J, Munch G (2007) Alpha-lipoic acid as a new treatment option for Alzheimer's disease—a 48 months follow-up analysis. *J Neural Transm Suppl*, pp. 189-193.
- [52] Maczurek A, Hager K, Kenkies M, Sharman M, Martins R, Engel J, Carlson D, Munch G (2008) Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer's disease. *Adv Drug Deliv Rev* **60**, 1463-1470.
- [53] Fava A, Pirritano D, Plastino M, Cristiano D, Puccio G, Colica C, Ermio C, De Bartolo M, Mauro G, Bosco D (2013) The effect of lipoic acid therapy on cognitive functioning in patients with Alzheimer's disease. *J Neurodegener Dis* **2013**, 454253.
- [54] Kristhal J, Metsla K, Bragina O, Tougu V, Palumaa P (2019) Toxicity of amyloid-beta peptides varies depending on differentiation route of SH-SY5Y cells. *J Alzheimers Dis* **71**, 879-887.
- [55] Yang MY, Armstrong JD, Vilinsky I, Strausfeld NJ, Kaiser K (1995) Subdivision of the *Drosophila* mushroom bodies by enhancer-trap expression patterns. *Neuron* **15**, 45-54.
- [56] Freeman M (1996) Reiterative use of the EGF receptor triggers differentiation of all cell types in the *Drosophila* eye. *Cell* **87**, 651-660.
- [57] Tamberg L, Jaago M, Saalik K, Sirp A, Tuvikene J, Shubina A, Kiir CS, Nurm K, Sepp M, Timmusk T, Palgi M (2020) Daughterless, the *Drosophila* orthologue of TCF4, is required for associative learning and maintenance of the synaptic proteome. *Dis Model Mech* **13**, dmm042747.
- [58] Agholme L, Lindstrom T, Kagedal K, Marcusson J, Hallbeck M (2010) An *in vitro* model for neuroscience: differentiation of SH-SY5Y cells into cells with morphological and biochemical characteristics of mature neurons. *J Alzheimers Dis* **20**, 1069-1082.
- [59] Kristhal J, Bragina O, Metsla K, Palumaa P, Tõugu V (2017) In situ fibrillizing amyloid-beta 1-42 induces neurite degeneration and apoptosis of differentiated SH-SY5Y cells. *PLoS One* **12**, e0186636.
- [60] Jeon Y, Lee JH, Choi B, Won SY, Cho KS (2020) Genetic dissection of Alzheimer's disease using *Drosophila* models. *Int J Mol Sci* **21**, 884.
- [61] Brand AH, Perrimon N (1993) Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. *Development* **118**, 401-415.
- [62] Squitti R, Simonelli I, Ventriglia M, Siotto M, Pasqualetti P, Rembach A, Doecke J, Bush AI (2014) Meta-analysis of serum non-ceruloplasmin copper in Alzheimer's disease. *J Alzheimers Dis* **38**, 809-822.
- [63] Capo CR, Arciello M, Squitti R, Cassetta E, Rossini PM, Calabrese L, Rossi L (2008) Features of ceruloplasmin in the cerebrospinal fluid of Alzheimer's disease patients. *Biomaterials* **21**, 367-372.
- [64] Squitti R, Siotto M, Arciello M, Rossi L (2016) Non-ceruloplasmin bound copper and ATP7B gene variants in Alzheimer's disease. *Metallomics* **8**, 863-873.
- [65] Muller UC, Deller T, Korte M (2017) Not just amyloid: physiological functions of the amyloid precursor protein family. *Nat Rev Neurosci* **18**, 281-298.
- [66] Young TR, Pukala TL, Cappai R, Wedd AG, Xiao ZG (2018) The human amyloid precursor protein binds copper ions dominated by a picomolar-affinity site in the helix-rich E2 domain. *Biochemistry* **57**, 4165-4176.
- [67] Young TR, Wedd AG, Xiao ZG (2018) Evaluation of Cu(I) binding to the E2 domain of the amyloid precursor protein - a lesson in quantification of metal binding to proteins via ligand competition. *Metallomics* **10**, 108-119.
- [68] Bellingham SA, Lahiri DK, Maloney B, La Fontaine S, Multhaup G, Camakaris J (2004) Copper depletion down-regulates expression of the Alzheimer's disease amyloid-beta precursor protein gene. *J Biol Chem* **279**, 20378-20386.
- [69] Baumkötter F, Schmidt N, Vargas C, Schilling S, Weber R, Wagner K, Fiedler S, Klug W, Radzimanowski J, Nickolaus S, Keller S, Eggert S, Wild K, Kins S (2014) Amyloid precursor protein dimerization and synaptogenic

- function depend on copper binding to the growth factor-like domain. *J Neurosci* **34**, 11159-11172.
- [70] Acevedo KM, Hung YH, Dalziel AH, Li QX, Laughton K, Wikhe K, Rembach A, Roberts B, Masters CL, Bush AI, Camakaris J (2011) Copper promotes the trafficking of the amyloid precursor protein. *J Biol Chem* **286**, 8252-8262.
- [71] Acevedo KM, Opazo CM, Norrish D, Challis LM, Li QX, White AR, Bush AI, Camakaris J (2014) Phosphorylation of amyloid precursor protein at threonine 668 is essential for its copper-responsive trafficking in SH-SY5Y neuroblastoma cells. *J Biol Chem* **289**, 11007-11019.
- [72] Borchardt T, Camakaris J, Cappai R, Masters CL, Beyreuther K, Multhaup G (1999) Copper inhibits beta-amyloid production and stimulates the non-amyloidogenic pathway of amyloid-precursor-protein secretion. *Biochem J* **344 Pt 2**, 461-467.
- [73] Angeletti B, Waldron KJ, Freeman KB, Bawagan H, Husain I, Miller CC, Lau KF, Tennant ME, Dennison C, Robinson NJ, Dingwall C (2005) BACE1 cytoplasmic domain interacts with the copper chaperone for superoxide dismutase-1 and binds copper. *J Biol Chem* **280**, 17930-17937.
- [74] Tögu V, Karafin A, Palumaa P (2008) Binding of zinc(II) and copper(II) to the full-length Alzheimer's amyloid-beta peptide. *J Neurochem* **104**, 1249-1259.
- [75] Alies B, Renaglia E, Rozga M, Bal W, Faller P, Hureau C (2013) Cu(II) affinity for the Alzheimer's peptide: tyrosine fluorescence studies revisited. *Anal Chem* **85**, 1501-1508.
- [76] Borghesani V, Alies B, Hureau C (2018) Cu-II binding to various forms of amyloid-beta peptides: are they friends or foes? *Eur J Inorg Chem* **2018**, 7-15.
- [77] Tögu V, Karafin A, Zovo K, Chung RS, Howells C, West AK, Palumaa P (2009) Zn(II)- and Cu(II)-induced non-fibrillar aggregates of amyloid-beta (1-42) peptide are transformed to amyloid fibrils, both spontaneously and under the influence of metal chelators. *J Neurochem* **110**, 1784-1795.
- [78] Faller P, Hureau C, Berthoumieu O (2013) Role of metal ions in the self-assembly of the Alzheimer's amyloid-beta peptide. *Inorg Chem* **52**, 12193-12206.
- [79] Miller LM, Wang Q, Telivala TP, Smith RJ, Lanzarotti A, Miklossy J (2006) Synchrotron-based infrared and X-ray imaging shows focalized accumulation of Cu and Zn co-localized with beta-amyloid deposits in Alzheimer's disease. *J Struct Biol* **155**, 30-37.
- [80] Jiang D, Zhang L, Grant GP, Dudzik CG, Chen S, Patel S, Hao Y, Millhauser GL, Zhou F (2013) The elevated copper binding strength of amyloid-beta aggregates allows the sequestration of copper from albumin: a pathway to accumulation of copper in senile plaques. *Biochemistry* **52**, 547-556.
- [81] Guilloreau L, Combalbert S, Sournia-Saquet A, Mazarguil H, Faller P (2007) Redox chemistry of copper-amyloid-beta: The generation of hydroxyl radical in the presence of ascorbate is linked to redox-potentials and aggregation state. *ChemBiochem* **8**, 1317-1325.
- [82] Cheignon C, Tomas M, Bonnefont-Rousselot D, Faller P, Hureau C, Collin F (2018) Oxidative stress and the amyloid beta peptide in Alzheimer's disease. *Redox Biol* **14**, 450-464.
- [83] Kessler H, Bayer TA, Bach D, Schneider-Axmann T, Supprian T, Herrmann W, Haber M, Multhaup G, Falkai P, Pajonk FG (2008) Intake of copper has no effect on cognition in patients with mild Alzheimer's disease: a pilot phase 2 clinical trial. *J Neural Transm (Vienna)* **115**, 1181-1187.
- [84] Kessler H, Pajonk FG, Bach D, Schneider-Axmann T, Falkai P, Herrmann W, Multhaup G, Wiltfang J, Schafer S, Wirths O, Bayer TA (2008) Effect of copper intake on CSF parameters in patients with mild Alzheimer's disease: a pilot phase 2 clinical trial. *J Neural Transm (Vienna)* **115**, 1651-1659.
- [85] Barnham KJ, Masters CL, Bush AI (2004) Neurodegenerative diseases and oxidative stress. *Nat Rev Drug Discov* **3**, 205-214.
- [86] Bush AI (2008) Drug development based on the metals hypothesis of Alzheimer's disease. *J Alzheimers Dis* **15**, 223-240.
- [87] Sampson EL, Jenagaratnam L, McShane R (2014) Metal protein attenuating compounds for the treatment of Alzheimer's dementia. *Cochrane Database Syst Rev*, CD005380.
- [88] Jenagaratnam L, McShane R (2006) Clioquinol for the treatment of Alzheimer's disease. *Cochrane Database Syst Rev*, CD005380.
- [89] Adlard PA, Bush AI (2018) Metals and Alzheimer's disease: how far have we come in the clinic? *J Alzheimers Dis* **62**, 1369-1379.
- [90] Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, Wilson J, Ritchie CW (2008) Safety, efficacy, and biomarker findings of PBT2 in targeting A β as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. *Lancet Neurol* **7**, 779-786.
- [91] Faux NG, Ritchie CW, Gunn A, Rembach A, Tsatsanis A, Bedo J, Harrison J, Lannfelt L, Blennow K, Zetterberg H, Ingelsson M, Masters CL, Tanzi RE, Cummings JL, Herd CM, Bush AI (2010) PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. *J Alzheimers Dis* **20**, 509-516.
- [92] Dedeoglu A, Cormier K, Payton S, Tseitlin KA, Kremisky JN, Lai L, Li X, Moir RD, Tanzi RE, Bush AI, Kowall NW, Rogers JT, Huang X (2004) Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis. *Exp Gerontol* **39**, 1641-1649.
- [93] Rodriguez-Rodriguez C, Sanchez de Groot N, Rimola A, Alvarez-Larena A, Lloveras V, Vidal-Gancedo J, Ventura S, Vendrell J, Sodupe M, Gonzalez-Duarte P (2009) Design, selection, and characterization of thioflavin-based intercalation compounds with metal chelating properties for application in Alzheimer's disease. *J Am Chem Soc* **131**, 1436-1451.
- [94] Choi JS, Braymer JJ, Nanga RP, Ramamoorthy A, Lim MH (2010) Design of small molecules that target metal-A β species and regulate metal-induced A β aggregation and neurotoxicity. *Proc Natl Acad Sci U S A* **107**, 21990-21995.
- [95] Zhao J, Shi Q, Tian H, Li Y, Liu Y, Xu Z, Robert A, Liu Q, Meunier B (2021) TDMQ20, a specific copper chelator, reduces memory impairments in Alzheimer's disease mouse models. *ACS Chem Neurosci* **12**, 140-149.
- [96] Wang CY, Xie JW, Xu Y, Wang T, Cai JH, Wang X, Zhao BL, An L, Wang ZY (2013) Trientine reduces BACE1 activity and mitigates amyloidosis via the AGE/RAGE/NF-kappaB pathway in a transgenic mouse model of Alzheimer's disease. *Antioxid Redox Signal* **19**, 2024-2039.

- [97] Squitti R, Pal A, Picozza M, Avani A, Ventriglia M, Rongioletti MC, Hoogenraad T (2020) Zinc therapy in early Alzheimer's disease: Safety and potential therapeutic efficacy. *Biomolecules* **10**, 1164.
- [98] Brewer GJ (2012) Copper excess, zinc deficiency, and cognition loss in Alzheimer's disease. *Biofactors* **38**, 107-113.
- [99] Camarata MA, Ala A, Schilsky ML (2019) Zinc maintenance therapy for Wilson disease: a comparison between zinc acetate and alternative zinc preparations. *Hepatol Commun* **3**, 1151-1158.
- [100] Appleby BS, Nacopoulos D, Milano N, Zhong K, Cummings JL (2013) A review: treatment of Alzheimer's disease discovered in repurposed agents. *Dement Geriatr Cogn Disord* **35**, 1-22.
- [101] Litwin T, Dziezyc K, Karlinski M, Chabik G, Czepiel W, Czlonkowska A (2015) Early neurological worsening in patients with Wilson's disease. *J Neurol Sci* **355**, 162-167.
- [102] Kirsipuu T, Zadorožnaja A, Smirnova J, Friedemann M, Plitz T, Töugu V, Palumaa P (2020) Copper(II)-binding equilibria in human blood. *Sci Rep* **10**, 5686.
- [103] Hegen H, Auer M, Zeileis A, Deisenhammer F (2016) Upper reference limits for cerebrospinal fluid total protein and albumin quotient based on a large cohort of control patients: implications for increased clinical specificity. *Clin Chem Lab Med* **54**, 285-292.
- [104] Petersen Shay K, Moreau RF, Smith EJ, Hagen TM (2008) Is alpha-lipoic acid a scavenger of reactive oxygen species *in vivo*? Evidence for its initiation of stress signaling pathways that promote endogenous antioxidant capacity. *IUBMB Life* **60**, 362-367.
- [105] Dos Santos SM, Romeiro CFR, Rodrigues CA, Cerqueira ARL, Monteiro MC (2019) Mitochondrial dysfunction and alpha-lipoic acid: beneficial or harmful in Alzheimer's disease? *Oxid Med Cell Longev* **2019**, 8409329.
- [106] Lang M, Fan Q, Wang L, Zheng Y, Xiao G, Wang X, Wang W, Zhong Y, Zhou B (2013) Inhibition of human high-affinity copper importer Ctr1 orthologous in the nervous system of *Drosophila* ameliorates Abeta42-induced Alzheimer's disease-like symptoms. *Neurobiol Aging* **34**, 2604-2612.
- [107] Hua HQ, Munter L, Harmeier A, Georgiev O, Multhaup G, Schaffner W (2011) Toxicity of Alzheimer's disease-associated A beta peptide is ameliorated in a *Drosophila* model by tight control of zinc and copper availability. *Biol Chem* **392**, 919-926.
- [108] Cao W, Song HJ, Gangi T, Kelkar A, Antani I, Garza D, Konsolaki M (2008) Identification of novel genes that modify phenotypes induced by Alzheimer's beta-amyloid overexpression in *Drosophila*. *Genetics* **178**, 1457-1471.
- [109] Zhang L, Xing GQ, Barker JL, Chang Y, Maric D, Ma W, Li BS, Rubinow DR (2001) Alpha-lipoic acid protects rat cortical neurons against cell death induced by amyloid and hydrogen peroxide through the Akt signalling pathway. *Neurosci Lett* **312**, 125-128.

Curriculum vitae

Personal data

Name: Kristel Metsla
Date of birth: 07.03.1993
Place of birth: Tallinn
Citizenship: Estonian

Contact data

E-mail: kristel.metsla@taltech.ee, kristelmetsla@gmail.com
Researcher ID: B-5135-2019
ORCID: 0000-0002-7274-1233

Education

2017– ... Tallinn University of Technology – PhD
Maternity leave: April 2023 – August 2025
2015–2017 Tallinn University of Technology – MSc (*cum laude*)
2012–2015 Tallinn University of Technology – BSc
2000–2012 Tallinn Mustamäe College – High school

Language competence

Estonian Native
English Fluent
Russian Elementary

Supervised dissertations

Lisanna Laanela, bachelor's degree, 2018, (sup) Kristel Metsla; Peep Palumaa, The toxicity of copper ions on differentiated SH-SY5Y cells. The effect of metal chelators. Tallinn University of Technology, School of Science, Department of Chemistry and Biotechnology

Sigrid Kirss, master's degree, 2020, (sup) Kristel Metsla; Peep Palumaa, Investigation of copper metabolism and its regulation in cell culture and Drosophila models of Alzheimer's disease, Tallinn University of Technology, School of Science, Department of Chemistry and Biotechnology

Elulookirjeldus

Isikuandmed

Nimi:	Kristel Metsla
Sünniaeg:	07.03.1993
Sünnikoht:	Tallinn
Kodakondsus:	Eesti

Kontaktandmed

E-post:	kristel.metsla@taltech.ee , kristelmetsla@gmail.com
Researcher ID	<u>B-5135-2019</u>
ORCID	<u>0000-0002-7274-1233</u>

Hariduskäik

2017– ...	Tallinna Tehnikaülikool, doktoriõpe <i>Vanemapuhkus: aprill 2023 – august 2025</i>
2015–2017	Tallinna Tehnikaülikool, magistrikraad (<i>cum laude</i>)
2012–2015	Tallinna Tehnikaülikool, bakalaureusekraad
2000–2012	Tallinna Mustamäe Gümnaasium, keskkharidus

Keelteoskus

Eesti keel	emakeel
Inglise keel	kõrgtase
Vene keel	algtase

Juhendatud diplomitööd

Lisanna Laanela, bakalaureusekraad, 2018, (juh) Kristel Metsla; Peep Palumaa, The toxicity of copper ions on differentiated SH-SY5Y cells. The effect of metal chelators. Tallinna Tehnikaülikool, Loodusteaduskond, Keemia ja biotehnoloogia instituut

Sigrid Kirss, magistrikraad, 2020, (juh) Kristel Metsla; Peep Palumaa, Investigation of copper metabolism and its regulation in cell culture and Drosophila models of Alzheimer's disease (Vase metabolismi ja selle regulatsiooni uurimine Alzheimeri tõve rakukultuuri ja äädikakärbse mudelis), Tallinna Tehnikaülikool, Loodusteaduskond, Keemia ja biotehnoloogia instituut

ISSN 2585-6901 (PDF)
ISBN 978-9916-80-388-2 (PDF)